Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
Patent Information
- Application Number
- HK62026126803
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-27
- Filing Date
- 2026-07-29
- Publication Date
- 2026-09-11
Smart Images

Figure 00000171_0000 
Figure 00000242_0000 
Figure 00000242_0001
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480044479.0 (22) Application Date 2024.08.01 (30) Priority Data 3233757 2024.03.27 CA 63 / 530319 2023.08.02 US 63 / 532252 2023.08.11 US (85) PCT International Application Entering National Phase Date 2025.12.30 (86) PCT International Application Application Data PCT / EP2024 / 071819 2024.08.01 (87) PCT International Application Publication Data WO2025 / 027138 EN 2025.02.06 (71) Applicant: Jansen Pharmaceuticals Ltd. Address: Belser, Belgium (72) Inventors: P. Francis Wang Guilin N.A. Hutnick M.P. Gormley K.A. Jutishak S. Thomas S. Dibaje W. King S.X. Li Zhangke A.M. Lopez-Gitlitz M. Gukert J. Zhang A.A. Delcoral (74) Patent Agency: China Patent Agency (Hong Kong) Ltd. 72001 Patent Attorneys: Li Jin Peng Chang (51) Int.Cl. A61K 31 / 454 (2006.01) A61K 31 / 573 (2006.01) A61K 31 / 58 (2006.01) A61P 35 / 04 (2006.01) (54) Invention Title: Niraparib and Abiraterone Combination for the Treatment of Metastatic Castration-Resistant Prostate Cancer (57) Abstract: This disclosure relates to a pharmaceutical product having at least one approved indication, wherein the pharmaceutical product comprises niraparib and abiraterone acetate. Claims: 5 pages Description: 185 pages Drawings: 6 pages CN 121443291 A 2026.01.30 CN 1 21 44 32 91 A 1. A pharmaceutical product approved by a government regulatory agency for at least one indication, wherein the pharmaceutical product comprises niraparib and abiraterone acetate. 2. The pharmaceutical product of claim 1, wherein the at least one approved indication is metastatic castration-resistant prostate cancer (mCRPC). 3. The pharmaceutical product of claim 1 or 2, wherein the pharmaceutical product is indicated in combination with prednisone for the treatment of patients with mCRPC who have been diagnosed with a harmful or suspected harmful breast cancer mutation (BRCAm) by testing. 4. The pharmaceutical product of claim 3, wherein the pharmaceutical product is administered orally once daily in a dose of 200 mg niraparib and 1,000 mg abiraterone acetate, and in combination with a daily dose of 10 mg prednisone.5. The pharmaceutical product of claim 3, wherein in cases of bone marrow suppression accompanied by: (i) a platelet count < 100,000 / mcL, or (ii) a neutrophil count < 1,000 / mcL or a hemoglobin count < 8 g / dL; or in cases of other non-hematological grade 3 or 4 adverse reactions, the pharmaceutical product is administered orally once daily at a reduced dose of 100 mg niraparib and 1,000 mg abiraterone acetate. 6. The pharmaceutical product of any one of claims 3 to 5, wherein the pharmaceutical product is administered on an empty stomach. 7. The pharmaceutical product of any one of claims 3 to 6, wherein no food is consumed for two hours before and one hour after taking the pharmaceutical product. 8. The pharmaceutical product of any one of claims 3 to 7, wherein the patient is concurrently receiving gonadotropin-releasing hormone (GnRH) analogue therapy, or the patient has undergone bilateral orchiectomy. 9. The pharmaceutical product of claim 8, wherein the GnRH analogue is selected from triptorelin, nafarelin, goserelin, leuprorelin, or leuprorelin, histaminerelin, gonadorelin, and buserelin. 10. The pharmaceutical product of any one of claims 3 to 9, wherein the pharmaceutical product is not administered to patients with moderate or severe hepatic impairment. 11. The pharmaceutical product of any one of claims 3 to 10, wherein the pharmaceutical product is not co-administered with the CYP3A4 inducer rifampin. 12. The pharmaceutical product of any one of the preceding claims, wherein the pharmaceutical product comprises a pharmaceutical composition comprising a pharmaceutically acceptable carrier; and (i) 100 mg niraparib and 500 mg abiraterone acetate, in an oral dosage form (conventional strength); or (ii) 50 mg niraparib and 500 mg abiraterone acetate, in an oral dosage form (lower strength). 13. The pharmaceutical product of any one of claims 4 to 12, wherein in patients with harmful or suspected harmful BRCAM mCRPC detected by approved testing, the pharmaceutical product induces a median overall survival (OS) of 30.4 months with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120). 14. The pharmaceutical product of claim 13, wherein, after multivariate Cox regression analysis, the HR for the median OS is 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for externally validated and clinically relevant baseline prognostic factors selected from prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (Alk Phos), age, Eastern Cooperative Oncology Group (ECOG) grade, number of bone lesions, and visceral disease. 15. The pharmaceutical product of any one of claims 4 to 14, wherein in patients with harmful or suspected harmful BRCAM detected by testing...In patients with mCRPC, the drug product induced an improved median time to progression of symptoms (TSP) compared to patients receiving placebo and abiraterone acetate plus prednisone, with a hazard ratio (HR) of 0.562 (95% CI: 0.371, 0.849). 16. The drug product according to any one of claims 4 to 15, wherein in patients with mCRPC who tested positive for harmful or suspected harmful BRCA, the drug product induced an improved median time to cytotoxic chemotherapy (TCC) compared to patients receiving placebo and abiraterone acetate plus prednisone, with an HR of 0.598 (95% CI: 0.387, 0.924). 17. The pharmaceutical product according to any one of claims 4 to 16, wherein in patients with harmful or suspected harmful BRCAm mCRPC detected by testing, the pharmaceutical product induces a median radiographic progression-free survival (rPFS) of 19.5 months, with an HR of 0.553 (95% CI: 0.392, 0.782). 18. The pharmaceutical product according to any one of claims 1 to 17, wherein the pharmaceutical product comprises 159.40 mg of niraparib tosylate monohydrate, equivalent to 100 mg of niraparib free base, as the active ingredient, and 500 mg of abiraterone acetate. 19. The pharmaceutical product according to any one of claims 1 to 17, wherein the pharmaceutical product comprises 79.70 mg of niraparib tosylate monohydrate, equivalent to 50 mg of niraparib free base, as the active ingredient, and 500 mg of abiraterone acetate. 20. The pharmaceutical product according to any one of claims 12 to 19, wherein the pharmaceutical composition is an oral dosage form selected from film-coated tablets, tablets, capsules, granules, and sachets. 21. The pharmaceutical product of claim 20, wherein the pharmaceutical composition is a film-coated tablet, further comprising colloidal anhydrous silica, cropovidone, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose, and sodium lauryl sulfate; and a film coating. 22. The pharmaceutical product of claim 21, wherein the film-coated tablet comprises 100 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide. 23. The pharmaceutical product of claim 21, wherein the film-coated tablet comprises 50 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide. 24. The pharmaceutical product of any of the preceding claims, wherein the pharmaceutical product is approved for marketing in the European Economic Area (EEA) or Canada.25. The pharmaceutical product according to any one of the preceding claims, wherein the pharmaceutical product is a generic drug, ANDA, sNDA, NDA product, or 505(b)(2) pharmaceutical product. 26. A method for treating a patient with mCRPC who has been found to have a harmful or suspected harmful BRCAM by testing, the method comprising administering the pharmaceutical product as defined in any one of the preceding claims in combination with prednisone to the patient. 27. The method for treating mCRPC according to claim 26, wherein the treatment comprises oral administration of the pharmaceutical product containing 200 mg niraparib and 1,000 mg abiraterone acetate once daily, while simultaneously administering 10 mg prednisone alone daily until disease progression or unacceptable toxicity occurs. 28. The method of treating mCRPC according to claim 26, wherein the treatment comprises, once daily, oral administration of a reduced dose of the pharmaceutical product containing 100 mg niraparib and 1,000 mg abiraterone acetate, in cases of myelosuppression accompanied by: (i) a platelet count < 100,000 / mcL, or (ii) a neutrophil count < 1,000 / mcL or a hemoglobin count < 8 g / dL; or in cases of other non-hematologic grade 3 or 4 adverse events, concurrently with daily administration of 10 mg prednisone alone. 29. The method of treating mCRPC according to any one of claims 26 to 28, wherein the treatment comprises improving the median overall survival (OS) to 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120). 30. The method for treating mCRPC according to claim 29, wherein the median OS was further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for baseline prognostic factors that were validated and clinically relevant, the baseline prognostic factors being selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease. 31. The method for treating mCRPC according to any one of claims 26 to 30, wherein the treatment includes improving the median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849). 32. The method for treating mCRPC according to any one of claims 26 to 31, wherein the treatment includes improving the median TCC, with a HR of 0.598 (95% CI: 0.387, 0.924). 33. The method for treating mCRPC according to any one of claims 26 to 32, wherein the treatment comprises improving median rPFS to 19.5 months, with a HR of 0.553 (95%).CI: 0.392, 0.782). 34. A method of marketing a pharmaceutical product comprising niraparib and abiraterone acetate as defined in any one of claims 1 to 25, the method comprising marketing such pharmaceutical product. 35. The marketing method of claim 34, wherein the pharmaceutical product is a generic drug, an ANDA pharmaceutical product, a supplemental new drug application pharmaceutical product, an NDA pharmaceutical product, or a 505(b)(2) pharmaceutical product. 36. The marketing method of claim 34 or 35, wherein a reference formulation of such pharmaceutical product improves OS, rPFS, TCC, TSP, or TPP. 37. The marketing method of claim 36, wherein the median OS is 30.4 months and the HR is 0.788 (95% CI: 0.554, 1.120). 38. The sales method of claim 37, wherein the HR for the median OS after multivariate Cox regression analysis is 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease. 39. The sales method of any one of claims 36 to 38, wherein the median TSP is improved, with an HR of 0.562 (95% CI: 0.371, 0.849). 40. The sales method of any one of claims 36 to 39, wherein the median TCC is improved, with an HR of 0.598 (95% CI: 0.387, 0.924). 41. The method of sales according to any one of claims 36 to 40, wherein the median rPFS is 19.5 months and the HR is 0.553 (95% CI: 0.392, 0.782). 42. A method of delivering a pharmaceutical product comprising niraparib and abiraterone acetate as defined in any one of claims 1 to 25, the method comprising delivering such pharmaceutical product. 43. The method of delivery according to claim 42, wherein the pharmaceutical product is a generic drug, an ANDA pharmaceutical product, a supplemental new drug application pharmaceutical product, an NDA pharmaceutical product, or a 505(b)(2) pharmaceutical product. 44. The method of delivery according to claim 42 or 43, wherein a reference formulation of such pharmaceutical product improves OS, rPFS, TCC, TSP, or TPP. 45. The method of delivery according to claim 44, wherein the median OS is 30.4 months and the HR is 0.788 (95% CI: 0.554, 1.120). 46. The sales method according to claim 45, wherein the HR of the median OS after multivariate Cox regression analysis is 0.663 (95%).CI: 0.464, 0.947), the multivariate Cox regression analysis adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease. 47. The method of sale according to any one of claims 44 to 46, wherein the median TSP is improved, HR is 0.562 (95% CI: 0.371, 0.849). 48. The method of sale according to any one of claims 44 to 47, wherein the median TCC is improved, HR is 0.598 (95% CI: 0.387, 0.924). 49. The method of sale according to any one of claims 44 to 48, wherein the median rPFS is 19.5 months, HR is 0.553 (95% CI: 0.392, 0.782). 50. The pharmaceutical product according to any one of claims 1 to 25, used in a method for treating mCRPC patients with harmful or suspected harmful BRCAM detected by testing, the method comprising administering the pharmaceutical product in combination with prednisone. 51. The pharmaceutical product according to any one of claims 1 to 25, used in the method of claim 50, wherein the treatment comprises oral administration once daily of the pharmaceutical product containing a dose of 200 mg niraparib and 1,000 mg abiraterone acetate, and 10 mg prednisone, until disease progression or unacceptable toxicity occurs. 52. The pharmaceutical product according to any one of claims 1 to 25, used in the method of claim 50, wherein the treatment comprises, once daily, oral administration of a reduced dose of the pharmaceutical product containing 100 mg niraparib and 1,000 mg abiraterone acetate, and 10 mg prednisone, in the presence of: (i) platelet count < 100,000 / mcL, or (ii) neutrophil count < 1,000 / mcL or hemoglobin count < 8 g / dL; or in the presence of other non-hematologic grade 3 or 4 adverse reactions. 53. The pharmaceutical product according to any one of claims 1 to 25, used in the method of any one of claims 50 to 52, wherein the treatment comprises improving the median overall survival (OS) to 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120). 54. The pharmaceutical product according to any one of claims 1 to 25, used in the method of claim 53, wherein the median overall survival (OS) is further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464).0.947), the multivariate Cox regression analysis adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease. 55. The pharmaceutical product according to any one of claims 1 to 25, used in the method of any one of claims 50 to 54, wherein the treatment comprises improving median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849). 56. The pharmaceutical product according to any one of claims 1 to 25, used in the method of any one of claims 50 to 55, wherein the treatment comprises improving median TCC, with a HR of 0.598 (95% CI: 0.387, 0.924). 57. The pharmaceutical product according to any one of claims 1 to 25, wherein the pharmaceutical product is used in the method of any one of claims 50 to 56, wherein the treatment comprises improving median rPFS to 19.5 months, with an HR of 0.553 (95% CI: 0.392, 0.782). 58. A pharmaceutical product comprising niraparib and abiraterone acetate, said pharmaceutical product being used in combination with prednisone or prednisolone in a method of treating adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1 / 2 mutations (germline and / or somatic mutations) for whom chemotherapy is not clinically indicated; wherein BRCA positivity is determined using a validated test method; wherein a single daily dose of said pharmaceutical product is 200 mg niraparib and 1,000 mg abiraterone acetate, and a daily dose of prednisone or prednisolone is 10 mg, until disease progression or unacceptable toxicity occurs; wherein said treatment comprises improving said median overall survival (OS) to 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120). 59. The pharmaceutical product used according to claim 58, wherein the median OS was further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for external validation claims 4 / 5 CN 121443291 A and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral diseases. 60. The pharmaceutical product used according to claim 58 or 59, wherein the treatment comprises improving the median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849). 61. The pharmaceutical product used according to any one of claims 58 to 60, wherein the treatment comprises improving the median TSP.The median rPFS improved to 19.5 months, with an HR of 0.598 (95% CI: 0.387, 0.924). 62. The pharmaceutical product used according to any one of claims 58 to 61, wherein the treatment comprises improving the median rPFS to 19.5 months, with an HR of 0.553 (95% CI: 0.392, 0.782). Claims 5 / 5 Page 6 CN 121443291 A Niraparib and Abiraterone combination for the treatment of metastatic castration-resistant prostate cancer
[0001] A portion of the disclosure of this patent document includes copyrighted material. The copyright holder does not object to any person reproducing this patent document or patent disclosure as is from the Patent and Trademark Office patent documents or records, but otherwise the copyright owner retains all related copyrights. Technical Field
[0002] This disclosure relates to a method of treating metastatic castration-resistant prostate cancer (mCRPC) using an approved pharmaceutical product containing niraparib and abiraterone acetate. This disclosure relates to an approved pharmaceutical product having at least one indication for the treatment of mCRPC. Methods for selling or providing a pharmaceutical product containing niraparib and abiraterone acetate are also disclosed, wherein the approved pharmaceutical product is approved for at least one indication.
[0003] This disclosure relates to methods for treating metastatic castration-resistant prostate cancer (mCRPC) using a pharmaceutical product containing niraparib and abiraterone acetate. This disclosure relates to a pharmaceutical product having at least one indication for treating mCRPC. Methods for selling or providing a pharmaceutical product containing niraparib and abiraterone acetate are also disclosed, wherein the pharmaceutical product is approved for at least one indication. Background Art
[0004] Globally, prostate cancer is the second most common cancer and the fifth leading cause of cancer death among men, with 1,400,000 new cancer cases (14.1%) and 375,304 cancer deaths (6.8%) in 2020.
[0005] While patients with localized prostate cancer can be cured with current therapies, the occurrence of metastasis foreshadows a deadly disease. Throughout the disease spectrum, prostate cancer growth and survival depend on androgen-mediated signaling. For decades, initial (first-line) treatment for metastatic prostate cancer has been surgical castration via bilateral orchiectomy or chemical castration using androgen deprivation therapy (ADT). ADT typically offers initial benefits; however, resistance to ADT inevitably develops.
[0006] In addition to androgen dependence, DNA repair abnormalities have been identified in approximately 25-30% of patients with metastatic prostate cancer. Examples of these homologous recombination repair (HRR) gene alterations include those in the BRCA1, BRCA2, CDK12, FANCA, PALB2, CHEK2, BRIP1, HDAC2, or ATM genes.
[0007] Several pieces of evidence suggest that HRR gene alterations act as a second oncogenic driver in patients with mCRPC, as demonstrated by worse tumor outcomes in these patients. Patients with both mCRPC and HRR gene alterations have shorter life expectancies (median CSS of 23.3 months for mCRPC) compared to patients with mCRPC without HRR gene defects (median etiology-specific survival [CSS] of 33.2 months for mCRPC).
[0008] Clinical trials using poly(ADP-ribose) polymerase inhibitors (PARPi) are ongoing, but not without obstacles. For example, clinical trials using veliparib and pamipanib have been halted. This data clearly demonstrates that the path to finding safer and more effective treatments for mCRPC remains complex and unpredictable to date.
[0009] In the pharmaceutical industry, the path from drug discovery to product approval is long and uncertain. For prostate cancer products, the average time from Phase 1 clinical trials to approval is 9.3 years. To date, ClinicalTrials.gov alone has registered 5,927 clinical studies on prostate cancer. The likelihood of a prostate cancer product obtaining regulatory approval from Phase 1 clinical trials is less than 5%. The final path to approval is also not certain or inevitable, as failures continue to occur until the approval stage from Phase 3 clinical trials. The average probability of a prostate cancer drug advancing from Phase 3 clinical trials is only 50%. This is not only due to the high unpredictability and uncertainty of how pharmaceutical products will affect human biology, but also because how regulatory agencies interpret data and whether the data is sufficient to support the approval of investigational drugs for commercial use is often unpredictable human behavior.
[0010] The Magnitude study was a phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of once-daily niraparib 200 mg in combination with abiraterone acetate (AA) 1,000 mg plus prednisone 10 mg versus placebo combination with abiraterone acetate plus prednisone (AAP) in mCRPC subjects. The Magnitude study has been conducted for several years, involving 318 study sites worldwide, and has enrolled 765 patients to date.
[0011] In the first interim analysis 1 (IA1), no adverse effect on overall survival (OS) was observed in cohort 1 with niraparib + AAP treatment in patients with mCRPC having HRR gene alterations, and the obtained hazard ratio (HR) was 0.938, with a 95% confidence interval (CI) of (0.648, 1.358) and a p-value of 0.7333. The significance threshold for OS in this first interim analysis was 0.0005. The median was not reached in either treatment group. A pre-specified analysis was conducted for subjects with all HRR except ATM alterations.The HR for OS was 0.910, with a 95% CI of (0.608, 1.362). Another pre-specified analysis of subjects with all HRR alterations but excluding ATM and CDK12 alterations showed an HR of 0.883 for OS favoring niraparib + AAP, with a 95% CI of (0.586, 1.330). OS analysis in the non-BRCA subgroup showed an HR of 0.917, with a 95% CI of (0.547, 1.536), nominal p = 0.7407; while OS analysis in the BRCA subgroup showed an HR of 0.961, with a 95% CI of (0.565, 1.633), nominal p = 0.8819.
[0012] Additional follow-up and further OS analyses are needed to understand the impact of individual genes and co-occurring mutations.
[0013] At IA2, an HR of 0.881 for OS was observed in the BRCA subgroup. The median overall survival (OS) for patients treated with niraparib plus AAP was 29.27 months (95% CI, 27.7, not estimable), while the median OS for patients treated with placebo plus AAP was 28.6 months (95% CI, 23.8, 32.95). Multivariate analysis considering the imbalance of baseline characteristics of the subjects showed that treatment with niraparib plus AAP was associated with better survival (HR = 0.682; 95% CI: 0.445, 1.046). Additionally, the data are still immature due to significant deletions at IA2.
[0014] Overall survival is generally defined as the average length of time a patient survives after starting treatment. Overall survival is often considered the “gold standard” (or ideal) primary endpoint in oncology because cancer patients often want medications that help them prolong their lives. However, demonstrating an overall survival advantage in clinical trials can be time-consuming, expensive, and challenging in other ways. Therefore, researchers use other clinical endpoints to demonstrate patient benefit, such as overall response rate and progression-free survival.
[0015] Therefore, there is a need to demonstrate, through overall survival data, the benefit of once-daily administration of niraparib 200 mg in combination with abiraterone acetate (AA) 1,000 mg and prednisone 10 mg in patients with mCRPC who have HRR gene alterations.
[0016] There is a need for approved pharmaceutical products that provide more effective and safer treatment options for patients with mCRPC who have HRR gene alterations, or that overcome potential treatment deficiencies of existing therapies.
[0017] There is a need for pharmaceutical products that provide more effective and safer treatment options for patients with mCRPC who have HRR gene alterations, or that overcome potential treatment deficiencies of existing therapies.
[0018] This disclosure addresses these needs by demonstrating improved overall survival in the BRCA-mutated subgroup of mCRPC patients compared to OS data obtained in IA1 and IA2.
[0019] The disclosed approved pharmaceutical products, treatments using these approved pharmaceutical products, and their medical uses are intended to meet these and other important needs.
[0020] The disclosed pharmaceutical products, treatments using these pharmaceutical products, and their medical uses are intended to meet these and other important needs. Specification 2 / 185 pages 8 CN 121443291 A Summary of the Invention
[0021] One object of the present invention is to provide a pharmaceutical product or approved pharmaceutical product having at least one indication or approved indication, wherein said pharmaceutical product or approved pharmaceutical product comprises niraparib and abiraterone acetate.
[0022] One object of the present invention is to provide a pharmaceutical product or approved pharmaceutical product wherein said pharmaceutical product or approved pharmaceutical product is indicated in combination with prednisone for the treatment of patients with a harmful or suspected harmful breast cancer mutation (BRCAm) mCRPC detected by a test or approved test.
[0023] One object of the present invention is to provide a pharmaceutical product or approved pharmaceutical product wherein, in patients with harmful or suspected harmful BRCAm mCRPC detected by a test or approved test, said pharmaceutical product or approved pharmaceutical product induces a median overall survival (OS) of 30.4 months with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
[0024] One object of the present invention is to provide a pharmaceutical product or approved pharmaceutical product wherein, after multivariate Cox regression analysis, the HR for median OS is 0.663 (95% CI: 0.464, 0.947), which adjusts for externally validated and clinically relevant baseline prognostic factors selected from prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (Alk Phos), age, Eastern Cooperative Oncology Group (ECOG) grade, number of bone lesions, and visceral disease.
[0025] One object of the present invention is to provide a method for treating a patient with metastatic castration-resistant prostate cancer (mCRPC) who has been diagnosed with a harmful or suspected harmful BRCAM by a test or approved test, the method comprising administering a pharmaceutical product or approved pharmaceutical product as defined herein in combination with prednisone to the patient.
[0026] One object of the present invention is to provide a pharmaceutical product or approved pharmaceutical product as defined herein for use in a method for treating a patient with metastatic castration-resistant prostate cancer (mCRPC) who has been diagnosed with a harmful or suspected harmful BRCAM by a test or approved test, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone.
[0027] One object of the present invention is to provide a pharmaceutical product or approved pharmaceutical product comprising niraparib and abiraterone acetate, which is used in combination with prednisone or prednisone in a method for treating an adult patient with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations (germline and / or somatic mutations) who has no clinical indication for chemotherapy.The drugs are used together; wherein a BRCA-positive status is determined using a validated test method; wherein a single daily dose of the drug product or approved drug product is 200 mg niraparib and 1,000 mg abiraterone acetate, and a daily dose of prednisone or prednisolone is 10 mg, until disease progression or unacceptable toxicity occurs; characterized in that the treatment improves median overall survival (OS) to 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120). Figure Description
[0028] Figure 1: Kaplan-Meier plot of overall survival in BRCA+ patients (cohort 1), one group receiving niraparib and abiraterone acetate plus prednisone, and the other group receiving placebo and abiraterone acetate plus prednisone.
[0029] Figure 2: Forest plot of overall survival for subgroups defined by baseline clinical disease characteristics (Cohort 1 BRCA) Figure 3a: Kaplan-Meier plot of time to symptom progression (TSP) for BRCA+ patients (Cohort 1), one group receiving niraparib and abiraterone acetate plus prednisone, and the other group receiving placebo and abiraterone acetate plus prednisone. Patients receiving niraparib and abiraterone acetate plus prednisone had a delayed TSP. NE: Not estimable.
[0030] Figure 3b: Kaplan-Meier plot of time to start cytotoxic chemotherapy (TCC) for BRCA+ patients (Cohort 1), one group receiving niraparib and abiraterone acetate plus prednisone, and the other group receiving placebo and abiraterone acetate plus prednisone. Patients receiving niraparib and abiraterone acetate plus prednisone had a delayed TCC. NE: Not estimable.
[0031] Figure 4: Kaplan-Meier plot of radiographic progression-free survival assessed by BICR in the BRCA population (MAGNITUDE, primary analysis) Instructions for use 3 / 185 pages 9 CN 121443291 A Figure 5: Kaplan-Meier plot of radiographic progression-free survival of BRCAm mCRPC patients in MAGNITUDE cohort 1 as reviewed by the center Figure 6: Kaplan-Meier plot of radiographic progression-free survival assessed by BICR in the BRCAm population (MAGNITUDE, primary analysis) Figure 7: Kaplan-Meier plot of overall survival in the BRCAm population (MAGNITUDE, final analysis) Figure 8: Method of administration. Press and hold Figure 9: Method of administration. Pull out Figure 10: Packaging instructions. Fold to close Figure 11: Packaging instructions. Flip open Detailed Description
[0032] The disclosed pharmaceutical product or approved pharmaceutical product, method and use can be more easily understood by referring to the following detailed description. It should be understood that the disclosed or approved drug products, methods, and uses are not limited to those described herein.And / or specific pharmaceutical products or approved pharmaceutical products, methods, and uses are shown, and the terminology used herein is for the purpose of describing particular embodiments by way of example only and is not intended to limit the pharmaceutical products or approved pharmaceutical products, methods, and uses protected by the claims.
[0033] Unless otherwise specifically stated, any description of possible mechanisms of action, modes of action, or reasons for improvement is intended to be illustrative only, and the disclosed pharmaceutical products or approved pharmaceutical products, methods, and uses are not limited to the correctness of any such suggested mechanisms of action, modes of action, or reasons for improvement.
[0034] Throughout this text, descriptions relate to pharmaceutical products or approved pharmaceutical products, methods, and uses. If this disclosure describes or claims a feature or embodiment associated with a pharmaceutical product or approved pharmaceutical product, that feature or embodiment also applies to the methods and uses. Similarly, if this disclosure describes or claims a feature or embodiment associated with the methods or uses, that feature or embodiment also applies to the pharmaceutical product or approved pharmaceutical product.
[0035] Every patent, patent application, and entire disclosure published that is referenced or described in this document is hereby incorporated by reference.
[0036] Definitions as used above and throughout this disclosure, unless otherwise specified, the following terms and abbreviations should be understood to have the following meanings.
[0037] In this disclosure, unless the context clearly indicates otherwise, the singular forms “an,” “a,” “the,” and “described” include plural meanings, and references to a given numerical value include at least that value. Thus, for example, a reference to “ingredient” refers to one or more such ingredients, as well as equivalents of that ingredient known to those skilled in the art, etc. Furthermore, when indicating that an element “may be” X, Y, or Z, such usage is not intended in all cases to exclude other options for that element.
[0038] When the term “about” is used above to express a value as an approximation, it should be understood that the specific value constitutes another embodiment. For the sake of providing a more concise description, some quantitative expressions given herein are not modified by the term “about.” It should be understood that, whether or not the term "about" is explicitly used, each quantity given herein is intended to refer to an actual given value, and also to an approximation of these given values that would be reasonably inferred based on ordinary techniques in the art, including approximations of these given values caused by experimental and / or measurement conditions.
[0039] For the sake of a more concise description, some quantitative expressions herein are stated as a range of about X to about Y. It should be understood that when a range is stated, the range is not limited to the upper and lower limits stated, but should include the entire range of about X to about Y, or any quantity or range therein. Where applicable, all ranges include end values and are combinable.For example, when referring to the range “1 to 5”, the range should be understood to include the ranges “1 to 4”, “1 to 3”, “1 to 2”, “1 to 2 and 4 to 5”, “1 to 3 and 5”, etc. Furthermore, when a list of alternatives is provided affirmatively, such a list may also include embodiments in which any of the alternatives may be excluded. For example, when describing the range “1 to 5”, such a description may cover cases in which any of 1, 2, 3, 4, or 5 is excluded; therefore, a reference to “1 to 5” may cover “1 and 3 to 5, but not 2”, or simply “not including 2”.
[0040] With respect to pharmaceutical formulations, compositions, or ingredients, the term “acceptable” as used herein means that it does not have a persistently harmful effect on the overall health of the human being treated.
[0041] The term “AAP” refers to abiraterone acetate plus prednisone or prednisolone.
[0042] The term "androgen deprivation therapy (ADT)" refers to a treatment method that reduces the level of androgens produced by the testes of a prostate cancer patient to castration levels (<50 ng / dL) through surgery or medication. This treatment may include orchiectomy or the use of gonadotropin-releasing hormone agonists or antagonists. ADT includes surgical castration (orchiectomy) and / or administration of a luteinizing hormone-releasing hormone ("LHRH") agonist. Examples of LHRH agonists include goserelin acetate, histaminerelin acetate, leuprorelin acetate, and triptorelin palmitate. Physicians may prescribe LHRH agonists based on instructions, advice, and practice. This may include: administering about 0.01 mg to about 20 mg of goserelin over a period of about 28 days to about 3 months, preferably about 3.6 mg to about 10.8 mg of goserelin over a period of about 28 days to about 3 months; administering about 0.01 mg to about 200 mg of leuprorelin acetate over a period of about 3 days to about 12 months, preferably about 3.6 mg of leuprorelin acetate over a period of about 3 days to about 12 months; or administering about 0.01 mg to about 20 mg of triptorelin over a period of about 1 month, preferably about 3.75 mg of triptorelin over a period of 1 month; or administering about 50 mg of histamine relin acetate or about 50 µg of histamine relin acetate daily over a period of 12 months.
[0043] The term “approved” when referring to a pharmaceutical product and at least one medical indication means that a pharmaceutical product containing one or more active pharmaceutical ingredients has been approved for marketing by a government regulatory agency for the treatment of at least one medical indication. Such government regulatory agencies include, but are not limited to, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the National Medical Products Administration of China (NMPA), the Pharmaceuticals and Medical Devices Agency of Japan (PMDA), or similar regulatory agencies in other countries. This disclosure also relates to approval by the EMA, FDA, or Health Canada, or similar regulatory agencies in other countries.Approved pharmaceutical products containing niraparib and abiraterone acetate, with at least one indication being prostate cancer.
[0044] The term "pharmaceutical product" means a pharmaceutical product containing one or more active pharmaceutical ingredients marketed for at least one indication, such as prostate cancer.
[0045] The term "ARi" refers to an androgen receptor inhibitor.
[0046] The term "BM" refers to a biomarker.
[0047] The term "BPI-SF" refers to a simplified version of the Brief Pain Scale.
[0048] The terms "BRCA+", "BRCAm", "BRCA positive status" or similar terms refer to the mutated or altered forms of breast cancer genes BRCA1 and BRCA2, whether germline and / or somatic mutations, which are harmful or suspected of being harmful in prostate cancer. BRCA+, BRCam, or BRCA positive status is determined or detected by an approved or validated test method.
[0049] As used herein, the term "cancer" refers to the abnormal growth of cells that tend to proliferate in an uncontrolled manner, and in some cases refers to metastasis (spread).
[0050] The term “chemotherapy-naïve metastatic castration-resistant prostate cancer” refers to metastatic castration-resistant prostate cancer that has not been previously treated with chemotherapy.
[0051] The term “clinically effective dose” means a dose of niraparib and abiraterone acetate pharmaceutical product or approved drug information leaflet 5 / 185 page 11 CN 121443291 A that achieves improved overall survival, delayed progression, controlled growth, delayed distant metastasis, improved symptoms or growth of prostate cancer in patients, or improved quality of life in patients with prostate cancer (measured by BPI-SF (Short Version of the Brief Pain Scale) pain score), as demonstrated by efficacy data obtained from clinical trials.
[0052] As used herein, the terms “co-administration” and the like cover the administration of selected therapeutic agents to a single patient and are intended to include treatment regimens that administer these agents via the same or different routes of administration or at the same or different times.
[0053] As used herein, the term “CRPC” refers to castration-resistant prostate cancer. CRPC is a type of prostate cancer that continues to grow despite the suppression of androgens that provide energy for the growth of prostate cancer cells.
[0054] The transitional terms “comprising,” “substantially consisting of,” and “consisting of” are intended to imply their accepted meaning in patent terminology; that is, (i) “comprising” is synonymous with “including,” “containing,” or “characterized by” and is inclusive of the end value or open at the end, and does not exclude additional, unlisted elements or method steps; (ii) “consisting of” excludes any element, step, or ingredient not specified in the claims; and (iii) “substantially consisting of” expands the scope of the claims.The limitation is to the specified materials or steps "and materials or steps that do not substantially affect the essential and novel features of the invention protected by the claims". Embodiments described in the phrase "comprising" (or its equivalents) are also provided, as are those independently described as "consisting of" and "substantially consisting of".
[0055] When a list is provided, it should be understood, unless otherwise indicated, that each individual element in the list and each combination of the list is a separate embodiment. For example, a list of embodiments presented as "A, B, or C" will be understood to include embodiments "A", "B", "C", "A or B", "A or C", "B or C", or "A, B, or C".
[0056] The term "ECOG PS" refers to Eastern Cooperative Oncology Performance Status.
[0057] The terms "HRR+" or "HRRm" refer to genes in a mutated or altered form within the homologous recombination repair gene family that are harmful or suspected of being harmful in prostate cancer.
[0058] The terms "excipient" and "vector" are used interchangeably in this disclosure. The European Pharmacopoeia (Ph.Eur.) defines excipients as "any component other than the active substance present in or used in the manufacture of a pharmaceutical product. The intended function of an excipient is to act as a carrier (mediator or base) or as a carrier of the active substance, and in doing so contributes to product properties such as stability, biopharmaceutical properties, appearance and patient acceptability, and to facilitate the manufacture of the product. Typically, more than one excipient is used in the formulation of a pharmaceutical product." The terms mediator and base are further defined in the same pharmacopoeia as: "a mediator is a carrier of the active substance in a liquid formulation consisting of one or more excipients" and "a base is a carrier of the active substance in a semi-solid and solid formulation consisting of one or more excipients."
[0059] As used herein, a "fixed-dose combination" (FDC) is a pharmaceutical formulation or composition comprising abiraterone acetate and niraparib, and any pharmaceutically acceptable salt, solvate, and hydrated form thereof (e.g., niraparib tosylate monohydrate), in a single oral dosage form.
[0060] A “free-dose combination” (FrDC) refers to a pharmaceutical preparation or composition containing two or more active ingredients administered to humans in separate dosage forms. For example, 1) a tablet containing abiraterone acetate; and 2) a single tablet containing niraparib and any pharmaceutically acceptable salt, solvate, and hydrate form thereof (e.g., niraparib tosylate monohydrate).
[0061] The terms “kit” and “manufactured article” are used as synonyms.
[0062] A “label” or “approved product label” refers to a label for a prescription drug for human use that (1) contains a summary of the essential scientific information required for the safe and effective use of the drug; and (2) includes prescription information, FDA-approved patient identification (medication guide, etc.).Patient medication guidelines and / or instructions for use), and / or box and container labeling. In some embodiments, the label or approved product label identifies niraparib and abiraterone acetate, or their trade name Akeega®, and provides instructions for their use in patients, page 6 / 185, 12 CN 121443291 A.
[0063] “Prescription Information” or “United States Prescription Information (USPI)” reflects the assessment of a regulatory agency (e.g., FDA, EMA) regarding the safety and efficacy of a human prescription drug under labeled conditions of use. Prescription information is prepared for a healthcare professional and must: 1. contain a summary of the essential scientific information required for the safe and effective use of the human prescription drug; 2. provide information accurately and in a tone that is neither promotional nor false or misleading; and 3. be updated when new information becomes available that would render the label inaccurate, false, or misleading.
[0064] A “Medication Guide” is a patient identifier and part of the labeling of FDA-approved prescription drugs. The FDA requires certain prescription drugs to be accompanied by this guide when it determines that: • the patient identifier may help prevent serious adverse reactions; • the drug presents a serious risk (relative to the benefit) that the patient should be aware of, as information about the risk may influence the patient’s decision to use or continue using the product; or • patient compliance with the instructions for use is essential to the effectiveness of the drug.
[0065] Patient medication guides contain information intended for patient use and may be required as part of the labeling of approved drug products.
[0066] Instructions for use (IFU) are: a form of prescription drug identifier typically created for drug products with complex or detailed patient instructions for use that have been reviewed and approved by the FDA under an NDA, BLA, or ANDA, and are typically provided to the patient when the drug product is dispensed.
[0067] According to European law (Council Directive 2001 / 83 / EEC Article 54), the following should appear on the outer packaging of the medicine, or, if no outer packaging is available, on the direct packaging: (a) the name of the medicine, followed by its strength and form, and (if applicable) whether it is intended for use in infants, children, or adults; if the product contains up to three active ingredients, the International Nonproprietary Name (INN) should be included, or if no INN is available, the generic name should be used; (b) a qualitative and quantitative description of the active ingredient contained in each dose unit or in the form of administration according to a specific volume or weight, and its generic name; (c) the dosage form and the weight, volume, or dose number of the product; (d) a list of excipients known to have recognized effects or benefits, which is included in the detailed guidance issued under Article 65. However, if the product is an injectable, or a topical or ocular preparation, all excipients must be described;(e) Method of administration, and, where necessary, route of administration. Sufficient space should be provided to indicate the prescribed dosage; (f) Special warnings indicating that the medicine must be stored out of the reach and sight of children; (g) Special warnings (if necessary for the medicine); (h) Clearly stated expiry date (month / year); (i) Special storage precautions (if any); (j) Specific precautions (if applicable) regarding the disposal of unused medicines or medicine-derived waste, and reference to any appropriate existing collection system; (k) Name and address of the marketing authorization holder, and (if applicable) the name of the representative designated by the holder to act on its behalf; (l) Marketing authorization number; (m) Manufacturer's batch number; Instructions for use 7 / 185 pages 13 CN 121443291 A (n) For over-the-counter medicines, instructions for use; (o) For medicines other than radiopharmaceuticals referred to in section 54a(1), safety features enabling wholesale distributors and authorized or qualified persons to supply medicines to the public to: — verify the authenticity of the medicine, and — identify individual packages, and allow for verification of whether the outer packaging has been tampered with.
[0068] The term “metastatic castration-resistant prostate cancer” or “mCRPC” refers to castration-resistant prostate cancer that has metastasized to other parts of the body (e.g., male bones, lymph nodes, or other parts of the body).
[0069] The term “metastatic castration-sensitive prostate cancer” refers to cancer that has spread (metastasized) to other areas of the body, such as bones, lymph nodes, or other parts of the male body and responds to androgen deprivation therapy (ADT).
[0070] The term “offer for sale” refers to a proposal by a seller to sell a pharmaceutical product, such as a pharmaceutical composition and an oral dosage form, to a buyer.
[0071] The term “overall survival” is defined as the average length of time a patient survives from the start of treatment.
[0072] The term “PFS” refers to progression-free survival.
[0073] The term “pharmaceuticalally acceptable”, when used in connection with the compositions described herein, refers to the molecular entity and other components of such compositions that are physiologically tolerable and generally do not produce adverse effects when administered to humans. The term “pharmaceuticalally acceptable” also means approved by a federal or state regulatory agency, or listed in the United States Pharmacopeia or other recognized pharmacopoeia for use in mammals, and more specifically for use in humans.
[0074] As used herein, the term “drug combination” means a product resulting from a mixture or combination of more than one active ingredient and including both fixed and non-fixed combinations of active ingredients.
[0075] As used herein, the term “placebo” means administration of a drug composition containing abiraterone acetate and prednisone but not niraparib.
[0076] “Progression-free survival at first follow-up treatment” (PFS2) is defined as the period from randomization to first follow-up treatment.The date of progression (radiographic, clinical, or PSA progression) or death from any cause (whichever occurs first). General rules for PFS2 events and censoring: 1. For patients starting subsequent anticancer therapy: a. If disease progression or death occurs during the first subsequent anticancer therapy, this is a PFS2 event, and the PFS2 date = the minimum of the disease progression date and the death date.
[0077] b. If there is no disease progression during the first subsequent anticancer therapy and no death before the start of the second subsequent anticancer therapy, this is not a PFS2 event, and the subject will be reviewed 1 day after the start date of the second subsequent anticancer therapy.
[0078] c. If there is no disease progression and no death during the first subsequent anticancer therapy and no start of the second subsequent anticancer therapy, this is not a PFS2 event, and the subject will be screened on the last known survival date.
[0079] 2. For patients who have not received any subsequent anticancer therapy: a. If the patient dies, this is a PFS2 event, and the PFS2 date is the date of death.
[0080] b. If the patient does not die, this is not a PFS2 event, and the subject will be censored on the last known survival date.
[0081] As used herein, the term “prostate cancer” refers to histologically or cytologically confirmed prostate adenocarcinoma.
[0082] The term “PSA” refers to prostate-specific antigen.
[0083] As used herein, the term “PSA50 response” means a 50% decrease in serum prostate-specific antigen from baseline. Specification 8 / 185 pages 14 CN 121443291 A
[0084] The term “radiographic progression-free survival” (rPFS) is defined as the time interval from the randomization date to the date of first radiographic progression or death from any cause (whichever occurs first). Radiographic progression is determined by the first occurrence of progression on bone scan (according to PCWG3 criteria) or by the first occurrence of soft tissue lesion progression on CT or MRI (according to RECIST 1.1 criteria).
[0085] Imaging progression should be evaluated as follows: • Progression of soft tissue lesions as measured by CT or MRI, defined according to RECIST 1.1.
[0086] • Progression of bone lesions as observed by bone scan and PCWG3. Under these criteria, any bone progression must be confirmed by a subsequent scan ≥6 weeks later. The week 8 scan (scan after the first treatment) is used as a baseline, and all subsequent scans are compared to it to determine progression. A bone scan is defined as one of the following: 1. Subjects whose week 8 scan shows ≥2 new bone lesions will fall into one of the following two categories: a. Subjects whose confirmatory scan (performed ≥6 weeks later) shows ≥2 new lesions compared to the week 8 scan (i.e., a total of ≥4 new lesions compared to the baseline scan) will be considered to have bone progression at week 8.
[0087] b. Subjects whose confirmatory scans did not show ≥2 new lesions compared to the week 8 scan will not be considered to have bone scan progression. The week 8 scan will be considered the baseline scan, and subsequent scans will be compared to it. The first scan time point showing ≥2 new lesions compared to the week 8 scan will be considered the bone scan progression time point, provided that these new lesions are confirmed by subsequent scans ≥6 weeks later.
[0088] 2. For patients whose week 8 scan did not show ≥2 new bone lesions compared to the baseline scan, the first scan time point showing ≥2 new lesions compared to the week 8 scan will be considered the bone scan progression time point if these new lesions are confirmed in subsequent scans ≥6 weeks later.
[0089] Patients who have not experienced radiographic progression or death will be censored if they have never started subsequent anticancer therapy, and if they have started subsequent anticancer therapy, the last disease assessment date before starting subsequent anticancer therapy will be censored. The key censoring rules are summarized below.
[0090] When referring to clinical trial design, the term “randomization” is the time it takes for a patient to be identified as eligible for a clinical trial and assigned to a particular treatment group.
[0091] The term “reference preparation (RLD)” is an approved pharmaceutical product to which a new generic version must be compared to demonstrate its bioequivalence (21 CFR 314.3(b)). It is also a pharmaceutical product that has obtained marketing authorization from an EU member state or the European Commission based on a complete dossier, i.e., by submitting quality, preclinical and clinical data in accordance with Articles 8(3), 10a, 10b or 10c of Directive 2001 / 83 / EC, and by demonstrating bioequivalence (usually by submitting appropriate bioavailability studies) in connection with a marketing authorization application for a generic / mixed pharmaceutical product.
[0092] In the United States, companies seeking approval to market a generic equivalent must include the product information in their Abbreviated New Drug Application (ANDA) along with the RLD. For example, ANDA applicants rely on FDA findings that previously approved drug products, i.e., RLDs, are safe and effective, and must, among other things, demonstrate that the proposed generic drug product is identical to the RLD in some respects. Specifically, with limited exceptions, the drug product for which an ANDA has been submitted must, among other things, have the same active ingredient, conditions of use, route of administration, dosage form, strength, and (with some permissible differences) labeling as the RLD. An RLD is a marketed drug for which an ANDA applicant must demonstrate that its proposed ANDA drug product is identical to the RLD in terms of active ingredient, dosage form, route of administration, strength, labeling, and other characteristics such as conditions of use. In the electronic Orange Book, there will be a section for RLDs and a section for reference standards. In the printed version of the Orange Book, RLDs and reference standards are identified by specific symbols.
[0093] In Europe, applicants identify a reference medicine (product name, strength, dosage form, marketing authorization holder (MAH), first authorization, member state / community) in their application for generic / mixed medicines (identical to ANDA or sNDA medicine products), which is synonymous with RLD, as follows: 1. A pharmaceutical product authorized or already authorized in the European Economic Area (EEA), used as the basis for demonstrating that the data protection period as defined in the European Medicines Regulation has expired. This reference medicine product is determined for the purpose of calculating the expiration of the data protection period and may differ from the generic / mixed medicine product in strength, dosage form, route of administration, or manifestation.
[0094] 2. A medicine (product name, strength, dosage form, MAH, marketing authorization number) whose file is cross-referenced in the generic / mixed application. For the purpose of calculating the expiration of the data protection period, this reference medicine product may have been authorized through a separate procedure and under a different name than the identified reference medicine product. The product information of this reference medicine product will, in principle, serve as the basis for the product information protected by the claims for the generic / mixed medicine product.
[0095] 3. Pharmaceutical products used for bioequivalence studies (product name, strength, form of medicine, MAH, member country of origin) (where applicable).
[0096] Different simplified approval pathways for pharmaceutical products under the FD&C Act are described in Sections 505(j) and 505(b)(2) of the FD&C Act (21 USC 355(j) and 21 USC 23 355(b)(2) respectively).
[0097] According to the FDA (www.fda.gov / downloads / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / UCM579751.pdf, the contents of which are incorporated herein by reference), NDAs and ANDAs can be classified into the following four categories: (1) An “independent NDA” is an application filed pursuant to section 505(b)(1) of the FD&C Act and approved pursuant to section 505(c), containing a complete report of safety and effectiveness studies performed by or on behalf of the applicant or which the applicant has the right to reference or use.
[0098] (2) A 505(b)(2) application is an NDA filed pursuant to section 505(b)(1) of the FD&C Act and approved pursuant to section 505(c), containing a complete report of safety and effectiveness studies, wherein at least some of the information required for approval comes from studies not performed by or on behalf of the applicant and which the applicant does not yet have the right to reference or use.
[0099] (3) An ANDA is an application for a copy of a previously approved drug product, filed and approved pursuant to Section 505(j) of the FD&C Act. An ANDA relies on the FDA’s finding that the previously approved drug product (i.e., the Reference Listed Drug (RLD)) is safe.And effective. ANDAs must generally contain information to show that the proposed generic product (a) is identical to the RLD in terms of active ingredient, conditions of use, route of administration, dosage form, strength, and labeling (with certain permissible differences), and (b) is bioequivalent to the RLD. If studies are required to determine the safety and effectiveness of the proposed product, an ANDA must not be submitted.
[0100] (4) A petition ANDA is an ANDA type for a pharmaceutical product that differs from the RLD in terms of its dosage form, route of administration, strength, or active ingredient (in products having more than one active ingredient), and the FDA, in response to a petition submitted under Section 505(j)(2)(C) (Adaptability Request) of the FD&C Act, has ruled that studies are not required to determine the safety and effectiveness of the proposed pharmaceutical product. Instructions for Use, 10 / 185 pages, 16 CN 121443291 A
[0101] The scientific premise of the Hatch-Waxman Amendment is that a pharmaceutical product approved in an ANDA under Section 505(j) of the FD&C Act is therapeutically equivalent to its RLD. When administered to a patient under the conditions specified on the label, a product classified as therapeutically equivalent may be substituted, and the substituted product is fully expected to produce the same clinical effects and safety characteristics as the prescription product. Compared to an ANDA, a 505(b)(2) application allows greater flexibility regarding the characteristics of the proposed product. A 505(b)(2) application will not necessarily be assessed as therapeutically equivalent to the marketed pharmaceutical product to which it was referenced at the time of approval.
[0102] The term “safe and effective amount” means the amount of an active ingredient that, in accordance with the revised Federal Food, Drug, and Cosmetic Act (Sections 201–902, 52 Statute 1040 and thereafter, revised; 21 USC §§ 321–392), elicits a desired biological or pharmaceutical response in a subject’s biological system, with a risk not exceeding the benefit of such response. Safety is typically measured by toxicity testing to determine the highest tolerated or optimal dose of the active pharmaceutical ingredient required to achieve the desired beneficial effect. Safety-focused studies also seek to identify any potential adverse effects that may result from exposure to the drug. When tested where appropriate, such as in tightly controlled clinical trials, efficacy is typically measured by determining whether the active pharmaceutical ingredient demonstrates a health benefit superior to placebo or other interventions.
[0103] In some embodiments, administration of the drug product or approved drug product results in an adverse event not exceeding Grade 2. In other embodiments, administration of the drug product or approved drug product results in an adverse event not exceeding Grade 3. In other embodiments, administration of the drug product or approved drug product results in an adverse event not exceeding Grade 4.
[0104] The terms “sale” or “disposal” mean the transfer of ownership of a pharmaceutical product or approved pharmaceutical product from a seller to a buyer in an arm’s length transaction.
[0105] The terms “subject” and “patient” and “person” are used interchangeably. Typically, a subject, patient, or person is a male subject, patient, or person.
[0106] As used herein, the term “survival benefit” refers to an increase in patient survival from the randomization time of drug administration trial to death. In some embodiments, the survival benefit is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 80, about 100 months, or more than 100 months.
[0107] The term “treatment” refers to achieving improved overall survival, delaying progression, controlling growth, postponing the occurrence of distant metastases, improving symptoms or growth of prostate cancer in a patient, or improving the quality of life of a patient with prostate cancer (measured by a BPI-SF (Short Version of the Brief Pain Scale) pain score). Delay in cancer progression includes inhibiting cancer progression, reducing the rate of cancer progression, or stopping the rate of cancer progression.
[0108] The term “time to start cytotoxic chemotherapy” or “time to start cytotoxic chemotherapy” (TCC) is defined as the time from randomization to the start of administration of a new cytotoxic chemotherapy to a subject (e.g., survival follow-up CRF). The time at which a subject who has not started cytotoxic chemotherapy begins cytotoxic chemotherapy is reviewed at the last contact date. Inadvertently, administration of the pharmaceutical product of this disclosure or an approved pharmaceutical product according to the product label provides treatment for mCRPC, and the effect is measured by the time to start cytotoxic chemotherapy.
[0109] Regarding the clinical trial design, “time to start subsequent treatment” is defined as the time from the randomization date to the date of initiation of subsequent anticancer therapy for prostate cancer. Patients who have not started subsequent anticancer therapy at the time of analysis will be at the last visit date prior to the last known survival date, or the last known survival date will be censored. Subsequent prostate cancer anticancer therapy will include the following categories: chemotherapy, hormone therapy, PARPi, and any other type of prostate cancer therapy.
[0110] The “time to PSA progression” in the clinical trial design is defined as the time from randomization to the date on which PSA progression is first recorded according to PCWG3 criteria. PSA progression is defined as a decrease from baseline of ≥25% and ≥2 ng / mL above the lowest point, confirmed by a second value ≥3 weeks later (i.e., a confirmed upward trend); and when there is no decrease from baseline (see page 11 / 185 of the instruction manual, 17 CN 121443291 A): an increase of ≥25% from baseline and ≥2 ng / mL over 12 weeks.
[0111] Patients without PSA progression at the time of analysis will be censored on the last known date of no progression. Patients with no baseline PSA or no post-baseline values will be censored on the randomization date.
[0112] The PSA response rate is the proportion of subjects who achieved a ≥50% decrease in PSA by week 12 according to PCWG3 criteria and whose response was confirmed after 3-4 weeks.
[0113] The “time to pain progression” in the clinical trial design was defined as the time from the randomization date to the date on which pain progression was first observed. Pain progression was defined as an increase of 2 points from baseline in the most severe pain intensity (item 3) observed in two consecutive assessments at an interval of ≥3 weeks in the BPI-SF. Subjects who did not experience pain progression at the time of analysis will be reviewed on the last date of the BPI-SF pain score collection.
[0114] The term “time to symptom progression” (TSP) in clinical trial design is defined as the time from randomization to the first occurrence of any of the following events: (i) external beam radiation therapy (EBRT) for skeletal symptoms; (ii) tumor-related orthopedic surgical intervention; (iii) other cancer-related procedures, such as nephrostomy, bladder catheterization, or surgery for non-skeletal tumor symptoms; (iv) initiation of new systemic anticancer therapy for cancer pain; (v) occurrence of cancer-related lesion events, such as fractures, symptomatic and / or pathological spinal cord compression, or urinary tract obstruction. These events are typically documented in a case report form (CRF) and may be reported as (1) occurrence of a skeletal-related event (SRE), such as a pathological fracture, spinal cord compression, or the need for surgical intervention or radiation therapy to the bones; (2) progression or worsening of pain in disease-related symptoms requiring the initiation of new systemic anticancer therapy; or (3) development of clinically significant symptoms due to local tumor progression requiring surgical intervention or radiation therapy. Administration of the pharmaceutical product of this disclosure or an approved pharmaceutical product provides improved treatment for mCRPC, the effect of which is measured by time to symptom progression.
[0115] Embodiments of this disclosure This disclosure relates to a pharmaceutical product or an approved pharmaceutical product having at least one indication or approved indication, wherein said pharmaceutical product or approved pharmaceutical product comprises niraparib and abiraterone acetate.
[0116] This disclosure relates to a pharmaceutical product or an approved pharmaceutical product having at least one indication or approved indication, wherein said pharmaceutical product or approved pharmaceutical product comprises niraparib and abiraterone acetate, wherein said at least one indication or approved indication is metastatic castration-resistant prostate cancer (mCRPC).
[0117] This disclosure relates to a pharmaceutical product or approved pharmaceutical product having at least one indication or approved indication, wherein the pharmaceutical product or approved pharmaceutical product comprises niraparib and abiraterone acetate, wherein the pharmaceutical product or approved pharmaceutical product is packaged, and wherein the package includes a label that identifies the pharmaceutical product or approved pharmaceutical product as indicated for use with prednisone in the treatment of patients with a pathogenic or suspected pathogenic breast cancer mutation (BRCAm) mCRPC detected by a test or approved test.
[0118] This disclosure relates to a pharmaceutical product or approved pharmaceutical product having at least one indication or approved indication, wherein the pharmaceutical product or approved pharmaceutical product is indicated in combination with prednisone for the treatment of patients with harmful or suspected harmful breast cancer mutations (BRCAm) mCRPC detected by a test or approved test.
[0119] This disclosure relates to a pharmaceutical product or approved pharmaceutical product having at least one indication or approved indication for the treatment of prostate cancer using a daily dose of 200 mg niraparib, 1,000 mg abiraterone acetate, and 10 mg prednisone, wherein niraparib and abiraterone acetate are administered as a fixed-dose combination pharmaceutical product or as a free-dose combination pharmaceutical product.
[0120] This disclosure relates to a pharmaceutical product or approved pharmaceutical product having at least one indication or approved indication, wherein the pharmaceutical product or approved pharmaceutical product is administered orally once daily in a dose of 200 mg niraparib and 1,000 mg abiraterone acetate, and in combination with a daily dose of 10 mg prednisone. Instructions for Use, Pages 12 / 185, CN 121443291 A
[0121] This disclosure relates to a pharmaceutical product or approved pharmaceutical product having at least one indication or approved indication, wherein in cases of bone marrow suppression accompanied by: (i) a platelet count < 100,000 / mcL, or (ii) a neutrophil count < 1,000 / mcL or a hemoglobin count < 8 g / dL; or in cases of other non-hematological grade 3 or 4 adverse reactions, the pharmaceutical product or approved pharmaceutical product is administered orally once daily at a reduced dose of 100 mg niraparib and 1,000 mg abiraterone acetate (together with 10 mg prednisone).
[0122] The pharmaceutical product or approved pharmaceutical product is administered on an empty stomach.
[0123] In one embodiment, no food is consumed for two hours before and one hour after taking the pharmaceutical product or approved pharmaceutical product.
[0124] Patients receiving this pharmaceutical product or an approved pharmaceutical product should also be receiving gonadotropin-releasing hormone (GnRH) analogue therapy concurrently, or the patient should have undergone bilateral orchiectomy.
[0125] GnRH analogues used as ADTs may be selected from, but are not limited to, triptorelin, nafarelin, goserelin, leuprorelin or leuprorelin, histaminerelin, gonadorelin and buserrelin.
[0126] This pharmaceutical product or an approved pharmaceutical product should not be administered to patients with moderate or severe hepatic impairment.
[0127] This pharmaceutical product or an approved pharmaceutical product should not be co-administered with the CYP3A4 inducer rifampin.
[0128] This disclosure relates to a pharmaceutical product or an approved pharmaceutical product comprising a pharmaceutical composition comprising a pharmaceutically acceptable carrier; and i. 100 mg niraparib and 500 mg abiraterone acetate, in an oral dosage form (conventional strength); orii. 50 mg niraparib and 500 mg abiraterone acetate, in oral dosage form (lower strength).
[0129] This disclosure relates to a pharmaceutical product or approved pharmaceutical product wherein, in patients with harmful or suspected harmful BRCAm mCRPC detected by a test or approved test, said pharmaceutical product or approved pharmaceutical product induces a median overall survival (OS) of 30.4 months with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
[0130] This disclosure relates to a pharmaceutical product or approved pharmaceutical product in which, after multivariate Cox regression analysis, the median overall survival (OS) hazard ratio (HR) was 0.663 (95% CI: 0.464, 0.947), which adjusted for external validation and clinically relevant baseline prognostic factors selected from prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (Alk Phos), age, Eastern Cooperative Oncology Group (ECOG) grade, number of bone lesions, and visceral disease.
[0131] This disclosure relates to a pharmaceutical product or approved pharmaceutical product in which, in patients with harmful or suspected harmful BRCAm mCRPC detected by a test or approved test, the pharmaceutical product or approved pharmaceutical product induced an improved median time to symptom progression (TSP) compared to patients receiving placebo and abiraterone acetate plus prednisone, with an HR of 0.562 (95% CI: 0.371, 0.849).
[0132] This disclosure relates to a pharmaceutical product or approved pharmaceutical product wherein, in patients with harmful or suspected harmful BRCAM mCRPC detected by a test or approved test, the pharmaceutical product or approved pharmaceutical product induces an improved median time to cytotoxic chemotherapy (TCC) compared to patients receiving placebo and abiraterone acetate plus prednisone, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0133] This disclosure relates to a pharmaceutical product or approved pharmaceutical product wherein, in patients with harmful or suspected harmful BRCAM mCRPC detected by a test or approved test, the pharmaceutical product or approved pharmaceutical product induces a median radiographic progression-free survival (rPFS) of 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0134] This disclosure relates to a pharmaceutical product or an approved pharmaceutical product, wherein the pharmaceutical product or approved pharmaceutical product comprises 159.40 mg of niraparib tosylate monohydrate (equivalent to 100 mg of niraparib free base) as an active ingredient, and 500 mg of abiraterone acetate. Specification 13 / 185 pages 19 CN 121443291 A
[0135] This disclosure relates to a pharmaceutical product or an approved pharmaceutical product, wherein the pharmaceutical product or approved pharmaceutical product comprises 7970 mg niraparib tosylate monohydrate (equivalent to 50 mg niraparib free base) is used as the active ingredient, and 500 mg abiraterone acetate.
[0136] This disclosure relates to a pharmaceutical product or approved pharmaceutical product, wherein the pharmaceutical composition is an oral dosage form selected from film-coated tablets, tablets, capsules, granules and sachets.
[0137] In one embodiment, the pharmaceutical composition is a film-coated tablet, further comprising colloidal anhydrous silica, cropovidone, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose and sodium lauryl sulfate; and a film coating.
[0138] In one embodiment, the film-coated tablet comprises 100 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc and titanium dioxide.
[0139] In one embodiment, the film-coated tablet comprises 50 mg of niraparib and 500 mg of abiraterone acetate; and the film coating comprises iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide.
[0140] In one embodiment, the pharmaceutical composition is a capsule comprising 100 mg of niraparib and 500 mg of abiraterone acetate, and a pharmaceutically acceptable carrier comprising cropovidone, hydroxypropyl methylcellulose, sodium lauryl sulfate (SLS), lactose monohydrate, and magnesium stearate.
[0141] In one embodiment, the pharmaceutical composition is a capsule comprising 50 mg of niraparib and 500 mg of abiraterone acetate, and a pharmaceutically acceptable carrier comprising cropovidone, hydroxypropyl methylcellulose, sodium lauryl sulfate, lactose monohydrate, and magnesium stearate.
[0142] These capsule formulations are capable of containing the active ingredients (niraparib and abiraterone acetate) in granule form. Chloroprene can be replaced by a suitable disintegrant; hydroxypropyl methylcellulose can be replaced by a suitable binder; SLS can be replaced by a suitable wetting agent; lactose monohydrate can be replaced by a suitable diluent or filler; and magnesium stearate can be replaced by a suitable lubricant.
[0143] This disclosure relates to a pharmaceutical product or approved pharmaceutical product, wherein the pharmaceutical product or approved pharmaceutical product is approved for marketing in the European Economic Area (EEA), Canada, the United States, Japan, China, and any other country.
[0144] This disclosure relates to a pharmaceutical product or approved pharmaceutical product, wherein the pharmaceutical product or approved pharmaceutical product is a generic drug, ANDA, sNDA, NDA product, or 505(b)(2) pharmaceutical product.
[0145] This disclosure also relates to a method for treating a patient with mCRPC who has been found to have a harmful or suspected harmful BRCAM by a test or approved test, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone to the patient.
[0146] This disclosure also relates to a method for treating a patient with mCRPC who has been diagnosed with harmful or suspected harmful BRCAM by a test or approved test, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone to the patient in the amount and manner described on the pharmaceutical product label or approved pharmaceutical product label.
[0147] The method of treating BRCAM mCRPC of this disclosure further includes oral administration once daily of a pharmaceutical product or approved pharmaceutical product containing 200 mg niraparib and 1,000 mg abiraterone acetate, while simultaneously administering 10 mg prednisone alone daily until disease progression or unacceptable toxicity occurs.
[0148] The method of treating BRCAM mCRPC of this disclosure further includes, in cases of myelosuppression accompanied by: (i) a platelet count < 100,000 / mcL, or (ii) a neutrophil count < 1,000 / mcL or a hemoglobin count < 8 g / dL; or, in cases of other non-hematologic grade 3 or 4 adverse events, oral administration once daily of a reduced dose of a pharmaceutical product or an approved pharmaceutical product containing 100 mg niraparib and 1,000 mg abiraterone acetate, concurrently with daily administration of 10 mg prednisone alone.
[0149] The method of treating BRCAM mCRPC of this disclosure further includes improving median OS to 30.4 months, with a HR of 0.788 (95% CI: 0.554, 1.120).
[0150] In one embodiment, median OS was further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464, 0.947). This multivariate Cox regression analysis adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0151] The method of treating BRCAM mCRPC of this disclosure also includes improvement in median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849).
[0152] The method of treating BRCAM mCRPC of this disclosure also includes improvement in median TCC, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0153] The method of treating BRCAm mCRPC according to this disclosure further includes improving the median rPFS to 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0154] This disclosure also relates to a method of marketing a pharmaceutical product or approved pharmaceutical product comprising niraparib and abiraterone acetate as defined herein, said method comprising marketing such pharmaceutical product or approved pharmaceutical product.
[0155] In one embodiment, the pharmaceutical product or approved pharmaceutical product is a generic drug, an ANDA pharmaceutical product, a supplemental new drug application pharmaceutical product, an NDA pharmaceutical product, or a 505(b)(2) pharmaceutical product.
[0156] In one embodiment, the reference formulation of such pharmaceutical product or approved pharmaceutical product improves OS, rPFS, TCC, TSP, or TPP.
[0157] In one embodiment, in the method of marketing the pharmaceutical product or approved pharmaceutical product disclosed herein, the median OS is 30.4 months, and the HR is 0.788 (95% CI: 0.554, 1.120).
[0158] In one embodiment, in the method of marketing a pharmaceutical product or an approved pharmaceutical product of this disclosure, the median overall survival (OS) hazard ratio (HR) was 0.663 (95% CI: 0.464, 0.947) after a multivariate Cox regression analysis that adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG classification, number of bone lesions, and visceral disease.
[0159] In one embodiment, in the method of marketing a pharmaceutical product or an approved pharmaceutical product of this disclosure, the median total sarcopenic purpura (TSP) was improved, with an HR of 0.562 (95% CI: 0.371, 0.849).
[0160] In one embodiment, in the method of marketing a pharmaceutical product or an approved pharmaceutical product of this disclosure, the median total toxicity (TCC) was improved, with an HR of 0.598 (95% CI: 0.387, 0.924).
[0161] In one embodiment, in the method of marketing a pharmaceutical product or approved pharmaceutical product of this disclosure, the median rPFS was 19.5 months, and the HR was 0.553 (95% CI: 0.392, 0.782).
[0162] This disclosure also relates to a method of marketing a pharmaceutical product or approved pharmaceutical product comprising niraparib and abiraterone acetate as defined herein, the method comprising marketing such pharmaceutical product or approved pharmaceutical product.
[0163] In one embodiment, the pharmaceutical product or approved pharmaceutical product is a generic drug, an ANDA pharmaceutical product, a supplemental new drug application pharmaceutical product, an NDA pharmaceutical product, or a 505(b)(2) pharmaceutical product.
[0164] In one embodiment, a reference formulation of such pharmaceutical product or approved pharmaceutical product improves OS, rPFS, TCC, TSP, or TPP.
[0165] In one embodiment of the method of providing a pharmaceutical product or an approved pharmaceutical product disclosed herein, the median overall survival (OS) was 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
[0166] In one embodiment, after multivariate Cox regression analysis, the HR for median OS was 0.663 (95% CI: 0.663).CI: 0.464, 0.947), this multivariate Cox regression analysis adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0167] In one embodiment, median TSP data was improved, with a HR of 0.562 (95% CI: 0.371, 0.849).
[0168] In one embodiment, median TCC data was improved, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0169] In one embodiment, median rPFS was 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0170] This disclosure also relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method of treating mCRPC patients who have been diagnosed with harmful or suspected harmful BRCAM by a test or approved test, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone.
[0171] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method of treating mCRPC patients who have been diagnosed with harmful or suspected harmful BRCAM by a test or approved test, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein the treatment comprises an oral administration once daily of a dose of 200 mg niraparib and 1,000 mg abiraterone acetate of the pharmaceutical product or approved pharmaceutical product, and 10 mg prednisone, until disease progression or unacceptable toxicity occurs.
[0172] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method of treating mCRPC patients with a harmful or suspected harmful BRCAM detected by a test or approved test, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein the treatment comprises, once daily, oral administration of a reduced dose of the pharmaceutical product or approved pharmaceutical product containing 100 mg niraparib and 1,000 mg abiraterone acetate, and 10 mg prednisone, in the presence of: (i) platelet count < 100,000 / mcL, or (ii) neutrophil count < 1,000 / mcL or hemoglobin count < 8 g / dL; or in the presence of other non-hematologic grade 3 or 4 adverse events.
[0173] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method of treating mCRPC patients with harmful or suspected harmful BRCAM detected by a test or approved test, the method comprising administering said pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein the treatment comprises improving median OS to 30.4 months, with a hazard ratio (HR) of 0.788 (95%).CI: 0.554, 1.120).
[0174] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method for treating mCRPC patients with harmful or suspected harmful BRCAM detected by a test or approved test, the method comprising administering said pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein, after a multivariate Cox regression analysis, median OS was further improved, with a HR of 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0175] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method of treating mCRPC patients with harmful or suspected harmful BRCAM detected by a test or approved test, the method comprising administering said pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein the treatment comprises improving median TSP, HR 0.562 (95% CI: 0.371, 0.849).
[0176] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method of treating mCRPC patients with harmful or suspected harmful BRCAM detected by a test or approved test, the method comprising administering said pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein the treatment comprises improving median TCC, HR 0.598 (95% CI: 0.387, 0.924).
[0177] This disclosure relates to a pharmaceutical product or approved pharmaceutical product as defined herein, used in a method for treating mCRPC patients who have a harmful or suspected harmful BRCAM detected by a test or approved test as described on page 16 / 185 of CN 121443291 A, the method comprising administering the pharmaceutical product or approved pharmaceutical product in combination with prednisone, wherein the treatment comprises improving median rPFS to 19.5 months, with an HR of 0.553 (95% CI: 0.392, 0.782).
[0178] This disclosure also relates to a pharmaceutical product or approved pharmaceutical product comprising niraparib and abiraterone acetate, used in combination with prednisone or prednisolone in a method of treating adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1 / 2 mutations (germline and / or somatic mutations) who have no clinical indication for chemotherapy; wherein BRCA positive status is determined using a validated test method; wherein a single daily dose of the pharmaceutical product or approved pharmaceutical product is 200 mg niraparib and 1,000 mg abiraterone acetate, and a daily dose of prednisone or prednisolone is 10 mg, until disease progression or unacceptable toxicity occurs;The treatment is characterized by improving median overall survival (OS) to 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
[0179] In one embodiment, median OS was further improved after multivariate Cox regression analysis, with an HR of 0.663 (95% CI: 0.464, 0.947), which adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0180] In one embodiment, the treatment includes improving median TSP, with an HR of 0.562 (95% CI: 0.371, 0.849).
[0181] In one embodiment, the treatment includes improving median TCC, with an HR of 0.598 (95% CI: 0.387, 0.924).
[0182] In one embodiment, the treatment includes improving median rPFS to 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0183] Niraparib is an orally available, highly selective poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor that is active against PARP-1 and PARP-2 deoxyribonucleic acid (DNA) repair polymerases. The preparation of niraparib is described in U.S. Patents Nos. 8,071,623 and 8,436,185, both of which are incorporated herein by reference.
[0184] As used herein, the term “niraparib” means the salt form (including pharmaceutically acceptable salts) of the free base compound (2-[4-[(3S)-piperidin-3-yl]phenyl]-2H-indazole-7-carboxamide), 2-[4-[(3S)-piperidin-3-yl]phenyl]-2H-indazole-7-carboxamide (e.g., 4-methylbenzenesulfonic acid; 2-[4-[(3S)-piperidin-3-yl]phenyl]-2H-indazole-7-carboxamide), and / or its solvated form, including the hydrated form (e.g., 2-[4-[(3S)-piperidin-3-yl]phenyl]-2H-indazole-7-carboxamide toluenesulfonate monohydrate). Such forms may be referred to as “niraparib free base,” “niraparib toluenesulfonate,” and “niraparib toluenesulfonate monohydrate,” respectively.
[0185] The terms “niraparib eq.” or “niraparib equivalent” refer to a dose of free base of niraparib.
[0186] In any embodiment of the pharmaceutical product or approved pharmaceutical product, the treatment method using the pharmaceutical product or approved pharmaceutical product, or its medical use as presented herein, niraparib is in the form of a salt of tosylate monohydrate. OtherNiraparib salt forms are also covered in this disclosure, provided that these niraparib salt forms are bioequivalent to niraparib tosylate monohydrate. Examples of such forms are sulfates, benzenesulfonates, fumarates, succinates, camphorate salts, mandelates, camphorsulfonates, lauryl sulfates, or mixtures of tosylate monohydrate and lauryl sulfates.
[0187] Abiraterone acetate Abiraterone acetate is a compound having the following formula: and is a prodrug of abiraterone, a highly selective orally active inhibitor of a key enzyme in testosterone synthesis (17α-hydroxylase-C17,20-lyase), also known as a steroid 17α-monooxygenase inhibitor or human cytochrome P450 17α. Inhibition of testosterone synthesis in patients with prostate cancer has been demonstrated with abiraterone acetate. This compound is disclosed in WO 93 / 20097 (A1) and is commercially available, for example, through the brand Zytiga®.
[0188] Abiraterone acetate plus prednisone or prednisolone is approved for patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). Abiraterone acetate tablets are currently marketed as 250 mg or 500 mg oral tablets.
[0189] In cases where “prednisone” is specifically mentioned in this disclosure, those skilled in the art will recognize that prednisone can be replaced with different glucocorticoids, such as prednisolone, hydrocortisone, methylprednisolone, or dexamethasone. Those skilled in the art will know how to substitute prednisone with these other drugs and adjust their dosages (if necessary).
[0190] Particularly suitable glucocorticoids include, but are not limited to: (1) dexamethasone (e.g., decadron, oral; decadron-LA injection, etc.), (2) prednisolone (e.g., Δ-CORTEF®, prednisolone acetate (ECONOPRED®), prednisolone sodium phosphate (HYDELTRASOL®), prednisolone tert-butyl acetate (HYDELTRA-TBA®, etc.)), (3) prednisone (DELTASONE®, etc.), or (4) methylprednisolone (e.g., MEDROL®), and combinations thereof. See, for example, The Pharmacological Basis of Therapeutics by Goodman and Gilman, 10th edition, 2001.
[0191] Testing or approved testing in any embodiment of the pharmaceutical product or approved pharmaceutical product, the treatment method using the pharmaceutical product or approved pharmaceutical product, or its medical use, as presented herein, germline and / or somatic HRR gene alterations, particularly harmful orSuspected harmful BRCA mutations (BRCAm) are identified using validated testing methods. BRCA genes refer to BRCA1 and BRCA2 genes.
[0192] Examples of commercially available germline and somatic tests for prostate cancer are provided below: Specification 18 / 185 pages 24 CN 121443291 A Test or approved test can determine a positive biomarker status for homologous recombination defect (HRD). HRD, also known as homologous recombination repair (HRR) gene defect or alteration, may originate from DNA repair gene defect (DRD) in a specific DNA repair gene. HRD or HRR gene alteration encompasses DRD as well as those gene mutations or alterations outside of DNA repair pathways.
[0193] The positive status for HRD (or HRR gene defect or harmful alteration) can be detected by evaluating monoallelic or bialelic, germline and / or somatic alterations in one or more DNA repair genes, or by evaluating genome-wide loss of heterozygosity (LOH) or homozygous harmful alterations in DNA repair genes. HRD (or HRR gene defect or alteration) positive status is also synonymous with PARP biomarker positive status.
[0194] Detrimental or suspected detrimental DNA repair genes include, but are not limited to: mutated BRCA2 (breast cancer gene 2), mutated BRCA1 (breast cancer gene 1), mutated ATM (ataxia-telangiectasia mutant gene), mutated BRIP1 (BRCA1 interacting protein C-terminal helicase 1 gene), mutated CHEK2 (checkpoint kinase 2 gene), mutated FANCA (Fanconi anemia complement A gene), mutated HDAC2 (histone deacetylase 2), mutated PALB2 (BRCA2 chaperone and localizer gene), or mutated CDK12 (cyclin-dependent kinase 12).
[0195] Germline and / or somatic HRR gene alterations are determined using validated assays. HRR status can be evaluated, preferably by plasma-based (Resolution Bioscience, Inc.) or tissue-based (Basic Medical, Inc.) tests, particularly by detecting circulating plasma DNA or circulating tumor cells. A list of tests for determining germline and / or somatic HRR gene alterations is provided above and below.
[0196] Gene expression profiling and protein biomarkers can also be used for risk stratification of patients with prostate cancer to guide treatment decisions. Commercially available tests include Prolaris® (Merlead Genetics, Salt Lake City, Utah); OncotypeDx® Prostate Cancer Assay (Genomic Health, Redwood City, California).City, CA); ProMark™ Protein Biomarker Test / ProMark™ Risk Score (Metamark Genetics, Cambridge, MA); FoundationOne® CDx (Basic Medical, Cambridge, MA); FoundationOne® Liquid CDx (Basic Medical, Cambridge, MA); Caris Molecular Intelligence (Caris Life Sciences, Oklahoma, Texas); Guardant360 (Quardent Health, Redwood City, CA); ProstateNext® (Ambri Genetics, Aristotle, CA); Color Genetic Cancer Test (Color Gene, Burlingame, CA); Invitae Prostate Cancer Kit (Invitae, San Francisco, CA); Prostate Genetics (Genome, Cambridge, UK); MyRisk® Genetic Cancer Test (MyRisk Genetics, Salt Lake City, Utah); and Decipher® Prostate Cancer Test (GenomeDx Biosciences, San Diego, CA). Diego), which is based on the expression patterns of 22 RNA markers in biopsy or radical prostatectomy samples. Prolaris®, OncotypeDx®, and Decipher® are tissue-based gene expression assays.
[0197] The test or approved test is performed using samples obtained from prostate cancer patients. These samples may be circulating tumor cells (CTC), circulating tumor DNA, blood, tissue samples, or tumor biopsy tissue.
[0198] Methods of treatment and medical use for treating prostate cancer, particularly BRCAm mCRPC as determined by the test or approved test, include, consist of, and / or substantially consist of the following steps: administering the disclosed pharmaceutical product or approved pharmaceutical product to a patient in need, the amount and manner of administration described in the product label or approved label of the pharmaceutical product or approved pharmaceutical product.
[0199] It should be understood that the embodiments of the treatment methods described herein include the use of the pharmaceutical product or approved pharmaceutical product in the manufacture of an agent, and the use of the pharmaceutical product or approved pharmaceutical product in the treatment method. Therefore, this document also describes the use of the pharmaceutical product or approved pharmaceutical product in the manufacture of a pharmaceutical preparation for treating patients with BRCAm mCRPC as determined by testing or approved testing, wherein the pharmaceutical preparation is labeled with the pharmaceutical product or approved pharmaceutical product label or approved pharmaceutical product label.The dosage described in the drug product label is applied.
[0200] Methods of treating prostate cancer, particularly BRCAm mCRPC, or medical use of the drug product or approved drug product, include, consist of, and / or substantially consist of the following steps: administering the drug product or approved drug product to a patient in need, plus a clinically effective amount of a glucocorticoid, such as prednisone or prednisolone.
[0201] Dosing regimens of the oral dosage forms disclosed herein are also disclosed, comprising, consist of, and / or substantially consist of the following steps: administering a dual-drug combination, dual-drug combination, or FDC of niraparib and abiraterone acetate, plus a clinically effective total amount of a glucocorticoid (e.g., prednisone or prednisolone) for the treatment of human prostate cancer.
[0202] Subjects may be surgically or chemically castrated.
[0203] Prior to first taking the drug product or the approved drug product plus prednisone, the patient may have received one or more other types of prostate cancer treatment. For example, the patient may have received taxane-based chemotherapy before administering the drug product or the approved drug product plus prednisone. Additionally or alternatively, the patient may have received at least one first-line androgen receptor-targeted therapy, such as apatamide and / or enzalutamide, before administering the drug product or the approved drug product plus prednisone. In one aspect, the patient was initially unresponsive or became refractory to prior treatment before administering the drug product or the approved drug product plus prednisone.
[0204] The pharmaceutical product or approved pharmaceutical product plus prednisone may be administered once daily, at least 1 hour before a meal or at least 2 hours after a meal, in the form of two tablets or two capsules comprising a dual-drug combination, dual-drug combination, or FDC of niraparib and abiraterone acetate, and prednisone (in a single dosage form). In one aspect, two tablets or two capsules comprising a dual-drug combination, dual-drug combination, or FDC of niraparib and abiraterone acetate are administered once daily with water on an empty stomach (at least 1 hour before a meal or at least 2 hours after a meal).
[0205] In one aspect, glucocorticoids are administered once or twice daily. In one aspect, prednisone or prednisolone tablets or capsules are administered once or twice daily.
[0206] In one aspect, one or two tablets or one or two capsules comprising a dual-drug combination, a combination of two drugs, or a fibrillator (FDC) of niraparib and abiraterone acetate are administered once daily, and one or two tablets or one or two capsules of a glucocorticoid (e.g., prednisone) are administered once or twice daily.
[0207] The usual once-daily dose of the pharmaceutical product or approved product is about 200 mg niraparib, about 500 mg abiraterone acetate, and about 10 mg prednisone. A conventional strength oral dosage form of the pharmaceutical product or approved product contains about 100 mg niraparib.Niraparib and approximately 500 mg abiraterone acetate. Therefore, the drug product or approved drug product is taken once daily in two oral dosage forms, plus 10 mg prednisone. The two oral dosage forms may be film-coated tablets, tablets, capsules, granule compositions or sachets. Preferably, the oral dosage form is a film-coated tablet.
[0208] In cases of myelosuppression accompanied by: (i) platelet count < 100,000 / mcL, or (ii) neutrophil count < 1,000 / mcL or hemoglobin count < 8 g / dL; or in cases of other non-hematological grade 3 or 4 adverse reactions requiring dose reduction, the once-daily dose of the drug product or approved drug product is reduced to approximately 100 mg niraparib, approximately 1,000 mg abiraterone acetate, and approximately 10 mg prednisone. The lower-strength oral dosage form of the drug product or approved drug product contains approximately 50 mg niraparib and approximately 500 mg abiraterone acetate. Therefore, the pharmaceutical product or approved pharmaceutical product is taken once daily in two oral dosage forms, plus 10 mg of prednisone. These two oral dosage forms may be film-coated tablets, tablets, capsules, granule compositions, or sachets. Preferably, the oral dosage form is a film-coated tablet.
[0209] The pharmaceutical product or approved pharmaceutical product of this disclosure, as well as glucocorticoids administered alone (e.g., prednisone, prednisolone, hydrocortisone, methylprednisolone, or dexamethasone; preferably prednisone or prednisolone), can be administered to patients with metastatic prostate cancer. Specifically, the dual-drug combination, dual-combination, or FDC drug product or approved drug product disclosed herein, as well as glucocorticoids administered alone (e.g., prednisone, prednisolone, hydrocortisone, methylprednisolone, or dexamethasone; preferably prednisone or prednisolone) are administered to patients with mCRPC (such as first-line (L1) mCRPC) (e.g., subjects in a metastatic castration-resistant setting who have not received any therapy other than ADT and limited exposure to abiraterone acetate plus prednisone). The patient is HRR-positive, preferably BRCA-positive, as determined by testing or an approved test. Metastatic prostate cancer can be confirmed by a positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI). The patient may have a castration level of testosterone ≤ 50 ng / dL and may be undergoing ADT. The patient may continue ADT. The patient may have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade of 0 or 1.
[0210] If surgical castration was not performed (i.e., subjects who did not undergo bilateral orchiectomy), patients may be able to continue ADT treatment while receiving the drug product or the approved drug product plus prednisone (or prednisolone). Patients may have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal to 1.
[0211] This document also discloses kits comprising pharmaceutical products or approved pharmaceutical products containing niraparib and abiraterone acetate, and optionally, individual compositions containing prednisone or prednisolone, particularly for BRCAm mCRPC as determined by a test or approved test. Instructions for use may be provided for once-daily administration of each composition. For example, the instructions may provide instructions for once-daily administration of a pharmaceutical product or approved pharmaceutical product containing niraparib and abiraterone acetate to a human patient with prostate cancer or BRCAm mCRPC, and instructions for once-daily or twice-daily administration of a composition containing prednisone or prednisolone to the same human patient.
[0212] This disclosure also relates to a method for determining the bioequivalence of a test fixed-dose combination (FDC) formulation of niraparib and abiraterone acetate relative to a pharmaceutical product of this disclosure or an approved pharmaceutical product, the method comprising i) measuring a bioequivalence parameter of the test FDC formulation and optionally measuring a bioequivalence parameter of the pharmaceutical product of this disclosure or an approved pharmaceutical product, and ii) comparing the bioequivalence parameter of the test FDC formulation with the corresponding bioequivalence parameter of the pharmaceutical product of this disclosure or an approved pharmaceutical product.
[0213] In one aspect, the bioequivalence parameter is selected from AUC(0-t), AUC(0-∞), residual area, Cmax and tmax, AUC(0-72 h), terminal rate constant (λz), t1 / 2, AUC(0-τ), Cmax,ss, tmax,ss, Ae(0-t), and Rmax, which are well known to those skilled in the art of bioequivalence and pharmacokinetics.
[0214] Marketing Methods and Methods of Providing a Pharmaceutical Product or Approved Pharmaceutical Product This document provides methods for marketing a pharmaceutical product or approved pharmaceutical product as disclosed herein, the methods comprising marketing such a pharmaceutical product or approved pharmaceutical product, wherein a pharmaceutical product label or approved pharmaceutical product label of a reference product of such pharmaceutical product or approved pharmaceutical product includes instructions for treating adult patients with BRCAm mCRPC determined by a test or approved test.
[0215] In some embodiments, the marketing method includes marketing a generic drug, wherein a pharmaceutical product label of a reference product of the generic drug includes instructions for treating adult patients with BRCAm mCRPC determined by a test or approved test.
[0216] In another aspect, this document describes methods for marketing a pharmaceutical product or approved pharmaceutical product of the present disclosure, the methods comprising, consisting of, or substantially consisting of the following steps: placing the pharmaceutical product or approved pharmaceutical product into commercial circulation, wherein the pharmaceutical product or approved pharmaceutical product is accompanied by a package insert containing instructions on the safe and effective use of the pharmaceutical product or approved pharmaceutical product for the treatment of prostate cancer or BRCAm mCRPC.
[0217] This document also provides a method for providing a pharmaceutical product or approved pharmaceutical product for sale, the method comprising providing a pharmaceutical product or approved pharmaceutical product for sale, wherein the pharmaceutical product or approved pharmaceutical product label of a reference product of such pharmaceutical product or approved pharmaceutical product includes instructions for treating adult patients with BRCAm mCRPC as determined by a test or approved test.
[0218] In some embodiments, the method of providing for sale comprises providing a generic drug for sale, wherein the pharmaceutical product label of a reference product of the generic drug or approved pharmaceutical product label includes instructions for treating adult patients with BRCAm mCRPC as determined by a test or approved test.
[0219] In some further aspects, this document describes a method for providing a pharmaceutical product or approved pharmaceutical product for sale, the method comprising, consisting of, or substantially consisting of the following steps: providing the pharmaceutical product or approved pharmaceutical product for commercial distribution, wherein the pharmaceutical product or approved pharmaceutical product is accompanied by a package insert containing instructions on the safe and effective use of the pharmaceutical product or approved pharmaceutical product for the treatment of BRCAm mCRPC.
[0220] In some embodiments, the sales method includes a method of selling a kit containing a generic drug, the method specification 22 / 185 pages 28 CN 121443291 A including the sale of the generic drug, wherein the drug product label or approved drug product label of the reference product of the generic drug includes instructions for treating patients with BRCAm mCRPC determined by a test or approved test.
[0221] This disclosure also provides a method of providing and selling a kit containing niraparib and abiraterone acetate, the method including providing and selling such a kit, wherein the drug product label or approved drug product label of the reference product of niraparib and abiraterone acetate includes instructions for treating patients with BRCAm mCRPC determined by a test or approved test.
[0222] This document also describes a method including the sale of a kit containing a generic drug or a drug product or approved drug product, wherein the drug product label or approved drug product of the generic drug or drug product or approved drug product includes overall survival data, adjusted OS data, TSP, TCC, or rPFS data.
[0223] Other embodiments: Embodiment 1. An approved pharmaceutical product having at least one indication approved by at least one of the FDA, EMA, and Health Canada, wherein the approved pharmaceutical product comprises niraparib and abiraterone acetate.
[0224] Embodiment 2. The approved pharmaceutical product according to Embodiment 1, wherein the at least one approved indication is metastatic castration-resistant prostate cancer (mCRPC).
[0225] Embodiment 3. The approved pharmaceutical product according to Embodiment 1 or 2, wherein the approved pharmaceutical product is designated as...Prednisone is indicated for the treatment of patients with harmful or suspected harmful breast cancer mutations (BRCAm) mCRPC detected by approved testing.
[0226] Embodiment 4. The approved pharmaceutical product according to Embodiment 3, wherein the approved pharmaceutical product is administered orally once daily in a dose of 200 mg niraparib and 1,000 mg abiraterone acetate, and in combination with a daily dose of 10 mg prednisone.
[0227] Embodiment 5. The approved pharmaceutical product according to Embodiment 3, wherein in cases of myelosuppression accompanied by: (i) a platelet count < 100,000 / mcL, or (ii) a neutrophil count < 1,000 / mcL or a hemoglobin count < 8 g / dL; or in cases of other non-hematological grade 3 or 4 adverse reactions, the approved pharmaceutical product is administered orally once daily in a reduced dose of 100 mg niraparib and 1,000 mg abiraterone acetate.
[0228] Embodiment 6. The approved pharmaceutical product according to any one of Embodiments 3 to 5, wherein the approved pharmaceutical product is administered on an empty stomach.
[0229] Embodiment 7. The approved pharmaceutical product according to any one of Embodiments 3 to 6, wherein no food is consumed for two hours before and one hour after taking the approved pharmaceutical product.
[0230] Embodiment 8. The approved pharmaceutical product according to any one of Embodiments 3 to 7, wherein the patient is simultaneously receiving gonadotropin-releasing hormone (GnRH) analog treatment, or the patient has undergone bilateral orchiectomy.
[0231] Embodiment 9. The approved pharmaceutical product according to Embodiment 8, wherein the GnRH analog is selected from triptorelin, nafarelin, goserelin, leuprorelin or leuprorelin, histaminerelin, gonarelin and buserrelin.
[0232] Embodiment 10. The approved pharmaceutical product according to any one of Embodiments 3 to 9, wherein the approved pharmaceutical product is not administered to patients with moderate or severe hepatic impairment.
[0233] Embodiment 11. An approved pharmaceutical product according to any one of Embodiments 3 to 10, wherein the approved pharmaceutical product is not co-administered with the CYP3A4 inducer rifampin.
[0234] Embodiment 12. An approved pharmaceutical product according to any one of the preceding embodiments, wherein the approved pharmaceutical product comprises a pharmaceutical composition comprising a pharmaceutically acceptable carrier; and (i) 100 mg niraparib and 500 mg abiraterone acetate, in an oral dosage form (conventional strength); or (ii) 50 mg niraparib and 500 mg abiraterone acetate, in an oral dosage form (lower strength).
[0235] Embodiment 13. An approved pharmaceutical product according to any one of Embodiments 4 to 12, wherein, upon approval...In patients with harmful or suspected harmful BRCAm mCRPC, the approved drug product resulted in a median overall survival (OS) of 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
[0236] Implementation Scheme 14. The approved drug product according to Implementation Scheme 13, wherein the HR for the median OS was 0.663 (95% CI: 0.464, 0.947) after multivariate Cox regression analysis, which adjusted for external validation and clinically relevant baseline prognostic factors selected from prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (Alk Phos), age, Eastern Cooperative Oncology Group (ECOG) grade, number of bone lesions, and visceral disease.
[0237] Embodiment 15. The approved pharmaceutical product according to any one of Embodiments 4 to 14, wherein in patients with harmful or suspected harmful BRCAM mCRPC detected by approved testing, the approved pharmaceutical product induced an improved median time to progression of symptoms (TSP), with an HR of 0.562 (95% CI: 0.371, 0.849), compared with patients receiving placebo and abiraterone acetate plus prednisone.
[0238] Embodiment 16. The approved pharmaceutical product according to any one of Embodiments 4 to 15, wherein in patients with harmful or suspected harmful BRCAM mCRPC detected by approved testing, the approved pharmaceutical product induced an improved median time to cytotoxic chemotherapy (TCC), with an HR of 0.598 (95% CI: 0.387, 0.924), compared with patients receiving placebo and abiraterone acetate plus prednisone.
[0239] Embodiment 17. The approved pharmaceutical product according to any one of Embodiments 4 to 16, wherein in patients with harmful or suspected harmful BRCAm mCRPC detected by the approved test, the approved pharmaceutical product induces a median radiographic progression-free survival (rPFS) of 19.5 months, with an HR of 0.553 (95% CI: 0.392, 0.782).
[0240] Embodiment 18. The approved pharmaceutical product according to any one of Embodiments 1 to 17, wherein the approved pharmaceutical product comprises 159.40 mg of niraparib tosylate monohydrate (equivalent to 100 mg of niraparib free base) as the active ingredient, and 500 mg of abiraterone acetate.
[0241] Embodiment 19. The approved pharmaceutical product according to any one of Embodiments 1 to 17, wherein the approved pharmaceutical product comprises 79.70 mg of niraparib tosylate monohydrate (equivalent to 50 mg of niraparib free base) as the active ingredient, and 500 mg of abiraterone acetate.
[0242] Implementation Scheme 20. The approved pharmaceutical product according to any one of Implementation Schemes 12 to 19, wherein the pharmaceutical composition is an oral dosage form selected from film-coated tablets, tablets, capsules, granules, and sachets.
[0243] Implementation Scheme 21. The approved pharmaceutical product according to Implementation Scheme 20, wherein the pharmaceutical composition is a film-coated tablet, further comprising colloidal anhydrous silica, cropovidone, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose, and sodium lauryl sulfate; and a film coating.
[0244] Implementation Scheme 22. The approved pharmaceutical product according to Implementation Scheme 21, wherein the film-coated tablet comprises 100 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide.
[0245] Embodiment 23. The approved pharmaceutical product according to Embodiment 21, wherein the film-coated tablet comprises 50 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide.
[0246] Embodiment 24. The approved pharmaceutical product according to any one of the preceding embodiments, wherein the approved pharmaceutical product is approved for marketing in the European Economic Area (EEA) or Canada.
[0247] Embodiment 25. The approved pharmaceutical product according to any one of the preceding embodiments, wherein the approved pharmaceutical product is a generic drug, ANDA, sNDA, NDA product, or 505(b)(2) pharmaceutical product.
[0248] Embodiment 26. A method for treating a patient with mCRPC who has been found to have a harmful or suspected harmful BRCAM by an approved test, the method comprising administering to the patient a combination of an approved pharmaceutical product as defined in any of the preceding embodiments and prednisone.
[0249] Embodiment 27. The method for treating mCRPC according to Embodiment 26, wherein the treatment comprises oral administration once daily of an approved pharmaceutical product containing 200 mg niraparib and 1,000 mg abiraterone acetate, and 10 mg prednisone alone daily until disease progression or unacceptable toxicity occurs.
[0250] Embodiment 28. The method for treating mCRPC according to Embodiment 26, wherein the treatment comprises, once daily, administration of an approved pharmaceutical product containing 200 mg niraparib and 1,000 mg abiraterone acetate.A reduced dose of the approved drug product containing 100 mg niraparib and 1,000 mg abiraterone acetate is administered orally once daily, while 10 mg prednisone is administered alone.
[0251] Embodiment 29. A method for treating mCRPC according to any one of Embodiments 26 to 28, wherein the treatment comprises improving the median OS to 30.4 months, with a HR of 0.788 (95% CI: 0.554, 1.120).
[0252] Embodiment 30. A method for treating mCRPC according to Embodiment 29, wherein the median OS is further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0253] Embodiment 31. A method for treating mCRPC according to any one of embodiments 26 to 30, wherein the treatment comprises improving median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849).
[0254] Embodiment 32. A method for treating mCRPC according to any one of embodiments 26 to 31, wherein the treatment comprises improving median TCC, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0255] Embodiment 33. A method for treating mCRPC according to any one of embodiments 26 to 32, wherein the treatment comprises improving median rPFS to 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0256] Embodiment 34. A method of marketing an approved pharmaceutical product comprising niraparib and abiraterone acetate as defined in any one of embodiments 1 to 25, the method comprising marketing such approved pharmaceutical product.
[0257] Embodiment 35. The sales method according to Embodiment 34, wherein the approved drug product is a generic drug, an ANDA drug product, a supplemental new drug application drug product, an NDA product, or a 505(b)(2) drug product.
[0258] Embodiment 36. The sales method according to Embodiment 34 or 35, wherein the reference formulation of such approved drug products improves OS, rPFS, TCC, TSP, or TPP.
[0259] Embodiment 37. The sales method according to Embodiment 36, wherein the median OS is 30.4 months and the HR is 0.788 (95% CI: 0.554, 1.120).
[0260] Embodiment 38. The sales method according to Embodiment 37, wherein after multivariate Cox regression analysis, theThe median OS had a HR of 0.663 (95% CI: 0.464, 0.947), and the multivariate Cox regression analysis adjusted for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0261] Embodiment 39. The sales method according to any one of Embodiments 36 to 38, wherein the median TSP was improved, with a HR of 0.562 (95% CI: 0.371, 0.849).
[0262] Embodiment 40. The sales method according to any one of Embodiments 36 to 39, wherein the median TCC was improved, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0263] Embodiment 41. A sales method according to any one of Embodiments 36 to 40, wherein the median rPFS is 19.5 months and the HR is 0.553 (95% CI: 0.392, 0.782).
[0264] Embodiment 42. A method of providing a marketed approved pharmaceutical product comprising niraparib and abiraterone acetate as defined in any one of Embodiments 1 to 25, the method comprising providing a marketed approved pharmaceutical product.
[0265] Embodiment 43. The method of providing a marketed product according to Embodiment 42, wherein the approved pharmaceutical product is a generic drug, an ANDA pharmaceutical product, a supplemental New Drug Application pharmaceutical product, an NDA pharmaceutical product, or a 505(b)(2) pharmaceutical product.
[0266] Embodiment 44. The method of providing a marketed product according to Embodiment 42 or 43, wherein a reference formulation of such an approved pharmaceutical product improves OS, rPFS, TCC, TSP, or TPP.
[0267] Embodiment 45. The sales method according to Embodiment 44, wherein the median OS is 30.4 months, and the HR is 0.788 (95% CI: 0.554, 1.120).
[0268] Embodiment 46. The sales method according to Embodiment 45, wherein after multivariate Cox regression analysis, the HR for the median OS is 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0269] Embodiment 47. The sales method according to any one of Embodiments 44 to 46, wherein the median TSP is improved, and the HR is 0.562 (95% CI: 0.371, 0.849).
[0270] Implementation Scheme 48. A method of marketing according to any one of Implementation Schemes 44 to 47, wherein the median TCC is improved, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0271] Implementation Scheme 49. A method of marketing according to any one of Implementation Schemes 44 to 48, wherein the median rPFS is 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0272] Implementation Scheme 50. An approved pharmaceutical product as defined in any one of the preceding Implementation Schemes 1 to 25, used in a method for treating mCRPC patients with a harmful or suspected harmful BRCAM detected by an approved test, the method comprising co-administering the approved pharmaceutical product with prednisone.
[0273] Embodiment 51. An approved pharmaceutical product as defined in any one of Embodiments 1 to 25 above, used in the method of Embodiment 50, wherein the treatment comprises oral administration once daily of the approved pharmaceutical product in a dose containing 200 mg niraparib and 1,000 mg abiraterone acetate, and 10 mg prednisone until disease progression or unacceptable toxicity occurs.
[0274] Embodiment 52. An approved pharmaceutical product as defined in any one of Embodiments 1 to 25 above, used in the method of Embodiment 50, wherein the treatment comprises, once daily, oral administration of the approved pharmaceutical product containing 100 mg niraparib and 1,000 mg abiraterone acetate, and 10 mg prednisone, in cases of myelosuppression accompanied by: (i) a platelet count < 100,000 / mcL, or (ii) a neutrophil count < 1,000 / mcL or a hemoglobin count < 8 g / dL; or in cases of other non-hematologic grade 3 or 4 adverse reactions.
[0275] Embodiment 53. An approved pharmaceutical product as defined in any one of Embodiments 1 to 25 above, used in the method of any one of Embodiments 50 to 52, wherein the treatment comprises improving the median OS to 30.4 months, with a HR of 0.788 (95% CI: 0.554, 1.120).
[0276] Embodiment 54. An approved pharmaceutical product as defined in any one of Embodiments 1 to 25 above, used in the method of Embodiment 53, wherein the median OS is further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464, 0.947), wherein the multivariate Cox regression analysis adjusts for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG classification, number of bone lesions, and visceral diseases.
[0277] Implementation Scheme 55. An approved pharmaceutical product as defined in any one of Implementation Schemes 1 to 25, used in the method of any one of Implementation Schemes 50 to 54, wherein the treatment includes improving median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849).
[0278] Implementation Scheme 56. An approved pharmaceutical product as defined in any one of Implementation Schemes 1 to 25, used in the method of any one of Implementation Schemes 50 to 55, wherein the treatment includes improving median TCC, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0279] Implementation Scheme 57. An approved pharmaceutical product as defined in any one of Implementation Schemes 1 to 25, used in the method of any one of Implementation Schemes 50 to 56, wherein the treatment includes improving median rPFS to 19.5 months, with a HR of 0.553 (95% CI: 0.392, 0.782).
[0280] Embodiment 58. An approved pharmaceutical product comprising niraparib and abiraterone acetate, used in combination with prednisone or prednisolone in a method of treating adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1 / 2 mutations (germline and / or somatic mutations) for whom chemotherapy is not clinically indicated; wherein BRCA positive status is determined using a validated test method; wherein a single daily dose of the approved pharmaceutical product is 200 mg niraparib and 1,000 mg abiraterone acetate, and a daily dose of prednisone or prednisolone is 10 mg, until disease progression or unacceptable toxicity occurs; characterized in that the treatment comprises improving the median overall survival (OS) to 30.4 months, with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
[0281] 59. An approved pharmaceutical product used according to embodiment 58, wherein the median OS was further improved after multivariate Cox regression analysis, with a HR of 0.663 (95% CI: 0.464, 0.947), the multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
[0282] 60. An approved pharmaceutical product used according to embodiment 58 or 59, wherein the treatment includes improving the median TSP, with a HR of 0.562 (95% CI: 0.371, 0.849).
[0283] 61. An approved pharmaceutical product used according to any one of embodiments 58 to 60, wherein the treatment includes improving the median TCC, with a HR of 0.598 (95% CI: 0.387, 0.924).
[0284] 62. An approved pharmaceutical product used according to any one of embodiments 58 to 61, wherein the treatment comprises improving the median rPFS to 19.5 months, with an HR of 0.553 (95% CI: 0.392, 0.782).
[0285] This disclosure is further defined in the following examples, which include unexpected and favorable results. It should be understood that these examples, while indicating preferred embodiments of this disclosure, are given by way of example only and should not be construed as limiting the appended claims. Based on the discussion above and these examples, those skilled in the art can determine the essential features of this disclosure and can make various changes and modifications to suit various uses and conditions without departing from the spirit and scope of this disclosure.
[0286] Examples Example 1 – Final analysis of the MAGNITUDE study: including efficacy results of the BRCA subgroup of cohort 1 (consisting of 225 subjects: 113 subjects in the niraparib + AAP group and 112 subjects in the placebo + AAP group), and safety results of the entire HRR population of cohort 1. This embodiment also summarizes the updated results from cohort 3.
[0287] Study Design The MAGNITUDE study was a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of niraparib 200 mg in combination with abiraterone acetate (AA) 1,000 mg plus prednisone 10 mg, versus placebo combination with abiraterone acetate plus prednisone (AAP) in subjects with metastatic castration-resistant prostate cancer (mCRPC). Subjects were prospectively recruited into cohort 1 or cohort 2 based on the presence or absence of homologous recombination repair (HRR) gene alterations. In addition, after enrollment in cohorts 1 and 2 was completed, a separate open-label cohort, cohort 3, was enrolled to obtain clinical experience with the combination of niraparib and AA in a fixed-dose combination (FDC) tablet formulation with prednisone.
[0288] The study population consisted of male subjects aged 18 years or older with mCRPC and with or without HRR gene alterations, who were not treated in a metastatic castration-resistant background (except for limited exposure to AAP and continuous ADT) and were eligible to participate in this study.
[0289] • Cohort 1: Subjects with HRR gene alterations – involving alterations in the BRCA1, BRCA2, ATM, BRIP1, CDK12, CHEK2, HDAC2, FANCA, or PALB2 genes.
[0290] • Cohort 2: Subjects without HRR gene alterations – this cohort met the invalidation criteria described below.
[0291] • Cohort 3: Subjects with HRR gene alterations – identical to the gene alterations listed in Cohort 1.
[0292] All subjects were enrolled after undergoing HRR gene alteration testing using Foundation One CDx histological assay, Resolution HRD plasma assay, Amoy Dx blood and tissue assay (China only), or a recognized local laboratory biomarker test that has been reviewed and certified by the center to indicate pathogenic germline or somatic alterations.
[0293] Randomized subjects were randomly assigned in a 1:1 ratio to receive niraparib + AAP or placebo + AAP and stratified by the following factors: prior exposure to taxane-based chemotherapy (yes or no); prior exposure to AR-targeted therapy (enzalutamide or apalutamide, versus no exposure) in the context of mHSPC or nmCRPC; and prior use of AAP in mCRPC (yes or no). Cohort 1 was also stratified by gene mutation group (BRCA1 or BRCA2 versus all other HRR gene alterations).
[0294] The treatment duration / trial duration study consisted of a pre-screening phase for biomarker evaluation only, a screening phase, a treatment phase, and a follow-up phase for collecting secondary endpoints. Treatment continues until clear clinical progression, unacceptable toxicity, death, or termination of the study by the sponsor. Treatment may be discontinued upon confirmation of radiographic progression by central imaging review.
[0295] Primary objectives: • Evaluate the efficacy of niraparib and AAP compared to AAP and placebo. Secondary objectives: • Assess the clinical benefit of niraparib and AAP compared to AAP and placebo. • Characterize the safety profile of niraparib when administered in combination with AAP compared to AAP and placebo. Primary efficacy variable: Radiographic progression-free survival (rPFS) assessed by blinded central review (BICR) is defined as the time interval from the randomization date to the date the BICR determines the first radiographic progression or death from any cause (whichever occurs first).
[0296] Primary secondary efficacy variables • Time to symptom progression (TSP) was defined as the time from randomization to the first occurrence of any of the following events: ○ External beam radiation therapy (EBRT) ○ Tumor-related orthopedic surgical intervention ○ Cancer-related procedures (e.g., nephrostomy tube insertion, or surgery for non-skeletal tumor symptoms) ○ Initiation of new systemic anticancer therapy for cancer pain ○ Cancer-related lesion events (e.g., fracture, spinal cord compression, urinary tract obstruction) • Time to cytotoxic chemotherapy (TCC) • Overall survival (OS) Efficacy analysis of the primary set of efficacy, cohort 1, used data from randomized subjects in cohort 1.
[0297] Study drug information All study treatments were provided directly by the sponsor. For cohorts 1 and 2, niraparib was provided in 100 mg capsules for oral administration. Niraparib placebo was provided in capsule formulation and was provided in terms of size, color, andThe shapes were matched to keep the study blinded. AA was provided in 250 mg tablets for oral administration, and prednisone was provided in 5 mg tablets for oral administration.
[0298] For cohort 3, niraparib / AA FDC was provided in regular strength tablets containing 100 mg niraparib / 500 mg AA per tablet. Prednisone was provided in 5 mg tablets for oral administration. If dose adjustment of niraparib is required, low strength (LS) FDC tablets containing 50 mg / 500 mg niraparib / AA per tablet are also available. For subjects who need to discontinue one drug due to toxicity, a single dose of niraparib is available as a 100 mg capsule and AA is available as a 250 mg tablet, both for oral administration.
[0299] Dosage and Administration: Subjects in Cohort 1 and Cohort 2 were randomized in a 1:1 ratio to receive 200 mg niraparib, 1,000 mg AA, and 10 mg prednisone daily (niraparib + AAP) and / or a matched placebo, 1,000 mg AA, and 10 mg prednisone daily (PBO + AAP). Subjects in Cohort 3 received 200 mg niraparib / 1,000 mg AAP (hereinafter referred to as FDC) and 10 mg prednisone daily (FDC + P).
[0300] The study treatment was taken on an empty stomach in the morning, with no food for at least 2 hours before and at least 1 hour after administration. The study treatment was swallowed whole with water. All study treatments except prednisone were taken concurrently. If a subject forgot to take the study treatment at the scheduled time, the missed dose could only be taken if the subject remembered on the same day.
[0301] Patients who have not undergone castration surgery must receive GnRHa background therapy to maintain castration testosterone concentrations (≤ 50 ng / dL). The choice of GnRHa is determined by the investigator. The dosage and dosing regimen (uninterrupted) should be consistent with the prescribing information for the GnRHa agent used and should only be adjusted if clinically indicated to maintain castration testosterone concentrations.
[0302] Contraindicated concomitant medications: The following medications / therapies are prohibited during the study: • Investigational agents other than the study treatment • Other anticancer therapies • Other agents targeting the androgen axis (e.g., antiandrogens such as enzalutamide and apalutamide, or CYP17 inhibitors such as ketoconazole) • Testosterone • Radiation therapy for tumor progression. Subjects may receive palliative radiation therapy in specific circumstances after discussion with the sponsor.
[0303] • Chemotherapy • Immunotherapy • Diethylhexylestradiol or similar estrogen receptor agonists (Instructions for Use, 29 / 185 pages, 35 CN 121443291 A) • Pomegranate and pomegranate juice • Spironolactone • Radiopharmaceuticals, such as radium-223, strontium, or samarium • Strong inducers of CYP3A4 (e.g., rifampin) • Limited concomitant drugsBased on the potential drug interaction between niraparib and AAP, the use of the following drugs is restricted: • CYP2D6 substrates: Caution is advised when AA is administered co-administered with pharmaceuticals activated or metabolized by CYP2D6, particularly with pharmaceuticals having a narrow therapeutic index. A reduction in the dose of pharmaceuticals metabolized by CYP2D6 with a narrow therapeutic index should be considered.
[0304] • CYP2C8 substrates: In CYP2C8 drug-drug interaction studies in healthy subjects, the AUC of pioglitazone increased by 46% when administered co-administered with a single dose of 1,000 mg AA. Although no clinically meaningful increase in exposure was observed when AA was combined with drugs primarily eliminated by CYP2C8, subjects should be monitored for signs of toxicity associated with CYP2C8 substrates with a narrow therapeutic index if used concomitantly with AA.
[0305] Inclusion criteria: Subjects must meet the following main inclusion criteria: 1. Have the following HRR gene alteration status (as identified by an initiator-requested assay or a local test for HRR gene alteration): a. Cohort 1: Positive for HRR gene alteration b. Cohort 2: Non-positive for HRR gene alteration (i.e., no HRR gene alteration) c. Cohort 3: Positive for HRR gene alteration 2. Have metastatic disease recorded by a positive bone scan or CT or MRI.
[0306] 3. Have metastatic prostate cancer in a castration environment of ≤ 50 ng / dL of testosterone at the time of GnRHa or bilateral orchiectomy, as confirmed by PSA progression or radiographic progression.
[0307] 4. Be able to continue GnRHa during the study period if surgical castration is not performed.
[0308] 5. Have an ECOG performance status of 0 or 1.
[0309] 6. A score ≤3 on item 3 of the BPI-SF questionnaire (most severe pain in the last 24 hours).
[0310] 7. Clinical laboratory values at screening: a. ANC ≥1.5 ×10⁹ / L.
[0311] b. Hemoglobin ≥ 9.0 g / dL (not related to transfusion) for at least 30 days.
[0312] c. Platelet count ≥100 ×10⁹ / L.
[0313] Exclusion Criteria Subjects should not be recruited to the study if they meet any of the following key exclusion criteria during pre-study screening: 1. Prior treatment with a PARP inhibitor.
[0314] 2. Systemic therapy in the context of mCRPC (i.e., novel second-generation AR-targeted therapy, such as enzalutamide, apatamide, or dalotamide; taxane-based chemotherapy; or AAP more than 4 months prior to randomization); or AAP outside of the mCRPC setting.
[0315] 3. Subjects who have received AAP for 2 to 4 months prior to randomization should show no signs of PSA progression during screening (according to PCWG3). These potential subjects need to have two PSA values during the pre-screening and screening phases. The second PSA value should occur within 2 weeks of randomization and be believed to be due to a disease flare-up, with the investigator confirming no radiographic progression.
[0316] 4. Presence of uncontrolled hypertension (sustained systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg). Subjects with a history of hypertension are permitted if BP is controlled within these limits by antihypertensive treatment.
[0317] 5. Subjects who have received the following within ≤28 days prior to randomization: a. Blood transfusion (platelets or red blood cells).
[0318] b. Hematopoietic growth factors.
[0319] c. Investigational agents for prostate cancer.
[0320] d. Major surgery (consult the initiator regarding what constitutes major surgery).
[0321] e. Expected effect size and planned sample size for radiotherapy. Cohort 1: Approximately 400 subjects with mCRPC and HRR gene alterations will be randomized 1:1 to receive either niraparib + AAP or PBO + AAP to observe approximately 220 rPFS events and provide 87% detectability at a two-sided significance level of 0.05, assuming an HR of 0.65. Approximately 50% of subjects will have BRCA1 or BRCA2 (BRCA) alterations to generate approximately 102 rPFS events in the BRCA subgroup and provide 93% detectability at a two-sided significance level of 0.05, assuming an HR of 0.50.
[0322] Cohort 2: If the waste factor test was not met, approximately 600 subjects with mCRPC without HRR gene alterations were randomized 1:1 to receive niraparib + AAP or PBO + AAP. A pre-planned waste factor test was performed on this cohort, and a total of 247 subjects were recruited (14 subjects with CDK12 alterations were excluded from the waste factor test). When the waste factor test was met, recruitment for Cohort 2 was stopped. Subjects were unblinded (except for the 14 subjects with CDK12 alterations), and the principal investigator determined, based on the benefit and risk assessment, whether to continue niraparib + AAP, niraparib (if AAP is discontinued due to toxicity), or discontinue niraparib + AAP and receive AAP alone.
[0323] Cohort 3: Approximately 100 subjects with HRR gene alterations (about half of whom had BRCA alterations) were recruited into Cohort 3.
[0324] Waste factor test for Cohort 2A pre-planned uselessness analysis was conducted on August 13, 2020, for cohort 2, which enrolled 247 participants. The pre-planned uselessness criterion of HR > 1 was met when 113 composite progression events (preceding PSA progression, radiographic progression, or death) were observed (40 rPFS events and 73 PSA events). This cohort was declared useless because the HR for the composite progression endpoint was 1.087 (95% CI: 0.751, 1.571). During the uselessness analysis, the time to PSA progression was also analyzed (83 PSA events, HR = 1.032, 95% CI: 0.671, 1.588), and rPFS was also analyzed (65 rPFS events, HR = 1.027, 95% CI: 0.631, 1.671). The Independent Data Monitoring Committee (IDMC) recommended that “therapeutic / enrollment of subjects in this cohort may be terminated.” The sponsoring committee accepted the IDMC’s recommendation, stopped recruitment, and unblinded the cohort. Subjects with CDK12 mutations in cohort 2 were excluded from the uselessness analysis and remained blinded. As part of Amendment 3, these subjects were included in the sensitivity analysis along with those prospectively randomized to cohort 1. Unblinded subjects were given the option to continue niraparib or continue AAP alone. Subjects continued to be followed up for safety.
[0325] Statistical Testing Strategy for Primary Endpoint The primary endpoint rPFS of the study was defined as the time interval from the date of randomization to the first date of radiographic progression or death from any cause (whichever comes first) as assessed by the Blinded Independent Central Review Specification 31 / 185 page 37 CN 121443291 A (BICR). BICR was evaluated using chest, abdominal and pelvic CT or MRI scans and whole-body skeletal scans (99mTc). Given that cohort 2 satisfies the uselessness criterion, the overall statistical approach is to test the primary endpoint of rPFS in cohort 1, where the total α is 0.05. Within cohort 1, rPFS is first tested in the BRCA subgroup of cohort 1 at α=0.05 (two-tailed). If the result is statistically significant, rPFS is tested in the entire cohort 1 at α=0.05 (two-tailed) based on a predefined test gradation. An analysis of rPFS in the non-BRCA subgroup of cohort 1 is pre-planned in SAP, but no formal statistical testing procedures are performed for this analysis, nor is α value assignment performed.
[0326] Interim Analysis of Secondary Endpoints In cohort 1, two interim analyses (IA) and one final analysis are planned for the primary secondary endpoints using a group-order design approach: overall survival (OS) and time to symptomatic progression (TSP), which are defined as requiring initiation: for boneEBRT for skeletal symptoms, tumor-related orthopedic surgical interventions, other cancer-related procedures (e.g., nephrostomy, bladder catheterization, EBRT, or surgery for tumor symptoms other than skeletal), new systemic anticancer therapy for cancer pain or with cancer-related pathological events (e.g., symptomatic and / or pathological fractures, spinal cord compression, urinary tract obstruction), and time to cytotoxic chemotherapy (TCC). If the rPFS result in cohort 1 is statistically significant, three secondary endpoints are tested simultaneously, allowing for alpha recycling via a group-order design approach.
[0327] Analytical methods: Kaplan-Meier estimates of survival distributions were used to obtain estimates of time-event endpoints, and HRs and associated 95% confidence intervals were obtained using a stratified Cox model. Testing of these other efficacy endpoints was based on stratified log-rank tests.
[0328] ORR and PSA response rates were summarized by treatment group using descriptive statistics (counts and percentages). Relative risks were reported along with the corresponding two-sided 95% CI. The two treatment groups were compared using the chi-square test; Fisher's exact test was used if the expected cell count was less than 5 in some cells.
[0329] Interim analyses 1 (IA1) and 2 (IA2) of the study results summarized that at the primary analysis of rPFS (IA1 for the secondary endpoint; Clinical cutoff (CCO) date of October 8, 2021, median follow-up time for cohort 1 and BRCA subgroups were 18.6 months and 16.7 months, respectively), the predefined BRCA subgroup and all HRR populations (cohort 1) showed statistically significant and clinically meaningful improvements in rPFS with niraparib + AAP. At IA2 (CCO June 17, 2022, median follow-up time for cohort 1 and BRCA subgroups were 26.8 months and 24.8 months, respectively), statistically significant and clinically meaningful prolongations of TSP were observed in all HRR populations and also in the BRCA subgroup. Treatment with niraparib + AAP also resulted in prolonged TCC in all HRR populations and BRCA subgroups. (Table 1).
[0330] Table 1: Results of rPFS, TSP and TCC in all HRR populations and BRCA subgroups at PA-IA1 and IA2. (Page 32 / 185, CN 121443291 A) * HR estimates are derived from stratified Cox proportional hazards models.
[0331] ** P-values are based on stratified log-rank tests.
[0332] # Statistically significant ## Nominal p-values are shown in Table 1 above. At IA2, the observed HR for OS in the BRCA subgroup was 0.881. Multivariate analysis considering imbalanced baseline characteristics of subjects indicated that treatment with niraparib + AAP resulted in prolonged TCC in all HRR populations and BRCA subgroups.AAP treatment was associated with favorable survival, HR=0.682; 95% CI: 0.445, 1.046. Data for all HRR populations remained confounded by baseline characteristic imbalances, and multivariate analysis (HR=0.815; 95% CI: 0.603, 1.101) strongly indicated no impairment of OS with niraparib + AAP treatment.
[0333] OS Final Analysis (FA) Summary (CCO date: May 15, 2023) The final analysis, pre-specified by SAP, was performed when approximately 246 OS events (deaths) were observed in cohort 1. Given that scanned BICR was discontinued after IA2, the rPFS analysis was not updated at FA, but all secondary endpoints for all HRR populations and BRCA subgroups were evaluated using more mature data. PRO analysis for the BRCA subgroups, along with updated safety data, is also provided in this report.
[0334] All p-values are two-sided according to SAP, and the p-values for secondary endpoint analyses at FA in the BRCA population are nominal p-values.
[0335] Cohort 1, Final Efficacy Analysis (BRCA Subgroup) At the FA CCO (May 15, 2023), the median follow-up duration for BRCA subjects in Cohort 1 was 35.9 months (an increase of 11.1 months since IA2). A total of 240 deaths were observed across the entire HRR population in Cohort 1 (98% of the planned FA events in SAP), of which 130 were in the BRCA subgroup. The median duration of treatment for BRCA subjects in the niraparib + AAP group was 20.5 months, compared to 14.4 months in the placebo + AAP group.
[0336] Nominal p-values are provided for descriptive purposes because no formal statistical tests were planned for secondary endpoints in the BRCA subgroups.
[0337] Overall Survival (OS) in the BRCA Subgroup (Prescription 33 / 185 pages, 39 CN 121443291 A) In the BRCA subgroup, more deaths were observed in the placebo + AAP group (70 / 112, 62.5%), compared to (60 / 113, 53.1%) in the niraparib + AAP group. OS at FA showed a strong trend toward improved OS with niraparib + AAP treatment in subjects with BRCA alterations (p=0.1828) (HR=0.788; 95% CI: 0.554, 1.120), with significant separation of Kaplan-Meier curves between the treatment groups as follow-up time increased (Figure 1). The median OS was 30.4 months in the niraparib + AAP group and 28.6 months in the placebo + AAP group.
[0338] Multivariate analysis of OS in BRCA subgroups revealed an imbalance in baseline characteristics between treatment groups: As described in the IA2 Clinical Research Report (CSR), several key baseline factors known to be survival predictors (Armstrong)The imbalance between treatment groups (2020; Halabi 2014; Lin 2009) may be detrimental to the niraparib + AAP group. These imbalances include: • The proportion of participants with a baseline ECOG PS score of 1 in the niraparib + AAP group (38.7%) was higher than that in the placebo + AAP group (30.8%). • The proportion of participants aged ≥75 years in the niraparib + AAP group (29.7%) was higher than that in the placebo + AAP group (23.2%). • The proportion of participants with bone lesions at randomization in the niraparib + AAP group (86.3%) was higher than that in the placebo + AAP group (80.6%). • The proportion of participants with visceral diseases at randomization in the niraparib + AAP group (24.1%) was higher than that in the placebo + AAP group (18.5%). An empirical prognostic model developed by Halabi et al. (2014) was used to calculate the composite risk score for each participant using eight established prognostic factors (opioid use, disease site, ECOG performance status score, LDH, albumin, hemoglobin, alkaline phosphatase, and PSA). As shown in Table 2 below, the median score along with the interquartile range indicates that the risk score of the subjects in the niraparib + AAP group was consistently higher in the BRCA subgroup, which confirms that the imbalance of prognostic factors does not support the niraparib + AAP regimen. This analysis highlights the importance of multivariate analysis adjusted for important prognostic factors.
[0339] Table 2: Summary of multivariate analysis results of Halabi prognostic risk score Based on SAP, pre-defined multivariate Cox regression analysis was performed on the OS of the BRCA subgroup. This analysis adjusted for external validation and clinically relevant baseline prognostic factors (Halabi 2014, Guinney 2017, Sartor 2018). The results showed that OS was improved (HR=0.663; 95% CI: 0.464, 0.947), supporting the use of niraparib + AAP treatment (Table TEFOS08_BRCA below).
[0340] Figure 2 presents the OS forest plot of the BRCA subgroups analyzed by predefined subgroups. The observed results generally and consistently supported the niraparib + AAP regimen, with point estimates of HR greater than 1 only in subjects who had previously received taxane-based chemotherapy, had previously used AAP, had visceral metastases, and had high PSA.
[0341] Updated analyses of time to symptom progression (TSP) and time to initiation of cytotoxic chemotherapy (TCC) in the BRCA subgroups confirmed that, in the BRCA subgroups, subjects treated with niraparib + AAP showed a consistent and clinically meaningful improvement in TSP compared to placebo + AAP (HR = 0.562; 95% CI: 0.371, 0.849). KaplanThe separation of the Meier curves appeared earlier and widened over time, supporting treatment with niraparib + AAP (Figure 3a); the median TSP was not reached in the niraparib + AAP group, while the median TSP in the placebo + AAP group was 21.7 months.
[0342] Updated analysis of TCC at FA continued to show delayed TCC in BRCA subjects receiving niraparib + AAP (HR = 0.598; 95% CI: 0.387, 0.924). Similar to TSP, the separation of the Kaplan Meier curves appeared earlier and widened over time, supporting treatment with niraparib + AAP (Figure 3b); the median TCC was not reached in the niraparib + AAP group, while the median TCC in the placebo + AAP group was 28.2 months.
[0343] Table 3: TSP and TCC *HR estimates of the BRCA subgroups at FA were derived from a stratified Cox proportional hazards model.
[0344] ** P-values were based on a stratified log-rank test.
[0345] TCC in all HRR populations did not cross the pre-specified significance boundary at FA. However, clinically meaningful improvements were observed.
[0346] Post-treatment for prostate cancer in the BRCA subgroups at FA: More BRCA subjects in the placebo + AAP group received post-treatment for prostate cancer compared to fewer in the niraparib + AAP group. Chemotherapy was the most common post-treatment received in both treatment groups; subsequent use of PARP inhibitors was more frequent in the placebo + AAP group (Table 4; Table below TEFSUBTX02_BRCA).
[0347] Table 4: Post-treatment for prostate cancer selected in cohort 1 BRCA subgroups. By the time of FA CCO, 180 subjects (80%) in the BRCA subgroups had discontinued treatment. Of these participants, 146 discontinued treatment due to disease progression: 60 / 113 (53.1%) in the niraparib + AAP group and 86 / 112 (76.8%) in the placebo + AAP group. Among participants who discontinued treatment due to disease progression, a higher proportion received PARP inhibitors in the placebo + AAP group compared to those treated with niraparib + AAP (niraparib + AAP: 3 / 60 [5.0%]; placebo + AAP: 29 / 86 [33.7%]). The proportion of participants who received subsequent chemotherapy after discontinuing treatment due to disease progression was similar in both treatment groups (niraparib + AAP: 34 / 60 [56.7%]; placebo + AAP: 51 / 86 [59.3%]), indicating that niraparib + AAP treatment did not prevent participants with disease progression from receiving subsequent chemotherapy. (Table below: TEFSUBTX02PD_BRCA).
[0348] Patient-reported outcomes in the BRCA subgroups: Updated patient-reported outcomes analysis in the BRCA subgroups showed that the efficacy benefit of niraparib + AAP was accompanied by a prolonged time to pain progression.
[0349] In the BRCA subgroups, the median time to clinically significant progression of BPI-SF most severe pain had not yet been reached in subjects receiving niraparib + AAP, compared to 32.2 months in subjects receiving placebo + AAP (HR = 0.809; 95% CI: 0.524, 1.249; p = 0.3378). In the niraparib + AAP group, the median time to progression of BPI-SF pain interference had not yet been reached, compared to 41.5 months in the placebo + AAP group (HR = 0.771; 95% CI: 0.481, 1.234; p = 0.2778).
[0350] Cohort 1, Final Safety Analysis (All HRR Populations) Product Information 35 / 185 Page 41 CN 121443291 A All subjects in Cohort 1 who received at least one dose of study treatment were included in the safety analysis. At the FA CCO, the median duration of treatment for subjects randomized to niraparib + AAP in Cohort 1 was 20.2 months, compared to 15.2 months for subjects randomized to placebo + AAP. The overall safety profile remained consistent with IA2 and the 4-month safety update (4MSU), with no new safety signals identified due to additional treatment exposure.
[0351] The overall summary of treatment-related adverse events (TEAEs) in Cohort 1 is presented in Table 6. The higher incidence of adverse events (AEs) observed in the niraparib + AAP group remained primarily driven by known hematologic AEs associated with niraparib. The most common TEAEs in the niraparib + AAP group remained unchanged since IA2, and the overall side effect profile of the niraparib + AAP regimen remained manageable. A slight increase in grade 3 to 4 TEAEs and serious adverse events (SAEs) was observed, reflecting an increase in study treatment exposure since IA2 and 4 MSU. Furthermore, the safety profile observed in the BRCA subgroup treated with niraparib + AAP was consistent with the safety profile of the entire HRR population in cohort 1 (updated tables of adverse event rates and laboratory abnormalities observed in the BRCA subgroups are provided in Table TSFAE07_modified below).
[0352] Table 6: Overall Safety Profile of Cohort 1 (All HRRs) Explanation: AAP = Abiraterone acetate plus prednisone, AE = Adverse event a. An AE is classified as relevant if the investigator assesses it as being associated with niraparib, abiraterone acetate, or prednisone.
[0353] b. AEs leading to death are based on AE outcomes classified as “fatal”.
[0354] c.If an AE leads to discontinuation of niraparib, abiraterone acetate, or prednisone, the AE is counted as a cause of discontinuation of the study drug.
[0355] TEAEs leading to death In cohort 1, at FA CCO, 22 subjects (10.4%) in the niraparib + AAP group experienced AEs leading to death, compared to 10 subjects (4.7%) in the placebo + AAP group (at IA2, 20 [9.4%] in the niraparib + AAP group and 9 [4.3%] in the placebo + AAP group). Although the most common TEAE leading to death in both treatment groups was COVID-19, no deaths due to COVID-19 have occurred since IA2.
[0356] Adverse events of particular concern In cohort 1, more subjects experienced adverse events of particular concern (AESIs) in the niraparib + AAP group compared to the placebo + AAP group (Table 6). Similar to IA2 and 4MSU, the higher incidence of AESIs in the niraparib + AAP group (Main Prescription 36 / 185 pages 42 CN 121443291 A) was driven by hematologic toxicities, which were manageable with dose modification and supportive care, and most subjects were able to continue treatment with niraparib + AAP. The overall incidence of other AESIs was similar to that reported in IA2 and 4MSU, including cardiac disease and hypertension. No cases of MDS or AML were reported in the niraparib + AAP group (in the placebo + AAP group, one subject with a TEAE of AML was observed at IA1).
[0357] Dose Modification: In all HRR populations in Cohort 1, more AEs leading to dose modification were observed in the niraparib + AAP group compared to the placebo + AAP group (Table 7). Since IA2, the number of subjects with AEs leading to niraparib dose interruption has increased, reflecting increased study treatment exposure between IA2 and FA CCO; the most common AEs leading to niraparib dose interruption in the niraparib + AAP group remained unchanged (anemia: 49 [23.1%], followed by thrombocytopenia: 24 [11.3%]). Since IA2, the number of subjects with AEs leading to niraparib or placebo dose reduction has remained unchanged, and anemia and thrombocytopenia were again the most common AEs leading to niraparib dose reduction in the niraparib + AAP group. Compared to IA2, 9 additional subjects experienced AEs leading to niraparib or placebo discontinuation at FA CCO (7 in the niraparib + AAP group and 2 in the placebo + AAP group); however, most subjects in both groups continued study treatment until disease progression or were still receiving study treatment.
[0358] Table 7: Final analysis of niraparib or placebo dose modification and treatment discontinuation cohort 3 at FA and IA2Cohort 3 was enrolled after enrollment in Cohorts 1 and 2 and consisted of 95 subjects with HRR gene alterations. All subjects received open-label FDC tablets (niraparib / AA) plus prednisone. Cohort 3 provided clinical experience with the FDC tablet formulation, and no formal hypothesis testing was performed on efficacy. At FA CCO, 19 BRCA subjects (36.5%) were still receiving study treatment. The most common reason for treatment discontinuation was disease progression (24 subjects [46.2%]); a small number of subjects discontinued due to AEs (6 subjects [11.5%]).
[0359] Overall, the safety profile observed in subjects treated with niraparib / AA FDC plus prednisone in Cohort 3 was consistent with the safety profile of niraparib + AAP SAC in all HRR populations and BRCA subgroups in Cohort 1. The median duration of treatment in Cohort 3 was 19.5 months, no new safety signals were identified, and the AE reporting pattern observed in subjects in Cohort 3 was similar to that in the niraparib + AAP group in Cohort 1.
[0360] Conclusion: In the primary analysis (PA-IA1), statistically significant and clinically meaningful improvements were observed in the primary endpoint rPFS in both the BRCA subgroup and all HRR populations in cohort 1.
[0361] This final analysis showed a strong trend toward improved OS in the BRCA subgroup with niraparib + AAP (HR=0.788; 95% CI: 0.544, 1.120; p=0.1828), with a sustained and clear separation of the Kaplan-Meier curve, despite a higher proportion of patients in the placebo + AAP group receiving subsequent treatment (particularly taxane-based chemotherapy and approved life-extending drugs such as PARP inhibitors). These results are further supported by consistent and clinically meaningful improvements in TSP and TCC, as detailed in the specification 37 / 185 pages 43 CN 121443291 A, clearly demonstrating the benefit of niraparib + AAP as first-line treatment for patients with mCRPC with BRCA genetic alterations.
[0362] An imbalance was found in the assessment of prognostic risk factors between the two treatment groups, supporting the placebo + AAP (median risk score based on the Halabi et al. model was 0.69 in the placebo + AAP group and 0.75 in the niraparib + AAP group), thus highlighting the importance of using a multivariate model to adjust for these imbalances. Indeed, prespecified multivariate analyses that adjusted for these imbalances showed a treatment benefit in OS for subjects treated with niraparib + AAP in the BRCA subgroup (HR=0.663; 95% CI: 0.464, 0.947).
[0363] Consistent and clinically meaningful improvements were observed in both TSP and TCC in the cohort 1 BRCA subgroup, both endpointsThe KM curves showed clear separation early on and this separation intensified with longer follow-up. In mCRPC, the benefits observed at these well-validated and highly patient-relevant endpoints were also reflected in patient-reported outcomes, with a trend toward longer time to clinically significant progression to the most severe pain intensity of BPI-SF and to clinically significant progression to pain interference observed in BRCA-altered subjects treated with niraparib + AAP.
[0364] The safety profile of niraparib + AAP at FA was consistent with previous analyses, with no new safety signals observed during longer exposure durations and additional follow-up. Despite the high baseline disease burden in the older population (26.5% of whom were over 75 years of age), the combination therapy of niraparib + AAP was well tolerated. In all HRR populations and BRCA subgroups in cohort 1, treatment with niraparib + AAP was manageable through dose interruption, reduction, and supportive care. Most subjects treated with niraparib + AAP were able to continue treatment until disease progression. The safety profile of niraparib / AA FDC plus prednisone observed in cohort 3 appeared consistent with that observed in cohort 1.
[0365] In summary, the results of the final analysis continue to demonstrate a positive benefit-risk ratio in BRCA-mutated mCRPC patients treated with niraparib plus AAP. Efficacy analyses showed a strong trend toward improvement in OS and clinically meaningful improvements in key secondary endpoints TSP and TCC, while overall health-related quality of life was maintained in patients treated with niraparib plus AAP. Updated safety analyses confirmed that niraparib plus AAP was tolerable and its toxicity was manageable. In conclusion, the MAGNITUDE study clearly demonstrates the significant benefit of niraparib plus AAP as first-line treatment for patients with BRCA alterations in mCRPC.
[0366] Results, Subjects and Treatment Information, Instructions for Use, Page 38 / 185, 44, CN 121443291 A; Instructions for Use, Page 39 / 185, 45, CN 121443291 A; Efficacy Instructions for Use, Page 40 / 185, 46, CN 121443291 A; Instructions for Use, Page 41 / 185, 47, CN 121443291 A; Instructions for Use, Page 42 / 185, 48, CN 121443291 A; Instructions for Use, Page 43 / 185, 49, CN 121443291 A; Safety Instructions for Use, Page 44 / 185, 50, CN 121443291 A; Instructions for Use, Page 45 / 185, 51, CN 121443291 A; Instructions for Use, Page 46 / 185, 52, CN 121443291 A.Pages 47 / 185, 53 CN 121443291 A, Instruction Manual; Pages 48 / 185, 54 CN 121443291 A, Instruction Manual; Pages 49 / 185, 55 CN 121443291 A, Instruction Manual; Pages 50 / 185, 56 CN 121443291 A, Instruction Manual; Pages 51 / 185, 57 CN 121443291 A, Instruction Manual; Pages 52 / 185, 58 CN 121443291 A, Instruction Manual; Pages 53 / 185, 59 CN 121443291 A, Instruction Manual; Pages 54 / 185, 60 CN 121443291 A, Instruction Manual; Pages 55 / 185, 61 CN 121443291 A, Instruction Manual; Pages 56 / 185, 62 CN 121443291 A, Instruction Manual; Pages 57 / 185, 63 CN 121443291 A Instructions for Use 58 / 185 pages 64 CN 121443291 A Example 2 – Drug Product Labeling Instructions for Use Approved by the European Medicines Agency (EMA) 59 / 185 pages 65 CN 121443291 A Approval Date: April 19, 2023 Appendix I Summary of Product Characteristics 1. Drug Name Akeega 50mg / 500mg Film-Coated Tablets Akeega 100mg / 500mg Film-Coated Tablets 2. Qualitative and Quantitative Composition Each film-coated tablet of Akeega 50mg / 500mg contains niraparib tosylate monohydrate equivalent to 50mg of niraparib and 500mg abiraterone acetate equivalent to 446mg of abiraterone.
[0367] Each Akeega 100mg / 500mg film-coated tablet contains niraparib tosylate monohydrate equivalent to 100mg niraparib and 500mg abiraterone acetate equivalent to 446mg abiraterone.
[0368] Excipients with known effects: Each film-coated tablet contains 241mg lactose (see Section 4.4). A complete list of excipients is provided in Section 6.1.
[0369] 3. Dosage Form: Film-coated tablets (tablets).
[0370] Akeega 50mg / 500mg film-coated tablets are yellow-orange to yellow-brown, oval, film-coated (22mm × 11mm), with "N 50 A" engraved on one side and blank on the other.
[0371] Akeega 100mg / 500mg film-coated tablets are orange, oval-shaped, and 22mm × 11mm in size. One side is engraved with "N 100 A", and the other side is blank.
[0372] 4. Clinical Matters 4.1 Therapeutic IndicationsAkeega is indicated in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1 / 2 mutations (germline and / or somatic mutations) who are not clinically indicated for chemotherapy.
[0373] 4.2 Dosage and Administration Treatment with niraparib and abiraterone acetate plus prednisone or prednisolone should be initiated and supervised by a specialist with experience in the drug therapy of prostate cancer.
[0374] BRCA positivity must be determined using a validated testing method before initiating Akeega treatment (see Section 5.1).
[0375] Dosage The recommended starting dose of Akeega is 200 mg / 1,000 mg (two 100 mg niraparib / 500 mg abiraterone acetate tablets) once daily at approximately the same time each day (see “Administration” below). 50 mg / 500 mg tablets may be used to reduce the dose.
[0376] For patients who have not undergone surgical castration, medical castration with a gonadotropin-releasing hormone (GnRH) analog should be continued during treatment.
[0377] Dosage instructions for prednisone or prednisolone 60 / 185 pages 66 CN 121443291 A Akeega is used daily with 10 mg of prednisone or prednisolone.
[0378] Duration of treatment Patients should continue treatment until disease progression or unacceptable toxicity occurs.
[0379] Missed doses If a dose of Akeega, prednisone, or prednisolone is missed, it should be taken as soon as possible on the same day and the normal schedule should be resumed the following day. No additional tablets should be taken to make up for the missed dose.
[0380] Dosage adjustment for adverse reactions Non-hematologic adverse reactions For patients experiencing a grade ≥3 non-hematologic adverse reaction, treatment should be interrupted and appropriate medical management should be implemented (see Section 4.4). Akeega treatment should not be restarted until the toxic symptoms have resolved to grade 1 or baseline levels.
[0381] Hematologic adverse reactions: For patients experiencing hematologic toxicity ≥ grade 3 or intolerable hematologic toxicity, Akeega administration should be interrupted rather than discontinued, and supportive management should be considered. If hematologic toxicity does not recover to an acceptable level within 28 days of the dose interruption period, Akeega should be permanently discontinued.
[0382] Dosage adjustment recommendations for thrombocytopenia and neutropenia are listed in Table 1.
[0383] Subsequent administration of Akeega may only be resumed when toxicity due to thrombocytopenia and neutropenia improves to grade 1 or resolves to baseline levels. Treatment can be resumed at a lower intensity of Akeega 50 mg / 500 mg (2 tablets). For the most common adverse reactions, see Section 4.8.
[0384] For ≥ grade 3 anemia, Akeega should be interrupted and supportive management should be provided until recovery to ≤ grade 2. If based on clinical...If anemia is determined to be persistent, a dose reduction (two 50mg / 500mg tablets) should be considered. Recommendations for dose adjustments for anemia are listed in Table 2.
[0385] Hepatotoxicity: For patients experiencing grade ≥3 hepatotoxicity (elevated alanine aminotransferase [ALT] or aspartate aminotransferase [AST] exceeding five times the upper limit of normal [ULN]), Akeega treatment should be interrupted and liver function closely monitored (see Section 4.4).
[0386] Treatment can only be restarted at a reduced dose level (one regular-strength Akeega tablet, equivalent to 100mg niraparib / 500mg abiraterone acetate) after liver function tests have returned to the patient's baseline levels. For patients restarting treatment, serum transaminases should be monitored at least every two weeks for the first three months, and monthly thereafter. If hepatotoxicity recurs at a reduced dose of 100 mg / 500 mg (1 tablet) daily, Akeega treatment should be discontinued.
[0387] If a patient develops severe hepatotoxicity (ALT or AST 20 times ULN) during Akeega use, treatment should be permanently discontinued.
[0388] For patients with concurrent elevations of ALT greater than 3 × ULN and total bilirubin greater than 2 × ULN, and without biliary obstruction or other causes of the elevations, Akeega should be permanently discontinued (see Section 4.4).
[0389] It is recommended that complete blood counts be obtained before the start of treatment, weekly for the first month, bi-weekly for the following two months, monthly for the first year thereafter, and then monthly for the remainder of treatment to monitor for any clinically significant changes in hematological parameters (see Section 4.4).
[0390] Serum aminotransferases and total bilirubin should be measured before the start of treatment, bi-weekly for the first three months of treatment, monthly for the first year thereafter, and then monthly for the duration of treatment. When starting a lower-intensity dose (two tablets) after a dose interruption, liver function should be monitored every two weeks for six weeks before resuming regular monitoring due to the increased risk of abiraterone exposure (see Section 5.2). Serum potassium should be monitored monthly during the first year, and then monthly for the duration of treatment (see Section 4.4).
[0391] Blood pressure should be monitored weekly for the first two months, monthly during the first year, and then monthly for the duration of treatment.
[0392] For patients with pre-existing hypokalemia or who develop hypokalemia during treatment with Akeega, consider maintaining the patient's potassium level at ≥4.0 mM.
[0393] Special Populations Instructions for Use 62 / 185 pages 68 CN 121443291 A Elderly Patients No dose adjustment is required (see Section 5.2).
[0394] Hepatic ImpairmentNo dose adjustment is required for patients with pre-existing mild hepatic impairment (Child-Pugh Class A). There are no clinical safety and efficacy data regarding multiple doses of Akeega in patients with moderate or severe hepatic impairment (Child-Pugh Class B or C). Dose adjustments cannot be predicted. Akeega should be carefully evaluated in patients with moderate hepatic impairment, and its benefits should clearly outweigh the potential risks (see Sections 4.4 and 5.2). Akeega is contraindicated in patients with severe hepatic impairment (see Sections 4.3, 4.4, and 5.2).
[0395] No dose adjustment is required for patients with mild to moderate renal impairment; however, for patients with moderate renal impairment, close monitoring for safety events is necessary due to the potential increase in niraparib exposure. There are no data on the use of Akeega in patients with severe renal impairment or end-stage renal disease undergoing hemodialysis. Akeega should only be used in patients with severe renal impairment when the benefits outweigh the potential risks, and patients should be carefully monitored for renal function and adverse events (see Sections 4.4 and 5.2).
[0396] Pediatric Population Akeega has no relevant use in the pediatric population.
[0397] Administration Akeega is for oral administration.
[0398] Tablets must be taken as a single dose once daily. Akeega should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal (see Section 5.2). For optimal absorption, Akeega tablets must be swallowed whole with water and should not be broken, crushed, or chewed.
[0399] Precautions to be taken before handling or administering the product Women who are pregnant or may become pregnant should wear gloves when handling tablets (see Section 6.6).
[0400] 4.3 Contraindications Hypersensitivity to the active substance or any of the excipients listed in Section 6.1.
[0401] Pregnancy or possible pregnancy in women (see Section 4.6).
[0402] Severe hepatic impairment [Child-Pugh C (see Sections 4.2, 4.4, and 5.2)].
[0403] Akeega plus prednisone or prednisolone is contraindicated in combination with Ra-223 treatment.
[0404] 4.4 Special Warnings and Precautions Hematological Adverse Reactions Hematological adverse reactions (thrombocytopenia, anemia, and neutropenia) have been reported in patients treated with Akeega (see Section 4.2).
[0405] It is recommended that complete blood counts be tested weekly during the first month of treatment, bi-weekly for the next two months, monthly for the first year thereafter, and then monthly for the remainder of treatment to monitor for any clinically significant changes in hematological parameters (see Section 4.2).
[0406] Based on individual laboratory values, weekly monitoring may be required during the second month.
[0407] If a patient develops severe, persistent hematologic toxicity (including pancytopenia) that does not improve within 28 days of treatment interruption, Akeega should be discontinued.
[0408] Due to the risk of thrombocytopenia, patients taking Akeega should use caution with other medications known to reduce platelet counts (see Section 4.8).
[0409] When starting a lower-intensity dose (two tablets) after a dose interruption due to hematologic adverse reactions, liver function should be monitored every two weeks for six weeks until regular monitoring (see Section 4.2) is resumed before resuming regular monitoring (see Section 4.2) due to the increased risk of abiraterone exposure (see Section 5.2).
[0410] Hypertension Akeega may cause hypertension, and pre-existing hypertension should be adequately controlled before starting Akeega treatment. During treatment with Akeega, blood pressure should be monitored weekly for at least the first two months, monthly for the first year thereafter, and then monthly thereafter.
[0411] Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions Due to Mineralocorticoid Overdose: Akeega may cause hypokalemia and fluid retention due to elevated mineralocorticoid levels caused by CYP17 inhibition (see Section 4.8) (see Section 5.1). Concomitant use of corticosteroids to inhibit adrenocorticotropic hormone (ACTH) drive can reduce the incidence and severity of these adverse reactions. Caution should be exercised when treating patients whose underlying health conditions may be exacerbated by hypokalemia (e.g., patients using cardiac glycosides) or fluid retention (e.g., patients with heart failure, severe or unstable angina, recent myocardial infarction or ventricular arrhythmias, and patients with severe renal impairment). QT interval prolongation has been observed in patients who developed hypokalemia associated with Akeega treatment. Hypokalemia and fluid retention should be corrected and controlled.
[0412] Heart failure should be treated and cardiac function optimized before treating patients at significant risk of congestive heart failure (e.g., a history of heart failure or cardiac events such as ischemic heart disease). Fluid retention (weight gain, peripheral edema) and other signs and symptoms of congestive heart failure should be monitored every two weeks for three months, and then monthly thereafter, with any abnormalities corrected. Akeega should be used with caution in patients with a history of cardiovascular disease.
[0413] Management of cardiac risk factors (including hypertension, dyslipidemia, and diabetes) in patients receiving Akeega treatment should be optimized, and these patients should be monitored for signs and symptoms of cardiac disease.
[0414] Abiraterone acetate (a component of Akeega) increases mineralocorticoid levels and carries a risk of cardiovascular events. Excessive mineralocorticoids may cause hypertension, hypokalemia, and fluid retention. Previous androgen deprivation therapy (ADT) exposureExposure and advanced age are additional risk factors for cardiovascular morbidity and mortality. The MAGNITUDE study excluded patients with clinically significant heart disease, evidence including myocardial infarction, arterial and venous thrombotic events within the past six months, severe or unstable angina, or NYHA class II to IV heart failure or a cardiac ejection fraction measurement <50%. Patients with a history of heart failure should be clinically optimized and given appropriate symptom management. Akeega should be discontinued if a clinically significant decline in cardiac function occurs.
[0415] Infections In the MAGNITUDE study, patients treated with Akeega had a higher frequency of serious infections, including COVID-19 infections with fatal outcomes. Patients should be monitored for signs and symptoms of infection. Serious infections may occur in the absence of neutropenia and / or leukopenia.
[0416] Pulmonary embolism (PE) In the MAGNITUDE study, the frequency of reported PE cases was higher in patients treated with Akeega than in the control group. Patients with a history of PE or venous thrombosis may face a higher risk of recurrence. Patients should be monitored for clinical signs and symptoms of PE. If clinical features of PE are present, the patient should be evaluated promptly and appropriate treatment should be administered.
[0417] Posterior Reversible Encephalopathy Syndrome (PRES) PRES is a rare, reversible neurological disorder that can present with rapidly evolving symptoms, including seizures, headache, altered mental status, visual disturbances or cortical blindness, with or without associated hypertension. Diagnosis of PRES requires confirmation by brain imaging (preferably magnetic resonance imaging (MRI)).
[0418] There have been reports of PRES occurring in patients with ovarian cancer who received 300 mg niraparib (a component of Akeega) as monotherapy. No cases of PRES were reported in prostate cancer patients treated with 200 mg niraparib in the MAGNITUDE study.
[0419] If PRES occurs, Akeega treatment should be permanently discontinued and appropriate medical management should be implemented.
[0420] Hepatotoxicity and Liver Impairment Hepatotoxicity has been identified as a significant, known risk associated with abiraterone acetate (a component of Akeega). The mechanisms of hepatotoxicity of abiraterone acetate are not fully understood. Patients with moderate to severe liver impairment (NCI classification) and Child-Turcotte-Pugh B and C were excluded from Akeega combination studies.
[0421] In the MAGNITUDE study and all combination clinical studies, patients with baseline hepatitis or significantly abnormal liver function tests (serum total bilirubin >1.5×ULN or direct bilirubin >1×ULN, and AST or ALT >3×ULN) were excluded.To mitigate the risk of hepatotoxicity.
[0422] Significant elevations of liver enzymes leading to treatment interruption or cessation have occurred in clinical studies, although these are not common (see Section 4.8). Serum aminotransferase and total bilirubin levels should be measured before starting treatment, every two weeks for the first three months of treatment, and monthly thereafter. When starting a lower intensity dose (two tablets) after a dose interruption, liver function should be monitored every two weeks for six weeks before resuming routine monitoring due to the increased risk of abiraterone exposure (see Section 5.2). Serum transaminases should be measured immediately if clinical symptoms or signs suggestive of hepatotoxicity occur. Patients with elevated aminotransferases treated with Akeega should be managed immediately by interrupting treatment. If ALT or AST increases by more than 5 times the ULN at any time, Akeega treatment should be interrupted and liver function closely monitored. Treatment can only be restarted at a reduced dose level after liver function tests have returned to the patient's baseline levels (see Section 4.2).
[0423] For patients with ALT or AST elevations >20 × ULN, treatment should be permanently discontinued. For patients with concurrent elevations of ALT > 3 × ULN and total bilirubin > 2 × ULN, and without biliary obstruction or other causes of the elevation, treatment should be permanently discontinued.
[0424] If a patient develops severe hepatotoxicity (ALT or AST 20 times ULN) at any time during treatment, Akeega treatment should be permanently discontinued.
[0425] Patients with active or symptomatic viral hepatitis were excluded from clinical studies; therefore, there is no data to support the use of Akeega in this population.
[0426] Moderate hepatic impairment (Child-Pugh B or any AST and TB > 1.5 × to 3 × ULN) has been shown to increase systemic exposure to abiraterone and niraparib (see Section 5.2). There are no data on the clinical safety and efficacy of repeated Akeega administration in patients with moderate or severe hepatic impairment. The use of Akeega should be carefully evaluated in patients with moderate hepatic impairment, and the benefits should clearly outweigh the potential risks (see Sections 4.2 and 5.2). Akeega should not be used in patients with severe hepatic impairment (see Sections 4.2, 4.3, and 5.2).
[0427] Hypoglycemia has been reported in patients with pre-existing diabetes who were receiving abiraterone acetate (a component of Akeega) plus prednisone or prednisolone while receiving pioglitazone or repaglinide (metabolized via CYP2C8) (see Section 4.5). Therefore, blood glucose levels should be monitored in diabetic patients.
[0428] Myelodysplastic syndrome / acute myeloid leukemia (MDS / AML) In ovarian cancer studies, patients receiving 300 mg niraparib (a component of Akeega) have experienced [hypoglycemia / AML].Reports of MDS / AML (including cases with fatal outcomes).
[0429] No cases of MDS / AML were observed in patients treated with 200 mg niraparib and 1,000 mg abiraterone acetate plus prednisone or prednisolone, see package insert 65 / 185 page 71 CN 121443291 A.
[0430] Patients with suspected MDS / AML or long-term hematologic toxicity that does not improve with treatment interruption or dose reduction should be referred to a hematologist for further evaluation. If MDS and / or AML is confirmed, Akeega treatment should be permanently discontinued and the patient should be treated appropriately.
[0431] Corticosteroid discontinuation and stress coverage: If a patient discontinues prednisone or prednisolone, caution is advised and adrenocortical insufficiency should be monitored. If Akeega is continued after discontinuation of corticosteroids, the patient should be monitored for symptoms of mineralocorticoid overdose (see information above).
[0432] For patients receiving prednisone or prednisolone treatment and experiencing unusual stress, the dose of corticosteroids may need to be increased before, during, and after the stressful event.
[0433] Bone Mineral Density: Men with metastatic advanced prostate cancer may experience decreased bone mineral density. The use of abiraterone acetate (a component of Akeega) in combination with glucocorticoids may exacerbate this effect.
[0434] Combination with Ra-223 Dichloride: Increased Fracture and Mortality: The combination of Akeega plus prednisone or prednisolone with Ra-223 treatment is contraindicated (see Section 4.3) because an increased risk of fracture and a trend toward increased mortality have been observed in clinical studies using abiraterone acetate (a component of Akeega).
[0435] It is recommended that subsequent Ra-223 treatment not be started until at least five days after the last administration of Akeega in combination with prednisone or prednisolone.
[0436] Hyperglycemia: Use of glucocorticoids may increase hyperglycemia; therefore, blood glucose levels should be measured frequently in diabetic patients.
[0437] Skeletal muscle effects: No cases of myopathy or rhabdomyolysis have been observed in patients treated with Akeega. In monotherapy studies of abiraterone acetate (a component of Akeega), most cases occurred within the first six months of treatment and recovered upon discontinuation of abiraterone acetate. Caution is advised for patients being treated concurrently with medications known to be associated with myopathy / rhabdomyolysis.
[0438] Interactions with other medications: Potent CYP3A4 inducers should be avoided during treatment unless no alternative treatment is available, as there is a risk of reduced abiraterone exposure (see Section 4.5).
[0439] Lactose and sodium: This medication contains lactose. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medication.
[0440] Each dose of this drug contains less than 1 mmol (23 mg) of sodium, which is essentially “sodium-free”.
[0441] 4.5 Interactions with Other Drugs and Other Forms of Interactions Pharmacokinetic Interactions have not been evaluated in clinical studies using Akeega. Interactions identified in studies of the individual components of Akeega (niraparib or abiraterone acetate) determine possible interactions with Akeega.
[0442] Effects of Other Drugs on Niraparib or Abiraterone Acetate CYP3A4 Inducers and Inhibitors Package Insert 66 / 185 pages 72 CN 121443291 A Abiraterone is a CYP3A4 substrate. In a clinical study in healthy subjects, a single dose of abiraterone acetate 1,000 mg followed by prior treatment with a potent CYP3A4 inducer rifampin (600 mg daily for six days) resulted in a 55% reduction in the mean plasma AUC∞ of abiraterone. Potent CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's wort [Hypericum perforatum]) should be avoided during treatment with Akeega unless no alternative treatment is available (see Section 4.4).
[0443] In another clinical study in healthy subjects, co-administration of the potent CYP3A4 inhibitor ketoconazole had no clinically significant effect on the pharmacokinetics of abiraterone.
[0444] Effects of niraparib or abiraterone acetate on other drugs Abiraterone, a CYP2D6 substrate, is a CYP2D6 inhibitor. In a clinical study to determine the effect of abiraterone acetate plus prednisone (AAP) on a single dose of the CYP2D6 substrate dextromethorphan, the systemic exposure (AUC) of dextromethorphan was increased by approximately 2.9-fold. The AUC24 of the active metabolite of dextromethorphan, dextromethorphan, was increased by approximately 33%. Reducing the dose of drugs metabolized by CYP2D6 and with a narrow therapeutic index should be considered. Examples of drugs metabolized by CYP2D6 include metoprolol, propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone, and tramadol.
[0445] Abiraterone, a CYP2C8 substrate, is a CYP2C8 inhibitor. In a clinical study in healthy subjects, when pioglitazone (a CYP2C8 substrate) was co-administered with a single dose of 1,000 mg abiraterone acetate, the AUC of pioglitazone increased by 46%, while the AUCs of the active metabolites M-III and M-IV of pioglitazone each decreased by 10%. If a CYP2C8 substrate with a narrow therapeutic index is used concomitantly with abiraterone acetate, patients should be monitored for signs of substrate-related toxicity due to the abiraterone acetate component. Examples of drugs metabolized by CYP2C8 include pioglitazone and repaglinide (see Section 4.4).
[0446] Pharmacodynamic interactions: The interaction of Akeega with vaccines or immunosuppressants has not been studied.
[0447] Data on the combination of niraparib with cytotoxic drugs are limited. Caution should be exercised when using Akeega in combination with live or attenuated live vaccines, immunosuppressants, or other cytotoxic drugs.
[0448] Use with products known to prolong the QT interval: Because androgen deprivation therapy may prolong the QT interval, caution is advised when administering Akeega with drugs known to prolong the QT interval or drugs that can induce torsades de pointes (such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, dofetilide, ibutilide), antiarrhythmic drugs, methadone, moxifloxacin, antipsychotics, etc.).
[0449] Use with spironolactone: Spironolactone binds to androgen receptors and may increase prostate-specific antigen (PSA) levels. Use with Akeega is not recommended (see Section 5.1).
[0450] 4.6 Fertility, Pregnancy and Lactation It is unclear whether any components of Akeega or its metabolites are present in semen in women of fertility / men and women.
[0451] During Akeega treatment and for four months after the last dose: • If the patient has sexual intercourse with a pregnant woman, condoms should be used.
[0452] • If the patient has sexual intercourse with a woman of fertility, condoms and another effective method of contraception should be used. Product Information 67 / 185 pages 73 CN 121443291 A
[0453] Animal studies have shown reproductive toxicity (see Section 5.3).
[0454] Pregnancy Akeega is not suitable for women (see Section 4.3).
[0455] There are no data on the use of Akeega in pregnant women. Based on the mechanism of action of both components and animal studies of abiraterone acetate, Akeega has been found to pose a potential risk of fetal harm. No animal developmental and reproductive toxicology studies have been conducted on niraparib (see Section 5.3).
[0456] Akeega is not suitable for breastfeeding women.
[0457] Fertility: There are no clinical data on the effects of Akeega on fertility. In animal studies, niraparib or abiraterone acetate reduced male fertility, but these effects were reversible upon discontinuation of treatment (see Section 5.3).
[0458] 4.7 Effects on the ability to drive or operate machinery: Akeega has a moderate effect on the ability to drive or operate machinery. Patients taking Akeega may experience weakness, fatigue, dizziness, or difficulty concentrating. Patients should exercise caution when driving or operating machinery.
[0459] 4.8 Summary of adverse effects and safety profile: The overall safety profile of Akeega is based on a phase 3, randomized, double-blind, placebo-controlled study (MAGNITUDE).Data from cohort 1 (N=212). The most common adverse reactions (incidence >10%) of all grades in the Nirapaniga AAP group were: anemia (50.0%), hypertension (33.0%), constipation (33.0%), fatigue (29.7%), nausea (24.5%), thrombocytopenia (23.1%), dyspnea (17.9%), back pain (17.0%), decreased appetite (15.6%), neutropenia (15.1%), arthralgia (15.1%), vomiting (14.6%), hypokalemia (13.7%), dizziness (12.7%), insomnia (11.3%), hyperglycemia (11.8%), and urinary tract infection (10.4%). The most frequently observed grade 3 to 4 adverse reactions were anemia (30.2%), hypertension (15.6%), thrombocytopenia (7.5%), neutropenia (6.6%), and elevated serum alkaline phosphatase (5.7%).
[0460] The adverse reactions observed during the clinical study are listed in a table below by frequency category. The frequency categories are defined as follows: very common (≥1 / 10); common (≥1 / 100 to <1 / 10); occasional (≥1 / 1,000 to <1 / 100); rare (≥1 / 10,000 to <1 / 1,000); very rare (<1 / 10,000); and unknown (frequency cannot be estimated based on available data).
[0461] Within each frequency group, adverse effects are presented in descending order of severity. Instructions for Use, Page 68 / 185, 74 CN 121443291 A
[0462] Description of Selected Adverse Reactions Instructions for Use, Page 69 / 185, 75 CN 121443291 A Hematologic Toxicity Hematologic toxicities (anemia, thrombocytopenia, and neutropenia), including laboratory test results, are the most common adverse reactions attributed to niraparib (a component of Akeega). These toxicities typically occur within the first two months of treatment, with the incidence decreasing over time.
[0463] In the MAGNITUDE study and other Akeega studies, the following hematologic parameters were included as inclusion criteria: absolute neutrophil count (ANC) ≥1,500 cells / μL; platelets ≥100,000 cells / μL and hemoglobin ≥9 g / dL. Hematologic adverse reactions are managed through laboratory monitoring and dose modification (see Sections 4.2 and 4.4).
[0464] Anemia was the most common adverse reaction (50.0%) and the most frequently observed grade 3 to 4 event (30.2%) in the MAGNITUDE study. Anemia occurred relatively early during treatment (median time to onset was 59 days). In the MAGNITUDE study,22.6% of patients experienced dose interruption, and 13.7% experienced dose reduction. 27% of patients received at least one anemia-related transfusion. Anemia led to a relatively small number of patient discontinuations (2.4%).
[0465] Thrombocytopenia: In the MAGNITUDE study, 23.1% of treated patients reported thrombocytopenia, while 7.5% experienced grade 3 to 4 thrombocytopenia. The median time from first dose to first occurrence was 56 days. In the MAGNITUDE study, thrombocytopenia was managed through dose modification (interruption 10.8%, dose reduction 2.8%) and platelet transfusion when appropriate (2.4%) (see Section 4.2). 0.5% of patients discontinued treatment. In the MAGNITUDE study, 1.4% of patients experienced non-life-threatening bleeding events.
[0466] Neutropenia: In the MAGNITUDE study, 15.1% of patients experienced neutropenia, of which 6.6% reported grade 3 to 4 neutropenia. The median time from first dose to first report of neutropenia was 54 days. Neutropenia led to treatment discontinuation in 6.6% of patients and dose reduction in 1.4% of patients. No treatment was discontinued due to neutropenia. In the MAGNITUDE study, 0.9% of patients had a concurrent infection.
[0467] Hypertension: Hypertension is an adverse reaction to both components of Akeega. Patients with uncontrolled hypertension (persistent systolic blood pressure [BP] ≥160 mmHg or diastolic blood pressure ≥100 mmHg) were excluded in all combination studies. 33% of patients reported hypertension, of which 15.6% were grade ≥3. The median time to hypertension was 60.5 days. Hypertension was controlled with adjunctive medication products.
[0468] Patients should have their blood pressure controlled before starting Akeega and should have their blood pressure monitored during treatment (see Section 4.4).
[0469] Cardiac events: In the MAGNITUDE study, the incidence of TEAEs (all grades) of cardiac disease was similar in both groups except for arrhythmia categories, with AEs observed in 13.7% of patients in the nirapaniga AAP group and 7.6% in the placebo plus AAP group (see Section 4.4). The higher frequency of arrhythmias was primarily due to low-grade palpitations, tachycardias, and atrial arrhythmias.
[0470] The median time to onset of arrhythmic events was 105 days in the nirapaniga AAP group and 262 days in the placebo plus AAP group. Arrhythmic events were resolved in 62% of patients in the nirapaniga AAP group and in 63% of subjects in the placebo plus AAP group.
[0471] The incidence of heart failure, acute heart failure, chronic heart failure, and congestive heart failure was 2.4% in the Nirapaniga AAP group, compared to 1.9% in the placebo plus AAP group. The median time to onset of AESI in the Nirapaniga AAP group was [missing information].The event duration was 206 days in the nirapaniga AAP group and 83 days in the placebo plus AAP group. Heart failure events were resolved in 20% of patients in the nirapaniga AAP group and 25% of patients in the placebo plus AAP group.
[0472] The incidence of ischemic heart disease grouping terms (including the preferred terms angina, acute myocardial infarction, acute coronary syndrome, unstable angina, and coronary atherosclerosis) was 4.2% in the nirapaniga AAP group and 4.3% in the placebo plus AAP group. The median time to onset of ischemic heart disease AESI was 538 days in the nirapaniga AAP group and 257 days in the placebo plus AAP group. Ischemic heart disease events were resolved in 78% of patients in both groups.
[0473] In the MAGNITUDE study, the overall incidence of hepatotoxicity was similar in the nirapaniga AAP group (12.7%) and the placebo plus AAP group (12.8%) (see Sections 4.2 and 4.4). Most of these events were low-grade transaminase elevations. Grade 3 events occurred in 1.4% of patients, and Grade 4 events occurred in only one patient (0.5%). The incidence of SAEs was also 0.9%. The median time to onset of hepatotoxicity in the MAGNITUDE study was 34 days. Hepatotoxicity was managed by dose interruption in 0.9% of patients and by dose reduction in 0.5% of patients. In the MAGNITUDE study, 0.5% of patients discontinued treatment due to hepatotoxicity.
[0474] Akeega has not been studied in pediatric patients.
[0475] Reporting of suspected adverse reactions is important after drug authorization. It allows for continuous monitoring of the beneficial / risk balance of the drug. Healthcare professionals are required to report any suspected adverse reactions listed in Appendix V via the National Reporting System.
[0476] 4.9 Overdose There is no specific treatment for an overdose of Akeega. In the event of an overdose, the physician should take general supportive measures and treat the patient symptomatically, including monitoring for signs and symptoms of arrhythmias, hypokalemia, and fluid retention. Liver function should also be assessed.
[0477] 5. Pharmacological Properties 5.1 Pharmacodynamic Properties Therapeutic Classification: Antineoplastic Drugs, Other Antineoplastic Drugs, ATC Code: L01XK Mechanism of Action Akeega is a combination of niraparib (a poly(ADP-ribose) polymerase (PARP) inhibitor) and abiraterone acetate (a prodrug of abiraterone) (a CYP17 inhibitor) that targets two oncogenic dependencies in patients with mCRPC and HRR gene mutations.
[0478] Niraparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) (PARP-1 and PARP-2), these enzymesIt plays a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzyme activity and increased formation of PARP-DNA complexes, leading to DNA damage, apoptosis, and cell death.
[0479] Abiraterone acetate Abiraterone acetate is converted in vivo to abiraterone, an inhibitor of androgen biosynthesis. Specifically, abiraterone selectively inhibits 17α-hydroxylase / C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostate tumor tissues and is essential for androgen biosynthesis in these tissues. CYP17 catalyzes the conversion of pregnenolone and progesterone to the testosterone precursors DHEA and androstenedione, respectively, through 17α-hydroxylation and cleavage of the C17,20 bond. Inhibition of CYP17 also leads to increased production of mineralocorticoids by the adrenal glands (see Section 4.4).
[0480] Androgen-sensitive prostate cancer responds to treatment that lowers androgen levels. Androgen deprivation therapy, such as the instructions on page 77 of 71 / 185 of CN 121443291 A, uses luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy to reduce androgen production in the testes without affecting androgen production in the adrenal glands or tumors. When combined with LHRH analogues (or orchiectomy), treatment with abiraterone reduces serum testosterone to undetectable levels (using commercial assays).
[0481] Pharmacodynamics Abiraterone Acetate Abiraterone reduces serum testosterone and other androgens to levels lower than those achieved by using LHRH analogues or orchiectomy alone. This is due to selective inhibition of the CYP17 enzyme required for androgen biosynthesis.
[0482] Clinical Efficacy and Safety The efficacy of Akeega as first-line treatment in patients with BRCA 1 / 2 mutant mCRPC was established in the randomized, placebo-controlled, multicenter phase 3 clinical trial MAGNITUDE (study 64091742PCR3001) in patients with mCRPC.
[0483] MAGNITUDE was a phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the combination of niraparib (200 mg) and abiraterone acetate (1,000 mg) plus prednisone (10 mg) daily versus standard AAP therapy. Efficacy data were based on cohort 1, which included 423 patients with mCRPC carrying a specific HRR gene mutation who were randomized (1:1) to receive niraparib plus AAP daily (N=212) or placebo plus AAP (N=211). Treatment continued until disease progression, unacceptable toxicity, or death.
[0484] Patients had not received prior systemic therapy in the context of mCRPC (except for short-term prior AAP (maximum 4 months)) and were currently receiving AAP.Patients with mCRPC undergoing ADT were eligible. Plasma, blood, and / or tumor tissue samples from all patients were tested using a validated next-generation sequencing assay to determine germline and / or somatic HRR gene mutation status. A total of 225 subjects carrying BRCA1 / 2 mutations were enrolled in the study (113 received Akeega). Another 198 patients carrying non-BRCA1 / 2 mutations (ATM, CHEK2, CDK12, PALB2, FANCA, BRIP1, HDAC2) were enrolled in the study (99 received Akeega).
[0485] The primary endpoint was radiographic progression-free survival (rPFS) determined by blinded independent central imaging (BICR) review based on the Evaluation Criteria for Treatment of Solid Tumors (RECIST) 1.1 (soft tissue and tissue lesions) and the Prostate Cancer Working Group-3 (PCWG-3) criteria (bone lesions). Time to symptom progression (TSP), time to cytotoxic chemotherapy (TCC), and overall survival (OS) were included as secondary efficacy endpoints.
[0486] In all HRR populations, the primary efficacy outcome at a median follow-up of 18.6 months showed a statistically significant improvement in rPFS as assessed by BICR, HR=0.729 (95% CI: 0.556, 0.956; p=0.0217).
[0487] Table 4 summarizes the demographic and baseline characteristics of BRCA patients enrolled in cohort 1 of the MAGNITUDE study. The median PSA at diagnosis was 41.07 ug / L (range 01–12080). At study enrollment, all patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1. All patients who had not previously undergone orchiectomy continued to receive background androgen deprivation therapy with GnRH analogs. Instructions for Use, 72 / 185 pages, 78 CN 121443291 A
[0488] In the primary analysis, a statistically significant improvement in BICR-assessed rPFS was observed in BRCA subjects treated with niraparib plus AAP compared to those treated with placebo plus AAP. Key efficacy outcomes in the BRCA population are presented in Table 5. Kaplan-Meier curves for BICR-assessed rPFS in the BRCA population are shown in Figure 4.
[0489] Pediatric Population The European Medicines Agency has exempted the submission of results from the Akeega study in all pediatric subgroups of prostate cancer. For information on pediatric use, see Section 4.2.
[0490] 5.2 Pharmacokinetic Properties The co-administration of niraparib and abiraterone had no effect on the exposure of their respective components. The AUC and Cmax of niraparib and abiraterone were comparable when administered as film-coated tablets at the standard strength of Akeega (100 mg / 500 mg) or as a combination of the components, compared to the exposures of their respective monotherapy treatments.
[0491] Absorption Akeega Product Information 73 / 185 pages 79 CN 121443291 A In patients with mCRPC, the median time to reach maximum plasma concentration of niraparib was 3 hours and that of abiraterone was 1.5 hours after administration of multiple doses of Akeega tablets under fasting and modified fasting conditions.
[0492] In a relative bioavailability study, the maximum (Cmax) and total (AUC0-72h) exposures of abiraterone in mCRPC patients (n=67) treated with lower-intensity film-coated tablets of Akeega (2×50mg / 500mg) were 33% and 22% higher, respectively, than those in patients (n=67) treated with either monotherapy (100mg niraparib capsules and 4×250mg abiraterone acetate tablets) (see Section 4.2). The inter-subject variability (%CV) of exposures was 80.4% and 72.9%, respectively. Niraparib exposure is comparable between Akeega's lower-strength film-coated tablets and monotherapy.
[0493] Niraparib has an absolute bioavailability of approximately 73%. Niraparib is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). However, due to its high permeability and bioavailability, the risk of clinically relevant interactions with drugs that inhibit these transporters is low.
[0494] Abiraterone acetate Abiraterone acetate is rapidly converted to abiraterone in vivo (see Section 5.1).
[0495] Compared to administration on an empty stomach, administration of abiraterone acetate with food results in a mean systemic exposure to abiraterone that is up to 10-fold (AUC) and up to 17-fold (Cmax), depending on the fat content of the diet. Considering normal variations in dietary contents and composition, administration of abiraterone acetate with food carries the potential risk of highly variable exposure. Therefore, abiraterone acetate should not be taken with food.
[0496] Distribution was based on population pharmacokinetic analysis. The apparent volumes of distribution for niraparib and abiraterone were 1,117 L and 25,774 L, respectively, indicating extensive extravascular distribution.
[0497] Niraparib is moderately bound to proteins (83.0%) in human plasma, primarily to serum albumin.
[0498] Abiraterone acetate 14C-Abiraterone has a plasma protein binding rate of 99.8% in human plasma.
[0499] Biotransformation of niraparib is primarily metabolized by carboxylesterase (CE) to form the major inactive metabolite M1. In a mass balance study, M1 and M10 (which subsequently forms M1 glucuronide) were the major circulating metabolites. At relevant niraparib concentrations, the potential for inhibition of CYP3A4 at intestinal levels has not been determined. Niraparib weakly induces CYP1A2 at high concentrations in vitro.
[0500] Abiraterone acetate oral administrationFollowing encapsulation with 14C-abiraterone acetate capsules, abiraterone acetate is hydrolyzed by CE to abiraterone, which then undergoes metabolism primarily in the liver, including sulfation, hydroxylation, and oxidation. Abiraterone is a substrate of CYP3A4 and sulfonyltransferase 2A1 (SULT2A1). The majority of circulating radioactivity (approximately 92%) is present in the form of abiraterone metabolites. Of the 15 detectable metabolites, the two major metabolites, abiraterone sulfate and N-oxide abiraterone sulfate, each account for approximately 43% of the total radioactivity. Abiraterone is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8 (see Section 4.5).
[0501] Elimination of Akeega: Based on population pharmacokinetic analysis of mCRPC subjects, the mean t½ of niraparib and abiraterone during combination administration was approximately 62 hours and 20 hours, respectively, with apparent CL / F of niraparib and abiraterone of 16.7 L / h and 1673 L / h, respectively.
[0502] Niraparib: Niraparib is primarily eliminated via the hepatobiliary and renal routes. Following a single oral dose of 300 mg [14C]-niraparib, an average of 86.2% (range 71% to 91%) of the dose was recovered in urine and feces within 21 days. Radioactive recovery in urine accounted for 47.5% (range 33.4% to 60.2%) of the dose, and in feces, 38.8% (range 28.3% to 47.0%). Of the mixed samples collected over six days, 40.0% of the dose was recovered in urine, primarily as metabolites; and 31.6% of the dose was recovered in feces, primarily as unchanged niraparib. Metabolite M1 is a substrate for multidrug and toxin efflux proteins (MATE) 1 and 2.
[0503] Following oral administration of 1,000 mg of 14C-abiraterone acetate, approximately 88% of the radioactive dose was recovered in feces, and approximately 5% in urine. The main compounds present in feces were unchanged abiraterone acetate and abiraterone (approximately 55% and 22% of the administered dose, respectively).
[0504] Effects of niraparib or abiraterone on transporters: Niraparib weakly inhibits P-gp, IC50 = 161 μM. Niraparib is an inhibitor of BCRP, organic cation transporter 1 (OCT1), MATE-1, and 2, with IC50 values of 5.8 μM, 34.4 μM, 0.18 μM, and ≤0.14 μM, respectively. Abiraterone's major metabolites, abiraterone sulfate and N-oxide abiraterone sulfate, have been shown to inhibit hepatic uptake of the transporter organic anion transporter polypeptide 1B1 (OATP1B1), therefore, plasma exposure to the drug eliminated via OATP1B1 may be increased. There are no available clinical data to confirm interactions based on the transporter OATP1B1.
[0505] Hepatic impairment in special populationsBased on population pharmacokinetic analysis of clinical study data from prostate cancer patients receiving niraparib monotherapy or niraparib / AA combination therapy, mild hepatic impairment (NCI-ODWG criteria, n=231) did not affect niraparib exposure.
[0506] In a clinical study of cancer patients classified by the degree of hepatic impairment using the NCI-ODWG criteria, after a single dose of 300 mg, the niraparib AUCinf in patients with moderate hepatic impairment (n=8) was 1.56 times that in patients with normal hepatic function (n=9) (90% CI: 1.06 to 2.30).
[0507] The pharmacokinetics of abiraterone were examined in subjects with pre-existing mild (n=8) or moderate (n=8) hepatic impairment (Child-Pugh A and B, respectively) and 8 healthy controls. Following a single oral dose of 1,000 mg, systemic exposure to abiraterone was approximately 1.11-fold and 3.6-fold increased, respectively, in subjects with pre-existing mild and moderate hepatic impairment.
[0508] In another study, the pharmacokinetics of abiraterone were examined in subjects with pre-existing severe (n=8) hepatic impairment (Child-Pugh C) and 8 healthy controls with normal hepatic function. Subjects with severe hepatic impairment showed approximately a 7-fold increase in abiraterone AUC and a 1.8-fold increase in free drug fraction compared to subjects with normal hepatic function. There is no clinical experience with the use of abiraterone in patients with moderate and severe hepatic impairment (see Section 4.2).
[0509] Renal impairment was assessed based on population pharmacokinetic analysis of clinical study data from prostate cancer patients receiving niraparib monotherapy or niraparib / AA combination therapy. Compared with individuals with normal renal function, patients with mild (creatinine clearance 60 to 90 mL / min, n=337) and moderate (creatinine clearance 30 to 60 mL / min, n=114) renal impairment showed a slight decrease in niraparib clearance (exposure increased by up to 13% in mild impairment and 13% to 40% in moderate impairment).
[0510] The pharmacokinetics of abiraterone were compared between end-stage renal disease patients (n=8) on a stable hemodialysis regimen and matched control subjects with normal renal function (n=8). Following a single oral dose of 1,000 mg, there was no increase in systemic abiraterone exposure in end-stage renal disease patients undergoing dialysis. There is no clinical experience with the use of Akeega in patients with severe renal impairment (see Section 4.2).
[0511] Population pharmacokinetic analysis of prostate cancer patients receiving niraparib or abiraterone acetate monotherapy or combination therapy based on weight, age, and race: • Weight versus niraparib (weight range: 43...)The exposure levels of niraparib (45 to 90 years) and abiraterone (56.0 kg to 135 kg) had no clinically significant effect.
[0512] • Age had no significant effect on the pharmacokinetics of niraparib (age range 45 to 90 years) and abiraterone (age range 19 to 85 years).
[0513] • There are insufficient data to draw conclusions about the effect of race on the pharmacokinetics of niraparib and abiraterone.
[0514] No studies have been conducted in pediatric populations to investigate the pharmacokinetics of Akeega in pediatric patients.
[0515] 5.3 Preclinical Safety Data No nonclinical studies of Akeega have been conducted. Nonclinical toxicology data are based on the results of individual studies of niraparib and abiraterone acetate.
[0516] In vitro, niraparib inhibits dopamine transporter at concentrations below human exposure levels. In mice, a single dose of niraparib increased intracellular levels of dopamine and its metabolites in the cortex. A reduction in spontaneous activity was observed in one of two single-dose studies in mice. The clinical relevance of these findings is unclear. In repeated-dose toxicity studies in rats and dogs, no effects on behavioral and / or neurological parameters were observed at estimated CNS exposure levels similar to or below the expected therapeutic exposure level.
[0517] In rats and dogs, a reduction in spermatogenesis was observed at exposure levels below the therapeutic exposure level and was largely reversible within four weeks after discontinuation of administration.
[0518] Niraparib was not mutagenic in the bacterial reverse mutagenesis assay (Ames test), but it exhibited chromosome breakage in vitro in the mammalian chromosome aberration assay and in vivo in the rat bone marrow micronucleus assay. This chromosome breakage is consistent with the genomic instability caused by the primary pharmacological activity of niraparib and suggests potential genotoxicity in humans.
[0519] Reproductive and developmental toxicity studies of niraparib have not been conducted.
[0520] Carcinogenicity studies of niraparib have not been conducted.
[0521] In animal toxicity studies, abiraterone acetate significantly reduced circulating testosterone levels. As a result, organ weight loss and morphological and / or histopathological changes in the reproductive organs, adrenal glands, pituitary gland, and mammary glands were observed. All changes showed complete or partial reversibility. Changes in reproductive organs and androgen-sensitive organs were consistent with the pharmacological effects of abiraterone. All treatment-related hormonal changes were reversed or showed signs of remission after a 4-week recovery period.
[0522] In fertility studies in male and female rats, abiraterone acetate reduced fertility, which was completely reversible within 4 to 16 weeks after discontinuation of abiraterone acetate.
[0523] In developmental toxicity studies in rats, abiraterone acetate affected pregnancy, including reducing fetal weight and survival. Effects on the external genitalia were observed, but abiraterone acetate was not teratogenic.
[0524] In these rat fertility and developmental toxicity studies, all effects were associated with the pharmacological activity of abiraterone.
[0525] Apart from the reproductive organ changes observed in all animal toxicology studies, non-clinical data based on routine safety pharmacology, repeated-dose toxicity, genotoxicity, and carcinogenic potential studies did not reveal any particular risk to humans. Abiraterone acetate was not carcinogenic in a 6-month study in transgenic (Tg.rasH2) mice. In a 24-month rat carcinogenicity study, abiraterone acetate increased the incidence of testicular interstitial cell tumors. This finding is considered to be associated with the pharmacological action of abiraterone and is rat-specific. Abiraterone acetate was not carcinogenic in female rats.
[0526] Environmental Risk Assessment (ERA) The active substance abiraterone poses an environmental risk to aquatic environments, particularly fish (see Section 6.6).
[0527] 6. Pharmaceutical Matters 6.1 List of Excipients Akeega 50mg / 500mg film-coated tablets Core colloidal anhydrous silica cyclopovidone hydroxypropyl methylcellulose lactose monohydrate magnesium stearate microcrystalline cellulose sodium lauryl sulfate film coating iron oxide black (E172) iron oxide red (E172) iron oxide yellow (E172) sodium lauryl sulfate glyceryl monocaprylate polyvinyl alcohol talc titanium dioxide (E171) Akeega 100mg / 500mg film-coated tablets Core colloidal anhydrous silica cyclopovidone hydroxypropyl methylcellulose lactose monohydrate magnesium stearate microcrystalline cellulose sodium lauryl sulfate film coating iron oxide red (E172) iron oxide yellow (E172) Instructions for Use 77 / 185 pages 83 CN 121443291 A Sodium lauryl sulfate glyceryl monocaprylate polyvinyl alcohol talc titanium dioxide (E171) 6.2 Incompatibilities: Not applicable.
[0528] 6.3 Shelf life: 30 months.
[0529] 6.4 Special precautions for storage: This pharmaceutical product does not require any special storage conditions.
[0530] 6.5 Nature of the container and contents: Each 28-day carton contains 56 film-coated tablets, packaged in two paper wallet-style packs, each containing 28 film-coated tablets, placed in a PVdC / PE / PVC blister pack with aluminum top foil.
[0531] 6.6 Special precautions for handling and other disposal: Based on its mechanism of action, this drug may harm a developing fetus. Therefore, women who are pregnant or may become pregnant should handle Akeega under protective measures (e.g., wearing gloves) (see Section 4.6).
[0532] Any unused drug or waste should be disposed of in accordance with local requirements. This drug may pose a risk to the aquatic environment (see Section 5.3).
[0533] 7. Marketing Authorization HolderJanssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse Belgium 8. Marketing Authorization Number EU / 1 / 23 / 1722 / 001 EU / 1 / 23 / 1722 / 002 9. Date of First Marketing Authorization / Update Date 10. Date of Revision of this Document Detailed information about this medicine can be found on the European Medicines Agency website www.ema.europa.eu.
[0534] Appendix II A. Manufacturers of bioactive substances and manufacturers responsible for batch release B. Conditions or restrictions on supply and use C. Other conditions and requirements for marketing authorization D. Conditions or restrictions on the safe and effective use of the medicine A. Manufacturers responsible for batch release Name and address of the manufacturer responsible for batch release Janssen Cilag SpA Instructions for use 78 / 185 pages 84 CN 121443291 A Via C. Janssen, Borgo San Michele Latina 04100 Italy B. Conditions or restrictions on supply and use The medicine must be used with a restricted medical prescription (see Appendix I: Summary of product characteristics, Section 4.2).
[0535] C. Other conditions and requirements for marketing authorization • Periodic Safety Update Report (PSUR) The requirement for submitting a PSUR for this medicine is detailed in the Union Reference Date List (EURD List) as set out in Article 107c(7) of Directive 2001 / 83 / EC and any subsequent updates published on the European Medicines Network Portal.
[0536] The Marketing Authorization Holder (MAH) shall submit the first PSUR for this product within six months of authorization.
[0537] D. Conditions or limitations for the safe and effective use of the medicine • Risk Management Plan (RMP) The Marketing Authorization Holder (MAH) shall implement the required pharmacovigilance activities and interventions as detailed in the approved RMP presented in Marketing Authorization Module 1.8.2 and any subsequent updated versions of the approved RMP.
[0538] Updated RMPs shall be submitted: • upon request from the European Medicines Agency; • whenever the risk management system changes, especially due to the receipt of new information that may result in a significant change in the benefit / risk profile, or when significant (pharmacovigilance or risk minimization) milestones are achieved.
[0539] • Obligation to take post-authorization measures: The MAH shall complete the following measures within the specified timeframe: Appendix III Label and Packaging Instructions A. Label Akeega 50mg / 500mg Film-Coated Tablets Niraparib / Abiraterone Acetate Each film-coated tablet contains 50mg niraparib and 500mg abiraterone acetate.
[0540] Contains lactose.
[0541] See instructions for more information. Instructions for use 79 / 185 pages85 CN 121443291 A
[0542] 56 film-coated Akeega tablets should be taken at least two hours after a meal. Do not eat any food for at least one hour after taking Akeega.
[0543] Swallow whole. Do not break, crush, or chew the tablets.
[0544] Please read the package instructions before use.
[0545] For oral use only.
[0546] Keep out of sight and reach of children.
[0547] Pregnant women or women who may be pregnant should wear gloves when handling Akeega.
[0548] Please dispose of unused contents properly according to local requirements before the expiration date.
[0549] Janssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse Belgium EU / 1 / 23 / 1722 / 001 Batch Akeega 50mg / 500mg with a two-dimensional barcode containing a unique identifier.
[0550] PC SN Instructions for Use 80 / 185 pages 86 CN 121443291 A NN Akeega 50mg / 500mg Film-Coated Tablets Niraparib / Abiraterone Acetate Each film-coated tablet contains 50mg niraparib and 500mg abiraterone acetate.
[0551] 28 film-coated tablets of Akeega should be taken at least two hours after a meal. Do not eat any food for at least one hour after taking Akeega.
[0552] Swallow whole. Do not break, crush or chew the tablet.
[0553] Please read the package instructions before use.
[0554] For oral use.
[0555] (1) Hold down (see Figure 8) (2) Pull out (see Figure 9) Keep out of sight and reach of children.
[0556] Pregnant women or women who may be pregnant should wear gloves when handling Akeega.
[0557] Please dispose of unused contents properly according to local requirements. Instructions 81 / 185 pages 87 CN 121443291 A
[0558] Janssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse Belgium EU / 1 / 23 / 1722 / 001 Batch Akeega 50mg / 500mg Akeega 50mg / 500mg film-coated tablets Niraparib / Abiraterone Acetate Janssen-Cilag International NV Expiry Date Batch Fold closed (see Figure 10) Open (see Figure 11) Akeega 50mg / 500mg film-coated tablets Niraparib / Abiraterone Acetate Janssen-Cilag International NVInstructions for Use, Pages 82 / 185, CN 121443291 A, Batch Akeega 100mg / 500mg Film-Coated Tablets Niraparib / Abiraterone Acetate. Each film-coated tablet contains 100mg niraparib and 500mg abiraterone acetate.
[0559] Contains lactose.
[0560] See instructions for use for more information.
[0561] 56 film-coated tablets of Akeega should be taken at least two hours after a meal. Do not eat any food for at least one hour after taking Akeega.
[0562] Swallow whole. Do not break, crush, or chew the tablet.
[0563] Please read the instructions on the package before use.
[0564] For oral use only.
[0565] Keep out of sight and reach of children.
[0566] Pregnant women or women who may be pregnant should wear gloves when handling Akeega.
[0567] Expiry Date. Dispose of unused contents properly according to local requirements.
[0568] Janssen-Cilag International NV Turnhoutseweg 30 Instructions for Use 83 / 185 pages 89 CN 121443291 AB-2340 Beerse Belgium EU / 1 / 23 / 1722 / 002 Batch Akeega 100mg / 500mg with a two-dimensional barcode containing a unique identifier.
[0569] PC SN NN Akeega 100mg / 500mg film-coated tablets Niraparib / Abiraterone acetate Each film-coated tablet contains 100mg niraparib and 500mg abiraterone acetate.
[0570] 28 film-coated tablets of Akeega should be taken at least two hours after a meal. Do not eat any food for at least one hour after taking Akeega.
[0571] Swallow the tablet whole. Do not break, crush, or chew the tablet.
[0572] Please read the package instructions before use.
[0573] For oral use.
[0574] (1) Hold down (see Figure 8) (2) Pull out (see Figure 9) Keep out of sight and reach of children. Instructions for use 84 / 185 pages 90 CN 121443291 A
[0575] Pregnant women or women who may be pregnant should wear gloves when handling Akeega.
[0576] Please dispose of unused contents properly according to local requirements before expiry date.
[0577] Janssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse Belgium EU / 1 / 23 / 1722 / 002 Batch Akeega 100mg / 500mg Akeega 100mg / 500mg Film-coated tablets Niraparib / Abiraterone acetateJanssen-Cilag International NV Expiry Date Batch Folded to Close (See Figure 10) Instructions for Use 85 / 185 Pages 91 CN 121443291 A Open (See Figure 11) Akeega 100mg / 500mg Film-Coated Tablets Niraparib / Abiraterone Acetate Janssen-Cilag International NV Expiry Date B. Packaging Instructions for Use: User Information Akeega 50mg / 500mg Film-Coated Tablets Niraparib / Abiraterone Acetate Before you begin taking this medication, please read the entire package insert carefully, as it contains information that is important to you.
[0578] • Keep this package insert. You may need to read it again.
[0579] • If you have any further questions, please consult your doctor or pharmacist.
[0580] • This medication is for your personal use only. Do not transfer it to others. It may cause harm to them, even if they have the same symptoms as you.
[0581] • If you experience any side effects, please tell your doctor or pharmacist. This includes any possible side effects not listed in this instruction manual (see Section 4).
[0582] This instruction manual contains: 1. What Akeega is and how it is used 2. Information you need to know before taking Akeega 3. How to take Akeega 4. Possible side effects 5. How to store Akeega 6. Packaging contents and other information 1. What Akeega is and how it is used Akeega is a medicine containing two active ingredients: niraparib and abiraterone acetate, which work in two different ways.
[0583] Akeega is used to treat adult men with prostate cancer who have specific genetic alterations, whose prostate cancer has spread to other parts of the body, and who no longer respond to medical or surgical treatments that lower testosterone (also known as metastatic castration-resistant prostate cancer).
[0584] Niraparib is a cancer drug called a PARP inhibitor. PARP inhibitors block an enzyme called poly(adenosine diphosphate-ribose) polymerase (PARP). PARP helps cells repair damaged DNA. When PARP is blocked, cancer cells cannot repair their DNA, leading to tumor cell death and helping to control cancer.
[0585] Abiraterone blocks your body from producing testosterone; this can slow the growth of prostate cancer.
[0586] When you take this medication, your doctor will also prescribe another medication called prednisone or prednisolone. This is to reduce your risk of high blood pressure, excess water in your body (fluid retention), or low levels of a chemical called potassium in your blood.
[0587] 2. Information you need to know before taking AkeegaDo not take Akeega if: • You are allergic to niraparib or abiraterone acetate or any other ingredient in this medication – see Section 6 for a list of ingredients.
[0588] • You are pregnant or may become pregnant.
[0589] • You have severe liver damage.
[0590] • You are using this medication in combination with Ra-223 treatment (used to treat prostate cancer). This is because the risk of fracture or death may be increased.
[0591] Do not take this medication if any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medication.
[0592] Warnings and Precautions: Tell your doctor or pharmacist before or during taking this medication if you have: • A low blood cell count. Signs and symptoms you need to watch for include fatigue, fever or infection, and unusual bruising or bleeding. Akeega may also lower your blood cell count. Your doctor will test your blood regularly throughout the course of treatment.
[0593] • High blood pressure or heart failure or low potassium (low potassium may increase the risk of heart rhythm problems), a history of other heart or vascular problems, irregular or rapid heartbeat, shortness of breath, rapid weight gain, or swelling in the feet, ankles, or legs. Your doctor will measure your blood pressure regularly throughout treatment.
[0594] • Headache, vision changes, confusion, or seizures. These may be signs of a rare neurological side effect called posterior reversible encephalopathy syndrome (PRES), which is associated with the use of niraparib, the active ingredient in Akeega.
[0595] • High fever, fatigue, and other signs and symptoms of serious infection.
[0596] • Pulmonary clots, or a history of them.
[0597] • Liver problems.
[0598] • Blood sugar levels that are too low or too high.
[0599] • Muscle weakness and / or muscle pain.
[0600] If any of the above applies to you (or you are unsure), consult your doctor or pharmacist before taking this medication.
[0601] If your blood cell count remains low for an extended period while taking Akeega, this could be a sign of a more serious bone marrow problem, such as myelodysplastic syndrome or acute myeloid leukemia (AML). Your doctor may want to test your bone marrow to check for these problems.
[0602] Before taking Akeega, also discuss with your doctor or pharmacist the following: • The potential effects of Akeega on your bones.
[0603] • Taking prednisone or prednisolone (another medication you must take with Akeega).
[0604] If you are unsure whether any of the above applies to you, consult your doctor or pharmacist before taking this medication.
[0605] Blood MonitoringAkeega may affect your liver, but you may not notice any symptoms of liver problems. Therefore, your doctor will check your blood regularly while you are taking this medication to watch for any effects on your liver.
[0606] Children and Adolescents This medication is not for children and adolescents. If a child or adolescent accidentally swallows Akeega, take them to a hospital immediately and show this package insert to an emergency room doctor.
[0607] Other Medications and Akeega If you are taking, have recently taken, or may take any other medications, tell your doctor or pharmacist. This is because Akeega may affect how some other medications work. Similarly, some other medications may affect how Akeega works.
[0608] Treatment with medications that block the body from producing testosterone may increase the risk of heart rhythm problems. If you are taking any of the following medications, tell your doctor: • Medications used to treat heart rhythm problems (e.g., quinidine, procainamide, amiodarone, and sotalol); • Medications known to increase the risk of heart rhythm problems (e.g., methadone), used for pain relief and as part of drug addiction treatment; moxifloxacin, an antibiotic; antipsychotics used for severe mental illness.
[0609] If you are taking any of the medications listed above, tell your doctor.
[0610] Akeega with food • This medication should not be taken with food (see Section 3, “Taking Akeega”), as this may increase your risk of side effects.
[0611] Pregnancy and breastfeeding Akeega is not suitable for women.
[0612] • If a pregnant woman takes this medication, it may cause harm to the unborn child.
[0613] • Women who are pregnant or may become pregnant should wear gloves if they need to handle or touch Akeega.
[0614] Male contraception with Akeega • If you are having sex with a woman who may become pregnant, use a condom and another effective method of contraception. Use contraception during treatment and for 4 months after stopping treatment. If you have any questions about contraception, consult your doctor.
[0615] • If you have sex with a pregnant woman, use a condom to protect the unborn child.
[0616] Driving and operating machinery Taking Akeega may make you feel weak, unable to concentrate, tired, or dizzy. This may affect your ability to drive and operate machinery. Exercise caution when driving or operating machinery.
[0617] Akeega contains lactose and sodium • Akeega contains lactose. If your doctor tells you that you are intolerant to certain sugars, contact your doctor before taking this medication.
[0618] • This medication contains less than 1 mmol (23 mg) of sodium per dose, which is essentially “sodium-free”.
[0619] 3. How to take Akeega Instructions for use 88 / 185 pages 94 CN 121443291 AAlways take this medication strictly as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
[0620] The recommended starting dose is 200 mg / 1,000 mg once daily.
[0621] Taking Akeega: • This medication is taken orally.
[0622] • Do not take Akeega with food.
[0623] • Akeega tablets should be taken once daily in a single dose on an empty stomach, at least one hour before or at least two hours after a meal (see Section 2, “Akeega with Food”).
[0624] • Swallow the tablet whole with water. Do not break, crush, or chew the tablet. This will ensure that the medication works to its fullest potential.
[0625] • Akeega should not be taken with a medication called prednisone or prednisolone.
[0626] ○ Take prednisone or prednisolone strictly as directed by your doctor.
[0627] ○ You will need to take prednisone or prednisolone daily while you are taking Akeega.
[0628] ○ If you experience a medical emergency, the dosage of your prednisone or prednisolone may need to be changed. Your doctor will inform you whether you need to change your dosage of prednisone or prednisolone. Do not stop taking prednisone or prednisolone unless told by your doctor.
[0629] Your doctor may prescribe other medications while you are taking Akeega.
[0630] If you have taken an overdose of Akeega If you have taken too many pills, contact your doctor. Your risk of side effects may be increased.
[0631] If you forget to take Akeega If you forget to take Akeega or prednisone or prednisolone, take your usual dose as soon as you remember on the same day.
[0632] If you forget to take Akeega or prednisone or prednisolone for more than one day - tell your doctor immediately.
[0633] Do not take a double dose to make up for a missed dose.
[0634] If you have any further questions about the use of this medication, ask your doctor, pharmacist, or nurse.
[0635] If you stop taking Akeega, do not stop taking Akeega or prednisone or prednisolone unless told by your doctor.
[0636] If you have any further questions about the use of this medication, talk to your doctor, pharmacist, or nurse.
[0637] 4. Possible side effects As with all medications, this medication may cause side effects, but not everyone will experience them.
[0638] Serious side effects If you notice any of the following symptoms, stop taking Akeega immediately and seek medical attention: Very common (may affect more than one in ten people) • Bruising or bleeding that takes longer than usual after an injury – these may be signs of a low platelet count (thrombocytopenia).
[0639] • Shortness of breath, feeling very tired, pale skin, or a fast heartbeat – these may be signs of a low red blood cell count (anemia).
[0640] • Fever or infection – A low white blood cell count (neutropenia) may increase your risk of infection. Signs may include fever, chills, feeling weak or confused, cough, painful or burning urination. Some infections can be serious and can be fatal. Instructions 89 / 185 pages 95 CN 121443291 A
[0641] • Muscle weakness, muscle twitching, or rapid heartbeat (palpitations). These may be signs of low potassium levels in your blood (hypokalemia).
[0642] • Unknown (unable to estimate) elevated levels of “alkaline phosphatase” in the blood – Not reported in the use of Akeega, but reported in the use of niraparib or abiraterone acetate (components of Akeega) • Allergic reactions (including potentially life-threatening severe allergic reactions). Signs include: a raised, itchy rash (urticaria) and swelling—sometimes occurring on the face or in the mouth (i.e., angioedema), leading to difficulty breathing, and collapse or loss of consciousness.
[0643] • A sudden increase in blood pressure, which may be a medical emergency and could lead to organ damage or be life-threatening.
[0644] Other side effects: Tell your doctor if you experience any other side effects. These may include: Very common (may affect more than one in ten people): • Urinary tract infection • Low white blood cell count (leukopenia), visible in blood tests • Loss of appetite • Difficulty sleeping (insomnia) • Dizziness • Shortness of breath • Constipation • Nausea • Vomiting • Back pain • Joint pain • Extreme fatigue • Weakness • Weight loss • Fractures Common (may affect up to one in ten people): • Pneumonia • Lung infection (bronchitis) • Nose and throat infection (nasopharyngitis) • A type of low white blood cell count (lymphopenia), visible in blood tests • A type of high blood lipid level (hypertriglyceridemia) • Depression • Anxiety • Headache • Rapid heartbeat • Rapid or irregular heartbeat (palpitations) • Arrhythmia (atrial fibrillation) Instruction manual 90 / 185 pages 96 CN 121443291 A • Heart failure, causing shortness of breath and leg swelling • Heart attack • Cough • Lung clot, causing chest pain and shortness of breath • Lung inflammation • Stomach pain • Indigestion • Diarrhea • Bloating • Mouth ulcers • Dry mouth • Liver inflammation (hepatitis), based on blood tests • Rash • Muscle aches • Blood in urine • Swelling of hands, ankles, or feet • Elevated creatinine levels in the blood • Elevated aspartate aminotransferase levels in the blood • Elevated alanine aminotransferase levels in the blood Occasionally (may affect up to 1% of people): • Severe infection (sepsis), spreading from the urinary tract throughout the body • Eye inflammation (conjunctivitis) • Feeling confused• Difficulty thinking, remembering information, or solving problems (cognitive impairment) • Changes in taste • Chest discomfort, often caused by physical activity • Abnormal ECG (electrocardiogram), which may be a sign of heart problems • Nosebleeds • Inflammation of protective linings of body cavities, such as the nose, mouth, or digestive system • Sudden liver failure • Increased skin sensitivity to sunlight • Unknown (unable to estimate) elevated levels of gamma-glutamyl transferase in the blood – not reported in the use of Akeega, but reported in the use of niraparib or abiraterone acetate (components of Akeega) • Low counts of all types of blood cells (pancytopenia) • Brain disorders with symptoms including seizures (convulsions), headache, confusion, and visual changes (posterior reversible encephalopathy syndrome or PRES), a medical emergency that may cause organ damage or be life-threatening.
[0645] • Adrenal problems (related to salt and water issues), producing too little hormone, may cause weakness, fatigue, loss of appetite, nausea, dehydration, and skin changes. (Instructions for Use, 91 / 185 pages, 97 CN 121443291 A) • Lung inflammation caused by an allergic reaction (allergic alveolitis) • Muscle disease (myopathy), which may cause muscle weakness, stiffness, or cramps • Muscle tissue breakdown (rhabdomyolysis), which may cause muscle cramps or pain, fatigue, and dark urine. Report Side Effects If you experience any side effects, tell your doctor or pharmacist. This includes any possible side effects not listed in this package insert. You may also report side effects directly through the national reporting systems listed in Appendix V (www.ema.europa.eu / docs / en_GB / document_library / Template_or_form / 2013 / 03 / WC500139752.doc). By reporting side effects, you can help provide more information about the safety of this medication.
[0646] 5. How to store Akeega Keep this medicine out of the sight and reach of children.
[0647] Do not use this medicine after the expiry date indicated after EXP on the container (blister foil, inner purse, outer purse, and box). The expiry date is the last day of the month.
[0648] This medicine does not require any special storage conditions.
[0649] Do not dispose of any medicine through wastewater or household waste. Consult your pharmacist on how to dispose of unused medicines. These measures will help protect the environment.
[0650] 6. Packaging contents and other information Akeega's ingredients • The active ingredients are niraparib and abiraterone acetate. Each film-coated tablet contains 50 mg of niraparib and 500 mg of abiraterone acetate.
[0651] • Other ingredients in the tablet core are colloidal anhydrous silica, cropovidone, hydroxypropyl methylcellulose, lactose monohydrate, stearinMagnesium sulfate, microcrystalline cellulose, sodium lauryl sulfate. The film coating contains iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide (E171) (see Section 2, Akeega contains lactose and sodium).
[0652] Appearance and Packaging of Akeega Akeega film-coated tablets are oval tablets ranging from yellow-orange to yellow-brown, with "N 50 A" engraved on one side and blank on the other.
[0653] Each 28-day carton contains 56 film-coated tablets, packaged in two paper wallet-style packs, each containing 28 film-coated tablets.
[0654] Marketing Authorization Holder: Janssen-Cilag International NV Turnhoutseweg 30 B-2340 Beerse Manufacturer: Janssen Cilag SpA Via C. Janssen, Borgo San Michele Latina 04100 Italian Package Insert 92 / 185 pages 98 CN 121443291 A For any information regarding this medicine, please contact the local representative of the Marketing Authorization Holder: Belgium: Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com Lithuania: UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 lt@its.jnj.com Bulgaria: "Джонсън & Джонсън Бълга рия" ЕООД Phone: +359 2 489 94 00 jjsafety@its.jnj.com Luxembourg Janssen-Cilag NV Phone: +32 14 64 94 11 janssen@jacbe.jnj.com Czech Republic Janssen-Cilag sro Phone: +420 227 012 227 Magyarország Janssen-Cilag Kft. Phone: +36 1 884 2858 janssenhu@its.jnj.com Denmark Janssen-Cilag A / S Phone: +45 4594 8282 jacdk@its.jnj.com Malta AM MANGION LTD Phone: +356 2397 6000 Germany Janssen-Cilag GmbH Phone: +49 2137 955 955 jancil@its.jnj.com NetherlandsJanssen-Cilag BV Tel: +31 76 711 1111 janssen@jacnl.jnj.com Estonia UAB “JOHNSON & JOHNSON” Eesti filiaal Tel: +372 617 7410 ee@its.jnj.com Norway Janssen-Cilag AS Tel: +47 24 12 65 00 jacno@its.jnj.com Greece Janssen-Cilag Φαρμακευτ ική Α .Ε .Β . Ε . Tel: +30 210 80 90 000 Austria Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 Spain Janssen-Cilag, SA Tel: +34 91 722 81 00 contacto@its.jnj.com Janssen-Cilag, Polska Sp. z oo, Poland Tel: +48 22 237 60 00 Janssen-Cilag, France Tel: 0 800 25 50 75 / + 33 1 55 00 40 03 medisource@its.jnj.com Janssen-Cilag, Farmacêutica, Lda., Portugal Tel: +351 214 368 600 Johnson & Johnson SE doo, Croatia Tel: + 385 1 6610 700 jjsafety@JNJCR.JNJ.com Johnson & Johnson Romania SRL, Romania Tel: +40 21 207 1800 Janssen Sciences Ireland UC, Ireland Tel: 1 800 709 122 medinfo@its.jnj.com Johnson & Johnson doo, Slovenia Tel: +386 1 401 18 00 Janssen_safety_ slo@its.jnj.com Janssen-Cilag AB, Iceland Forwarded by Visitor Tel: +354 535 7000 janssen@vistor.is Johnson & Johnson, sro, Slovakia Tel: +421 232 408 400 Janssen-Cilag SpA, ItalyTelephone: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com Janssen-Cilag Oy, Finland Telephone: +358 207 531 300 jacfi@its.jnj.com Cyprus Telephone: +357 22 207 700 Janssen-Cilag AB, Sweden Telephone: +46 8 626 50 00 jacse@its.jnj.com UAB "JOHNSON & JOHNSON" filiāle Latvij ā, Latvia Telephone: +371 678 93561 lv@its.jnj.com United Kingdom (Northern Ireland) Janssen Sciences Ireland UC Telephone: +44 1 494 567 444 medinfo@its.jnj.com This instruction manual was last revised in YYYY / MM.
[0655] Other sources of information Detailed information about this medicine can be found on the website of the European Medicines Agency: www.ema.europa.eu Packaging instructions: User information Akeega 100mg / 500mg film-coated tablets Niraparib / Abiraterone acetate Before starting to take this medicine, please read the entire instruction manual carefully as it contains information that is important to you.
[0656] • Keep this instruction manual. You may need to read it again.
[0657] • If you have any further questions, please consult your doctor or pharmacist.
[0658] • This medicine is for your personal use only. Do not transfer it to others. Even if they have the same symptoms and signs as you, it may cause them harm.
[0659] • If you experience any side effects, please inform your doctor or pharmacist. This includes any possible side effects not listed in this instruction manual (see Section 4).
[0660] This instruction manual contains the following: 1. What Akeega is and how it is used 2. Information you need to know before taking Akeega 3. How to take Akeega 4. Possible side effects 5. How to store Akeega 6. Packaging contents and other information 1. What Akeega is and how it is used Akeega is a medicine containing two active ingredients: niraparib and abiraterone acetate, which work in two different ways.
[0661] Akeega is used to treat adult men with prostate cancer who have specific genetic alterations, whose prostate cancer has spread to other parts of the body, and who no longer respond to medical or surgical treatments that lower testosterone (also known as metastatic castration resistance).(Prostate cancer).
[0662] Niraparib is a cancer drug called a PARP inhibitor. PARP inhibitors block an enzyme called poly[adenosine diphosphate-ribose] polymerase (PARP). PARP helps cells repair damaged DNA. When PARP is blocked, cancer cells cannot repair their DNA, leading to tumor cell death and helping to control cancer.
[0663] Abiraterone prevents your body from producing testosterone; this can slow the growth of prostate cancer.
[0664] When you take this medication, your doctor will also prescribe another medication called prednisone or prednisolone. This is to reduce your risk of high blood pressure, excess water in your body (fluid retention), or low levels of a chemical called potassium in your blood.
[0665] 2. Information you need to know before taking Akeega Do not take Akeega: • If you are allergic to niraparib or abiraterone acetate or any other ingredient in this medication – see Section 6 for a list of ingredients.
[0666] • If you are pregnant or may become pregnant.
[0667] • If you have severe liver damage.
[0668] • Use in combination with Ra-223 treatment (used to treat prostate cancer). This is because the risk of fracture or death may be increased.
[0669] Do not take this medicine if any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medicine.
[0670] Warnings and Precautions Tell your doctor or pharmacist before or during taking this medicine if you have: • Low blood cell count. Signs and symptoms you need to watch out for include fatigue, fever or infection, and unusual bruising or bleeding. Akeega may also lower your blood cell count. Your doctor will test your blood regularly throughout the course of treatment.
[0671] • High blood pressure or heart failure or low potassium (low potassium may increase the risk of heart rhythm problems), a history of other heart or vascular problems, irregular or rapid heartbeat, shortness of breath, rapid weight gain, or swelling in the feet, ankles or legs. Your doctor will measure your blood pressure regularly throughout the treatment.
[0672] • Headache, vision changes, confusion, or seizures. These may be signs of a rare neurological side effect called posterior reversible encephalopathy syndrome (PRES), which is associated with the use of niraparib, the active ingredient in Akeega.
[0673] • High fever, fatigue, and other signs and symptoms of severe infection.
[0674] • Pulmonary clots, or a history of them.
[0675] • Liver problems.
[0676] • Blood sugar levels that are too low or too high.
[0677] • Muscle weakness and / or muscle pain.
[0678] If any of the above applies to you (or you are unsure), consult your doctor or pharmacist before taking this medication.
[0679] If your blood cell count remains low for an extended period while taking Akeega, this could be a sign of a more serious bone marrow problem, such as myelodysplastic syndrome or acute myeloid leukemia (AML). Your doctor may want to test your bone marrow to check for these problems.
[0680] Before taking Akeega, also discuss with your doctor or pharmacist: • The potential effects of Akeega on your bones.
[0681] • Taking prednisone or prednisolone (another medication you must take with Akeega).
[0682] If you are unsure whether any of the above applies to you, consult your doctor or pharmacist before taking this medication.
[0683] Blood Monitoring Akeega may affect your liver, but you may not notice any symptoms of liver problems. Therefore, your doctor will check your blood regularly while you are taking this medication to monitor for any effects on your liver.
[0684] Children and Adolescents This medication is not intended for children and adolescents. If a child or teenager accidentally swallows Akeega, take them to a hospital immediately and bring this package insert to show to an emergency room doctor.
[0685] Other Medications and Akeega If you are taking, have recently taken, or may take any other medications, tell your doctor or pharmacist. This is because Akeega may affect how some other medications work. Similarly, some other medications may affect how Akeega works.
[0686] Treatment with medications that block the body from producing testosterone may increase the risk of heart rhythm problems. Tell your doctor if you are taking any of the following medications: • Medications used to treat heart rhythm problems (e.g., quinidine, procainamide, amiodarone, and sotalol); • Medications known to increase the risk of heart rhythm problems (e.g., methadone), used for pain relief and as part of drug addiction treatment; moxifloxacin, an antibiotic; antipsychotics used for serious mental illness.
[0687] Tell your doctor if you are taking any of the medications listed above.
[0688] Akeega with Food • This medication should not be taken with food (see Section 3, “Taking Akeega”), as this may increase your risk of side effects. Instructions for Use 95 / 185 pages 101 CN 121443291 A
[0689] Pregnancy and Breastfeeding Akeega is not suitable for women.
[0690] • If a pregnant woman takes this medication, it may cause harm to the unborn child.
[0691] • Women who are pregnant or may become pregnant should wear gloves if they need to handle or come into contact with Akeega.
[0692] Male Contraception with Akeega • If you are having sexual intercourse with a woman who may become pregnant, use a condom and another effective method of contraception.Use contraception during treatment and for 4 months after stopping treatment. If you have any questions about contraception, consult your doctor.
[0693] • If you have sex with a pregnant woman, use a condom to protect the unborn child.
[0694] Driving and operating machinery Taking Akeega may make you feel weak, unable to concentrate, tired, or dizzy. This may affect your ability to drive and operate machinery. Exercise caution when driving or operating machinery.
[0695] Akeega contains lactose and sodium • Akeega contains lactose. If your doctor tells you that you are intolerant to certain sugars, contact your doctor before taking this medication.
[0696] • Each dose of this medication contains less than 1 mmol (23 mg) of sodium, which is essentially “sodium-free”.
[0697] 3. How to take Akeega Always take this medication strictly as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
[0698] Dosage The recommended starting dose is 200 mg / 1,000 mg (two tablets) once daily.
[0699] Taking Akeega • This medication is taken orally.
[0700] • Do not take Akeega with food.
[0701] • Akeega tablets should be taken once daily in a single dose on an empty stomach, at least one hour before or at least two hours after a meal (see Section 2, “Akeega with Food”).
[0702] • Swallow the tablet whole with water. Do not break, crush, or chew the tablet. This will ensure the medication works to its fullest potential.
[0703] • Akeega may be taken with a medication called prednisone or prednisolone.
[0704] ○ Follow your doctor’s instructions strictly when taking prednisone or prednisolone.
[0705] ○ You will need to take prednisone or prednisolone daily while you are taking Akeega.
[0706] ○ If you experience a medical emergency, the dosage of prednisone or prednisolone you are taking may need to be changed. Your doctor will inform you if you need to change the dosage of prednisone or prednisolone. Do not stop taking prednisone or prednisolone unless instructed by your doctor.
[0707] Your doctor may prescribe other medications while you are taking Akeega.
[0708] If you have taken an overdose of Akeega, contact your doctor. Your risk of side effects may be increased.
[0709] If you forget to take Akeega, prednisone, or prednisolone, take your usual dose as soon as you remember on the same day.
[0710] If you forget to take Akeega, prednisone, or prednisolone for more than one day, tell your doctor immediately. Instructions for Use 96 / 185 pages 102 CN 121443291 A
[0711] Do not take a double dose to make up for a missed dose.
[0712] If you have any further questions about the use of this medication, please consult your doctor, pharmacist, or nurse.
[0713] If you stop taking Akeega Do not stop taking Akeega or prednisone or prednisolone unless told by your doctor.
[0714] If you have any further questions about the use of this medication, please consult your doctor, pharmacist, or nurse.
[0715] 4. Possible side effects As with all medications, this medication may cause side effects, but not everyone will experience them.
[0716] Serious side effects If you notice any of the following symptoms, stop taking Akeega immediately and seek medical attention: Very common (may affect more than one in ten people) • Bruising or bleeding that takes longer than usual after an injury – these may be signs of a low platelet count (thrombocytopenia).
[0717] • Shortness of breath, feeling very tired, pale skin, or a fast heartbeat – these may be signs of a low red blood cell count (anemia).
[0718] • Fever or infection – a low white blood cell count (neutropenia) may increase your risk of infection. Signs may include fever, chills, feeling weak or confused, cough, painful or burning urination. Some infections can be serious and can lead to death.
[0719] • Muscle weakness, muscle twitching, or rapid heartbeat (palpitations). These may be signs of low potassium levels in your blood (hypokalemia).
[0720] • Unknown (unable to estimate) elevated levels of alkaline phosphatase in the blood – not reported in the use of Akeega, but reported in the use of niraparib or abiraterone acetate (components of Akeega). • Allergic reactions (including potentially life-threatening severe allergic reactions). Signs include: raised and itchy rash (urticaria) and swelling – sometimes occurring on the face or in the mouth (i.e., angioedema), causing difficulty breathing, and collapse or loss of consciousness.
[0721] • Sudden increase in blood pressure, which may be a medical emergency and could lead to organ damage or be life-threatening.
[0722] Other side effects: Tell your doctor if you experience any other side effects. These may include: Very common (may affect more than one in ten people): • Urinary tract infection • Low white blood cell count (leukopenia), visible in blood tests • Loss of appetite • Difficulty sleeping (insomnia) • Dizziness • Shortness of breath • Constipation • Nausea • Vomiting • Back pain • Joint pain • Extreme fatigue • Weakness • Weight loss • Fractures Common (may affect up to one in ten people): • Pneumonia • Lung infection (bronchitis) • Nose and throat infection (nasopharyngitis) • A type of low white blood cell count (lymphopenia), visible in blood tests • A type of high blood lipid level (hypertriglyceridemia) • Depression• Feeling anxious • Headache • Rapid heartbeat • Rapid or irregular heartbeat (palpitations) • Irregular heartbeat (atrial fibrillation) • Heart failure, causing shortness of breath and leg swelling • Heart attack • Cough • Lung clot, causing chest pain and shortness of breath • Lung inflammation • Stomach pain • Indigestion • Diarrhea • Abdominal distension • Mouth ulcers • Dry mouth • Liver inflammation (hepatitis), based on blood tests • Rash • Muscle aches • Blood in urine • Swelling of hands, ankles, or feet • Elevated levels of creatinine in the blood • Elevated levels of aspartate aminotransferase in the blood • Elevated levels of alanine aminotransferase in the blood Occasionally (may affect up to 1% of people): • Severe infection (sepsis), spreading from the urinary tract to the whole body • Eye inflammation (conjunctivitis) Instructions 98 / 185 pages 104 CN 121443291 A • Feeling confused • Difficulty thinking, remembering information, or solving problems (cognitive impairment) • Changes in taste • Chest discomfort, often caused by physical activity • Abnormal ECG (electrocardiogram) results, which may be a sign of heart problems • Nosebleeds • Inflammation of protective linings of body cavities, such as the nose, mouth, or digestive system • Sudden liver failure • Increased skin sensitivity to sunlight • Unknown (unable to estimate) elevated levels of gamma-glutamyl transferase in the blood – not reported in the use of Akeega, but reported in the use of niraparib or abiraterone acetate (components of Akeega) • Low counts of all types of blood cells (pancytopenia) • Brain disorders with symptoms including seizures (convulsions), headache, confusion, and visual changes (posterior reversible encephalopathy syndrome or PRES), a medical emergency that may lead to organ damage or be life-threatening.
[0723] • Adrenal problems (related to salt and water issues), producing too little hormone, can cause weakness, fatigue, loss of appetite, nausea, dehydration, and skin changes. • Lung inflammation caused by an allergic reaction (allergic alveolitis). • Muscle disease (myopathy), which can cause muscle weakness, stiffness, or cramps. • Muscle tissue breakdown (rhabdomyolysis), which can cause muscle cramps or pain, fatigue, and dark urine. Report Side Effects If you experience any side effects, tell your doctor or pharmacist. This includes any possible side effects not listed in this package insert. You can also report side effects directly through the national reporting systems listed at www.ema.europa.eu / docs / en_GB / document_library / Template_or_form / 2013 / 03 / WC500139752.doc. By reporting side effects, you can help provide more information about the safety of this medication.
[0724] 5. How to Store Akeega Keep this medication out of the sight and reach of children.
[0725] Do not use this medication after the expiry date indicated after EXP on the container (blister foil, inner purse, outer purse, and box). The expiry date is the last day of the month.
[0726] This medication does not require any special storage conditions.
[0727] Do not dispose of any medication through wastewater or household waste. Consult your pharmacist on how to dispose of medications that are no longer in use. These measures will help protect the environment.
[0728] 6. Packaging Contents and Other Information Akeega's Ingredients • The active ingredients are niraparib and abiraterone acetate. Each film-coated tablet contains 100 mg of niraparib and 500 mg of abiraterone acetate.
[0729] • Other ingredients in the tablet core are colloidal anhydrous silica, cropovidone, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The film coating contains iron oxide red (E172), iron oxide yellow (E172), sodium lauryl sulfate, glyceryl monocaprylate, polyvinyl alcohol, talc, and titanium dioxide (E171) (see Section 2, Akeega contains lactose and sodium, page 99 / 185 of the instruction manual, 105 CN 121443291 A). Akeega's appearance and packaging: Akeega film-coated tablets are orange oval tablets with "N 100 A" engraved on one side and blank on the other.
[0730] Each 28-day carton contains 56 film-coated tablets, packaged in two paper wallet-style packs, each containing 28 film-coated tablets.
[0731] Marketing Authorization Holder: Janssen-Cilag International NV, Turnhoutseweg 30 B-2340, Beerse, Belgium; Manufacturer: Janssen Cilag SpA, Via C. Janssen, Borgo San Michele Latina 04100, Italy. For any information regarding this drug, please contact the local representative of the Marketing Authorization Holder: Belgium: Janssen-Cilag NV, Tel: +32 14 64 94 11, janssen@jacbe.jnj.com; Lithuania: UAB “JOHNSON & JOHNSON”, Tel: +370 5 278 68 88, lt@its.jnj.com; Bulgaria: “Джонсън & Джонсън Бълга рия” ЕООД, Tel: +359 2 489 94 00 jjsafety@its.jnj.com Janssen-Cilag NV, Luxembourg Tel: +32 14 64 94 11 janssen@jacbe.jnj.com Janssen-Cilag sro, Czech Republic Tel: +420 227 012227 Magyarország Janssen-Cilag Kft. Tel: +36 1 884 2858 janssenhu@its.jnj.com Janssen-Cilag A / S, Denmark Tel: +45 4594 8282 jacdk@its.jnj.com AM MANGION LTD, Malta Tel: +356 2397 6000 Janssen-Cilag GmbH, Germany Tel: +49 2137 955 955 jancil@its.jnj.com Janssen-Cilag BV, Netherlands Tel: +31 76 711 1111 janssen@jacnl.jnj.com UAB "JOHNSON & JOHNSON" Eesti filiaal, Estonia Tel: +372 617 7410 ee@its.jnj.com Janssen-Cilag AS, Norway Tel: +47 24 12 65 00 jacno@its.jnj.com Janssen-Cilag Φαρμακευτ ική Α .Ε .Β . Ε . Tel: +30 210 80 90 000 Janssen-Cilag Pharma GmbH, Austria Tel: +43 1 610 300 Janssen-Cilag, SA, Spain Tel: +34 91 722 81 00 contacto@its.jnj.com Janssen-Cilag Polska Sp. z oo, Poland Tel: +48 22 237 60 00 Janssen-Cilag, France Tel: 0 800 25 50 75 / + 33 1 55 00 40 03 medisource@its.jnj.com Janssen-Cilag Farmacêutica, Lda., Portugal Tel: +351 214 368 600 Johnson & Johnson SE doo, Croatia Tel: +385 1 6610 700 jjsafety@JNJCR.JNJ.com Johnson & Johnson Romania SRL, Romania Tel: +40 21 207 1800 Janssen Sciences Ireland UC, Ireland Tel: 1 800 709 122 medinfo@its.jnj.com SloveniaJohnson & Johnson doo Tel: +386 1 401 18 00 Janssen_safety_ slo@its.jnj.com Iceland Janssen-Cilag AB Forwarded by Visitor Tel: +354 535 7000 janssen@vistor.is Slovakia Johnson & Johnson, sro Tel: +421 232 408 400 Instruction manual 100 / 185 pages 106 CN 121443291 A Italy Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com Finland Janssen-Cilag Oy Tel: +358 207 531 300 jacfi@its.jnj.com Cyprus Βαρν ά βας Χατζηπαναγής Λ τδ Telephone: +357 22 207 700 Sweden Janssen-Cilag AB Telephone: +46 8 626 50 00 jacse@its.jnj.com Latvia UAB “JOHNSON & JOHNSON” filiāle Latvij ā Telephone: +371 678 93561 lv@its.jnj.com United Kingdom (Northern Ireland) Janssen Sciences Ireland UC Telephone: +44 1 494 567 444 medinfo@its.jnj.com This manual was last revised on YYYY / MM.
[0732] Other sources of information Detailed information about this drug can be found on the website of the European Medicines Agency: www.ema.europa.eu Example 3 – Drug product label approved by Health Canada; Approval date: June 23, 2023 Product monograph including patient drug information PrAKEEGA™ Niraparib and Abiraterone Acetate Tablets 100mg Niraparib (in the form of niraparib tosylate) / 500mg Abiraterone Acetate, 50mg Niraparib (in the form of niraparib tosylate) / 500mg Abiraterone Acetate Oral Administration Antineoplastic Drug / Androgen Biosynthesis Inhibitor Janssen Inc. Toronto, Ontario M3C 1L9 Initial Authorization Date: June 7, 2023 Submission Control Number: 265223 Table of Contents Sections or subsections not applicable at the time of authorization Not listed Product Information 101 / 185 pages 107 CN 121443291A Table of Contents 2 Part I: Information for Healthcare Professionals 4 1 Indications 4 1.1 Pediatrics (<18 years) 4 1.2 Elderly Patients (≥65 years) 4 2 Contraindications 4 3 Serious Warnings and Precautions Box 4 4 Dosage and Administration 5 4.1 Dosage Considerations 5 4.2 Recommended Dosage and Dosage Adjustment 5 4.3 Reconstitution 7 4.4 Administration 8 4.5 Missed Dosage 8 5 Overdose 8 6 Dosage Forms, Strengths, Ingredients, and Packaging 8 7 Warnings and Precautions 9 7.1 Special Populations 14 7.1.1 Pregnant Women 14 7.1.3 Pediatrics (<18 years) 14 7.1.4 Elderly Patients (≥65 years) 14 8 Adverse Reactions 14 8.1 Overview of Adverse Reactions 14 8.2 Adverse Reactions in Clinical Trials 15 8.3 Less Common Adverse Reactions in Clinical Trials 18 8.4 Abnormal Laboratory Test Results: Hematology, Clinical Chemistry, and Other Quantitative Data 19 8.5 Post-Marketing Adverse Reactions 19 9 Drug Interactions 20 9.2 Overview of Drug Interactions 20 9.3 Drug-Behavioral Interactions 21 9.4 Drug-Drug Interactions 21 9.5 Drug-Food Interactions 23 9.6 Drug-Herbal Interactions 23 9.7 Drug-Laboratory Test Interactions 23 10 Clinical Pharmacology 23 10.1 Mechanism of Action 23 10.2 Pharmacodynamics 24 10.3 Pharmacokinetics 26 11 Storage, Stability, and Disposal 28 12 Special Handling Instructions 28 Package Insert 102 / 185 pages 108 CN 121443291 A Part II: Scientific Information 29 13 Drug Information 29 14 Clinical Trials 30 14.1 Clinical Trials Classified by Indication 30 15 Microbiology 36 16 Non-Clinical Toxicology 36 Patient Medication Information 39 Part I: Information for Healthcare Professionals Indication PrAKEEGA™ (niraparib and abiraterone acetate) is indicated in combination with prednisone or prednisolone for: the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have a harmful or suspected harmful BRCA mutation (germline and / or somatic mutation) and who are asymptomatic or have mild symptoms and for whom there is no clinical indication for chemotherapy. The presence of a BRCA mutation must be confirmed before initiating AKEEGA™ treatment.
[0733] Conditional marketing authorization based on radiographic progression-free survival, time to symptom progression, and time to cytotoxic chemotherapy (see Clinical Trials 14). Continued approval for this indication may be contingent upon validation and description of clinical benefit in subsequent analyses.
[0734] The efficacy of AKEEGA™ in patients with visceral metastases is not yet established (see Clinical Trials 14). Pediatrics (<18 years) No data available from Health Canada; therefore, Health Canada has not approved this indication for pediatrics. Elderly Patients (≥65 years)No overall difference in safety and efficacy of the combination therapy of niraparib and abiraterone acetate was observed between these patients and younger patients, but the possibility of higher sensitivity in some older individuals cannot be ruled out (see 7 Warnings and Precautions).
[0735] Contraindications AKEEGA™ is contraindicated in patients who: • have a hypersensitivity to any component or container part of this drug or formulation. See 6 Dosage Forms, Strengths, Ingredients and Packaging for a complete list.
[0736] Serious Warnings and Precautions Box Dosage and Administration Considerations AKEEGA™ is a fixed-dose combination of niraparib and abiraterone acetate. Before initiating AKEEGA™ treatment, confirm the presence of a BRCA mutation using a validated test (see 14 Clinical Trials).
[0737] Recommended Dosage and Dosage Adjustment Instructions 103 / 185 pages 109 CN 121443291 A The recommended dose of AKEEGA™ is 200 mg niraparib and 1,000 mg abiraterone acetate (two 100 mg / 500 mg tablets), once daily, and must be taken on an empty stomach at approximately the same time each day (see 4 Dosage and Administration, Dosage). For dose reduction to 100 mg niraparib and 1,000 mg abiraterone acetate, low-strength tablets (two 50 mg / 500 mg tablets) are recommended (see 4 Dosage and Administration, Dosage Modification). If a further reduction of the niraparib dose to below 100 mg / day is required, AKEEGA should be discontinued.
[0738] Dosage of Prednisone or Prednisolone AKEEGA™ is used daily with 10 mg of prednisone or prednisolone.
[0739] Discontinuation of Treatment Treatment should continue until disease progression, clear clinical progression, or unacceptable toxicity occurs.
[0740] Dosage Modification Hematological Adverse Reactions Dosage adjustment recommendations for anemia, thrombocytopenia, and neutropenia are listed in Tables 1 and 2.
[0741] Table 1: Dosage Adjustment Recommendations for Anemia 1 During AKEEGA™ treatment interruption, physicians may consider administering abiraterone acetate and prednisone to maintain the daily dose of abiraterone acetate (see Abiraterone Acetate Product Monograph).
[0742] Table 2: Recommendations for Dosage Adjustment of Thrombocytopenia and Neutropenia 1. During AKEEGA™ treatment interruption associated with hematologic toxicity, physicians should generally continue abiraterone acetate plus prednisone or prednisolone (see Abiraterone Acetate Product Monograph) 104 / 185 pages 110 CN 121443291 A 2. If the patient requires platelet transfusion, or experiences neutropenic fever or neutropenia requiring granulocyte colony-stimulating factor, and a grade ≥3 AE is considered to be associated with AKEEGA™ toxicity, the study drug should be interrupted and restarted at a reduced dose level after remission to grade 1 or baseline. If AKEEGA™ has previously been reduced due to the same hematologic toxicity...If the toxicity cannot be clearly attributed to niraparib or abiraterone acetate alone, AKEEGA™ should be discontinued. For non-hematologic adverse reactions of grade ≥3, if the toxicity cannot be clearly attributed to niraparib alone or abiraterone acetate alone, AKEEGA™ should be discontinued. AKEEGA™ treatment should not be restarted until the toxicity symptoms have resolved to grade 1 or baseline. To resume treatment, start with monotherapy AAP combination therapy first. If the toxicity continues to resolve to baseline / grade 1, switch to AKEEGA™ treatment at least 7 days after restarting AAP.
[0743] If the patient is taking a reduced dose of AKEEGA™ (100 mg / 1,000 mg), AKEEGA™ must be discontinued for grade ≥3 treatment-related adverse reactions lasting more than 28 days.
[0744] For treatment-related hypertensive crises, AKEEGA™ should be permanently discontinued.
[0745] Hepatotoxicity: For patients experiencing grade 3 hepatotoxicity (elevated alanine aminotransferase [ALT] or aspartate aminotransferase [AST] exceeding five times the upper limit of normal [ULN]), AKEEGA™ treatment should be interrupted and liver function closely monitored. Treatment can only be restarted at a reduced dose level (one regular strength AKEEGA™ tablet, equivalent to 100 mg niraparib and 500 mg abiraterone acetate) after liver function tests have returned to the patient's baseline levels. For patients restarting treatment, serum transaminases should be monitored at least every two weeks for the first three months, and monthly thereafter. If hepatotoxicity recurs at a reduced dose of 100 mg / 500 mg (one tablet) daily, AKEEGA™ treatment should be discontinued.
[0746] For patients experiencing severe hepatotoxicity (ALT or AST exceeding 20 times the ULN), AKEEGA™ should be permanently discontinued. For patients with concurrent elevations of ALT greater than 3 × ULN and total bilirubin greater than 2 × ULN, and without biliary obstruction or other cause of such elevation, permanently discontinue AKEEGA™ (see 7 Warnings and Precautions). Recommended monitoring: For monitoring required before and during AKEEGA™ treatment, see 7 Warnings and Precautions.
[0747] Special Populations: Pediatrics (<18 years): Health Canada has not approved pediatric indications.
[0748] Elderly Patients (≥65 years): No dose adjustment is required for elderly patients (see 10.3 Pharmacokinetics).
[0749] Hepatic Impairment: No dose adjustment is required for patients with mild hepatic impairment (AST or ALT ≤3 × ULN or serum total bilirubin ≤1.5 × ULN). AKEEGA™ should not be used in patients with moderate to severe hepatic impairment (see 3 Serious Warnings and Precautions box; 10.3 Pharmacokinetics).
[0750] Renal Impairment: No dose adjustment is required for patients with mild to moderate renal impairment (see 10.3 Pharmacokinetics). Not yet in severe kidney diseaseAKEEGA™ was studied in patients with functional impairment (creatinine clearance <30 mL / min).
[0751] Reconstitution is not applicable. AKEEGA™ must be taken on an empty stomach. AKEEGA™ must be taken at least two hours after a meal, and no food should be consumed for at least one hour after taking AKEEGA™. Tablets must be swallowed whole with water (see 10.3 Pharmacokinetics – Absorption). Do not break, crush, or chew the tablets.
[0752] A gonadotropin-releasing hormone (GnRH) agonist must be taken during AKEEGA™ treatment, or the patient must have previously undergone orchiectomy.
[0753] Missed doses: If a dose of AKEEGA™, prednisone, or prednisolone is missed, the regular daily dose and normal daily schedule should be resumed the following day. No additional tablets should be taken to make up for the missed dose.
[0754] Overdose: There is no specific treatment for AKEEGA™ overdose. In case of overdose, the physician should take general supportive measures and treat the patient symptomatically.
[0755] Dosage Forms, Strengths, Ingredients and Packaging: AKEEGA™ tablets are available in regular strength (100 mg niraparib (in the form of niraparib tosylate) and 500 mg abiraterone acetate) and low strength (50 mg niraparib (in the form of niraparib tosylate) and 500 mg abiraterone acetate): AKEEGA™ 100 mg niraparib (in the form of niraparib tosylate) and 500 mg abiraterone acetate tablets: orange, oval, tablet (22 mm × 11 mm), with “N 100 A” engraved on one side and blank on the other side.
[0756] AKEEGA™ 50 mg niraparib (in the form of niraparib tosylate) and 500 mg abiraterone acetate tablets: yellow-orange to yellow-brown, oval tablets (22 mm × 11 mm), with "N 50 A" engraved on one side and blank on the other.
[0757] Both strengths of AKEEGA™ tablets will be supplied in 150 ml high-density polyethylene (HDPE) bottles of 60 tablets each.
[0758] Warnings and precautions are listed in box 3, Serious Warnings and Precautions.
[0759] Generic AKEEGA™ is used daily with 10 mg prednisone or prednisolone. A gonadotropin-releasing hormone (GnRH) agonist must be taken during AKEEGA™ treatment, or the patient must have previously undergone orchiectomy.
[0760] AKEEGA™ must be taken on an empty stomach. AKEEGA™ must be taken at least two hours after a meal, and no food should be consumed for at least one hour after taking AKEEGA™. Tablets must be swallowed whole with water (see 4 Dosage and Administration, and 10.3 Pharmacokinetics – Absorption). Lactose intolerance.This drug contains lactose. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption problems should not take this drug.
[0761] Carcinogenicity and Mutagenicity of Myelodysplastic Syndromes / Acute Myeloid Leukemia (MDS / AML) MDS / AML (including fatal outcomes) have been reported in patients receiving niraparib monotherapy in trials of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (see ZEJULA® Product Monograph).
[0762] In the MAGNITUDE study cohort 1 (see 8 Adverse Events), the median follow-up duration was 26.8 months in the niraparib + AAP group and 26.9 months in the placebo + AAP group. No AML cases were reported in the niraparib + AAP group, while one subject (0.5%) reported AML in the placebo + AAP group.
[0763] For suspected MDS / AML or long-term hematologic toxicity that does not improve with treatment interruption or dose reduction, patients should be referred to a hematologist for further evaluation. If MDS and / or AML is confirmed, AKEEGA™ treatment should be permanently discontinued.
[0764] Cardiovascular: Patients with a history of cardiovascular disease should use AKEEGA™ with caution. Heart failure should be treated and cardiac function optimized before and during treatment in patients at significant risk of congestive heart failure (e.g., a history of heart failure, or a history of cardiac events such as ischemic heart disease). Symptoms of congestive heart failure should be monitored every two weeks for the first three months, and monthly thereafter. The safety of AKEEGA™ in patients with clinically significant cardiac disease (evidence including myocardial infarction, arterial and venous thrombotic events within the past six months, severe or unstable angina, or NYHA class II to IV heart failure or a cardiac ejection fraction measurement <50%) is unknown because these patients were excluded from the MAGNITUDE study.
[0765] Hypertension: AKEEGA™ may cause hypertension. Pre-existing hypertension should be adequately controlled before initiating AKEEGA™ treatment. During AKEEGA™ treatment, blood pressure should be monitored weekly for at least the first two months, monthly for the first year, and then every other month thereafter.
[0766] Hypokalemia, Fluid Retention: AKEEGA™ may cause hypokalemia and fluid retention due to increased mineralocorticoid levels caused by CYP17 inhibition (see 8 Adverse Reactions) (see 10.2 Pharmacodynamics). Concomitant use of corticosteroids to inhibit adrenocorticotropic hormone (ACTH) drive reduces the incidence and severity of these adverse reactions. For underlying health conditions that may be exacerbated by hypokalemia...Patients should exercise caution when using this treatment. QT interval prolongation has been observed in patients with hypokalemia associated with AKEEGA™ treatment. Hypokalemia and fluid retention should be corrected and controlled.
[0767] Fluid retention (weight gain, peripheral edema) should be monitored every two weeks for the first three months, then monthly thereafter, and any abnormalities should be corrected.
[0768] Venous thromboembolic events (VTEs), including pulmonary embolism, have occurred in patients treated with AKEEGA™ (see 8 Adverse Reactions). Monitor patients for clinical signs and symptoms of venous thrombosis and pulmonary embolism, and provide appropriate medical attention.
[0769] Driving and operating machinery: Patients taking AKEEGA™ may experience weakness, fatigue, and dizziness. AKEEGA™ may affect the ability to drive or operate machinery. Patients should exercise caution when driving or operating vehicles or potentially hazardous machinery.
[0770] Endocrine and metabolic hypoglycemia has been reported in patients with pre-existing diabetes who were receiving abiraterone acetate plus prednisone or prednisolone while receiving pioglitazone or repaglinide (see 9 Drug Interactions); therefore, blood glucose should be monitored in diabetic patients.
[0771] Hematologic adverse reactions (anemia, neutropenia, and thrombocytopenia) have been reported in patients treated with niraparib monotherapy and in combination therapy (see 8 Adverse Reactions).
[0772] In the MAGNITUDE study, in cohort 1 patients receiving niraparib + AAP, the overall incidence of grade ≥3 anemia, neutropenia, and thrombocytopenia was 29.7%, 6.6%, and 6.6%, respectively.
[0773] It is recommended to test complete blood counts weekly during the first month, bi-weekly for the next two months, monthly for the first year thereafter, and then monthly for the remainder of treatment (see 4 Dosage and Administration).
[0774] Based on individual laboratory values, weekly monitoring may be required during the second month. AKEEGA™ should be discontinued if a patient develops serious, persistent hematologic toxicity (including pancytopenia) that does not improve within 28 days of treatment interruption. Due to the risk of thrombocytopenia, patients taking AKEEGA™ should use other medications known to reduce platelet counts with caution.
[0775] Hepatic / biliary / pancreatic impairment There are no data on the clinical safety and efficacy of AKEEGA™ administration in patients with moderate or severe hepatic impairment (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤3×ULN, or Child-Pugh class B or C). AKEEGA™ should not be used in patients with moderate to severe hepatic impairment (see 3 Serious Warnings and Precautions box, 4 Dosage).Dosage and administration, and 10.3 Pharmacokinetics).
[0776] Hepatotoxicity has occurred in clinical studies of abiraterone acetate (including the MAGNITUDE study), with significant increases in liver enzymes leading to treatment interruption or cessation (2% of patients in cohort 1 experienced dose modifications, and one patient (0.5%) discontinued treatment) (see 8 Adverse Reactions). Serious hepatotoxicity (including fatal outcomes) has been reported in post-marketing experience with abiraterone acetate monotherapy (see ZYTIGA® Product Monograph).
[0777] Serum aminotransferase and total bilirubin levels should be measured before starting treatment, every two weeks for the first three months of treatment, and monthly thereafter. Serum aminotransferase and bilirubin should be measured immediately if clinical symptoms or signs suggestive of hepatotoxicity occur. If at any time ALT or AST increases to more than five times the upper limit of normal (ULN) or bilirubin increases to more than three times the ULN, AKEEGA™ treatment should be interrupted and liver function closely monitored. For patients with concurrent elevations of ALT greater than 3 × ULN and total bilirubin greater than 2 × ULN, and without biliary obstruction or other cause of such elevation, AKEEGA™ should be permanently discontinued.
[0778] Treatment can only be restarted at a reduced dose level after liver function tests have returned to the patient's baseline (see 4 Dosage and Administration). If a patient experiences severe hepatotoxicity (ALT or AST being twenty times the ULN) at any time during treatment, AKEEGA™ treatment should be permanently discontinued. Patients with active or symptomatic viral hepatitis were excluded from clinical trials; therefore, there is no data to support the use of AKEEGA™ in this population.
[0779] Immunity: In patients receiving abiraterone acetate monotherapy, there have been post-marketing reports of allergic reactions requiring rapid medical intervention (see ZYTIGA® Product Monograph). Monitoring and Laboratory Testing: • Complete blood counts should be obtained before starting treatment, weekly for the first month, bi-weekly for the next two months, monthly for the first year thereafter, and then monthly for the remainder of treatment (see 4 Dosage and Administration).
[0780] • Serum aminotransferases and total bilirubin should be measured before starting treatment, bi-weekly for the first three months, monthly for the first year thereafter, and then monthly for the duration of treatment.
[0781] • Serum potassium should be monitored monthly for the first year, and then monthly for the duration of treatment.
[0782] • Blood pressure should be monitored weekly for at least the first two months, monthly for the first year thereafter, and then monthly for the duration of treatment during treatment with AKEEGA™.
[0783] • For patients who develop hypokalemia during treatment with AKEEGA™, consider maintaining the patient’s potassium level at ≥ 4.0 mM (see 4 Dosage and Administration)• If a patient discontinues prednisone or prednisolone, caution is advised and adrenocortical insufficiency should be monitored. If AKEEGA™ is continued after discontinuation of corticosteroids, the patient should be monitored for symptoms of mineralocorticoid overdose. For patients receiving prednisone or prednisolone treatment and experiencing abnormal stress, the dose of corticosteroids may need to be increased before, during, and after the stressful event.
[0784] Musculoskeletal combination with radium dichloride increases fracture and mortality. AKEEGA™ is not recommended for combination therapy with radium dichloride. In a randomized clinical trial in patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer with bone metastases, the addition of radium-223 dichloride to abiraterone plus prednisone / prednisolone showed increased mortality and fracture incidence (see ZYTIGA® Product Monograph).
[0785] Myopathy / rhabdomyolysis: Cases of myopathy / rhabdomyolysis have been reported in patients receiving abiraterone acetate monotherapy (see ZYTIGA® Product Monograph). Caution is advised for patients who are being treated concurrently with medications known to be associated with myopathy / rhabdomyolysis.
[0786] Posterior Reversible Encephalopathy Syndrome (PRES) Posterior reversible encephalopathy syndrome (PRES) is a rare, reversible neurological disorder that can present with rapidly evolving symptoms, including seizures, headache, altered mental status, visual disturbances or cortical blindness, with or without associated hypertension. Diagnosis of PRES requires confirmation by brain imaging (preferably magnetic resonance imaging (MRI)).
[0787] There have been reports of PRES occurring in patients receiving niraparib monotherapy in populations with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (see ZEJULA® product monograph).
[0788] If PRES occurs, AKEEGA™ treatment should be permanently discontinued and appropriate medical management should be implemented.
[0789] Reproductive Health: The female and male potential is unclear regarding the presence of components of AKEEGA™ or its metabolites in semen. If the patient has sexual intercourse with a pregnant woman or a woman of childbearing potential, condoms and another highly effective method of contraception should be used during AKEEGA™ treatment and for three months after the last dose.
[0790] Animal studies have shown reproductive toxicity; see 7.1.1 Pregnancy.
[0791] • Fertility: There are no clinical data on the effects of AKEEGA™ on fertility. In animal studies, niraparib or abiraterone acetate reduced male fertility, but these effects were reversible upon discontinuation of treatment (see 16 Nonclinical Toxicology).
[0792] • Teratogenic Risk Statement 109 / 185 pages 115 CN 121443291 A Based on the mechanism of action of the two components and animal studies of abiraterone acetate, AKEEGA™ has been found to have the potential to cause teratogenicity.Potential risk of fetal harm (see 16 Nonclinical Toxicology).
[0793] Special populations 1.1.1 Pregnant women AKEEGA™ is not approved for use in women (see 10.3 Pharmacokinetics).
[0794] There are no data on the use of AKEEGA™ in pregnant women. Based on the mechanism of action of the two components and animal studies of abiraterone acetate, AKEEGA™ has been found to pose a potential risk of fetal harm. No animal developmental and reproductive toxicology studies have been conducted on niraparib (see 16 Nonclinical Toxicology – Reproductive and Developmental Toxicology).
[0795] To avoid accidental exposure, pregnant women or women who may be pregnant should not handle AKEEGA™ tablets without protection (e.g., wearing gloves).
[0796] 7.1.2 Lactation AKEEGA™ is not approved for use in women.
[0797] 7.1.3 Pediatrics (<18 years old) Health Canada has no available data; therefore, Health Canada has not approved this indication for pediatric use. 1.1.4 Elderly Patients (≥65 years old) In the MAGNITUDE cohort 1, 70.9% of the participants were ≥65 years old, and 26.5% were ≥75 years old. No overall difference in safety and efficacy of the combination therapy of niraparib and abiraterone acetate was observed between these patients and younger participants. However, the possibility that individuals ≥75 years old may be more sensitive cannot be ruled out. Enhanced surveillance of elderly individuals (≥75 years old) may be recommended.
[0798] Adverse Reactions Overview of Adverse Reactions The overall safety profile of AKEEGA™ is based on data from a phase 3, randomized, double-blind, placebo-controlled study, MAGNITUDE Cohort 1 (HRR positive), in which patients received once-daily oral nirapaniga abiraterone acetate and prednisone (AAP) (n=212) or placebo plus AAP (n=211) as a monotherapy combination (see 14 Clinical Trials). The median duration of exposure to nirapaniga AAP was 13.8 months (range: 0–29). Baseline and disease characteristics included a median age of 69 years (range 43–100), racial distribution of 74% White, 16.5% Asian, 1.2% Black, and others or unreported (8.3%); Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 0:66%, ECOG PS1:34%. At study enrollment, 83.5% of patients had bone involvement and 21.3% had visceral disease. All patients who had not previously undergone orchiectomy continued to receive background androgen deprivation therapy with GnRH analogs.
[0799] Serious adverse events occurred in 36% of subjects treated with nirapaniga AAP and 25% of subjects treated with placebo plus AAP. Anemia (5.7%) was a serious adverse event reported in ≥2% of subjects receiving nirapaniga AAP.
[0800] Fatal adverse events occurred in 5.7% of subjects treated with nirapaniga AAP and 3.3% of subjects treated with placebo plus AAP. Fatal adverse events due to pneumonia occurred in 0.5% of subjects receiving nirapaniga AAP, but not in any subjects receiving placebo plus AAP.
[0801] In patients in the MAGNITUDE cohort 1, the most common adverse events of all grades with an incidence >20% were anemia, hypertension, constipation, fatigue, nausea, and thrombocytopenia. The most frequently observed grade ≥3 adverse events were anemia, hypertension, thrombocytopenia, neutropenia, and elevated serum alkaline phosphatase.
[0802] Discontinuation of dosing of any component of the combination therapy due to adverse events occurred in 43% of subjects treated with nirapaniga AAP and 23% of patients treated with placebo plus AAP. In Cohort 1, 22% of subjects required to discontinue niraparib and use abiraterone acetate monotherapy (page 116, CN 121443291 A, package insert 110 / 185). The median duration of abiraterone acetate monotherapy was 102 days (range: 6; 518). In the niraparib plus AAP group, the most common adverse events leading to dosing discontinuation were anemia (22%), thrombocytopenia (9%), and neutropenia (7%). The incidence of all other TEAEs leading to dosing discontinuation was <5%.
[0803] In Cohort 1, dose reductions due to adverse events occurred in 27% of patients in the niraparib plus AAP group and 9.5% of subjects in the placebo plus AAP group. In the niraparib plus AAP group, the most common adverse events leading to dose reduction were anemia (13%), thrombocytopenia (3%), and fatigue (2%).
[0804] In Cohort 1, permanent discontinuation due to adverse events occurred in 10.8% of patients treated with nirapaniga AAP and 6.2% of patients treated with placebo plus AAP. In the nirapaniga AAP group, the most common adverse events leading to discontinuation were COVID-19 / COVID-19 pneumonia (2.8%) and anemia (2.4%).
[0805] Overall, the safety and tolerability profile of AKEEGA™ was consistent with the known safety profiles of its two monotherapy agents, and no new safety signals were identified.
[0806] Adverse Reactions in Clinical Trials Clinical trials are conducted under very specific conditions. Therefore, the incidence of adverse reactions observed in clinical trials may not reflect the incidence observed in practice and should not be compared with the incidence in clinical trials of another drug. Adverse reaction information from clinical trials may help identify and estimate the incidence of adverse drug reactions in real-world use. In the MAGNITUDE study, the safety of nirapaniga AAP and AKEEGA™ in patients with mCRPC with HRR mutations was evaluated in cohort 1 and cohort 3, respectively (Table 3).
[0807] Table 3: Adverse drug reactions in mCRPC patients with HRR gene mutations, Cohort 1 (Niraparib + AAP incidence increased by ≥2% compared to placebo + AAP) Product Information 111 / 185 pages 117 CN 121443291 A *CTCAE = Common Terminology Standard for Adverse Events Version 5.0 a Grouping terminology for arrhythmias: tachycardia, palpitation, atrial fibrillation, sinus tachycardia, supraventricular premature contractions, atrial tachycardia, cardiac and respiratory arrest, ventricular premature contractions, atrial flutter, bradycardia, tachycardia, ventricular tachycardia b Grouping terminology for thromboembolism (venous): embolism, pulmonary embolism, thrombosis, deep vein thrombosis, venous thrombosis Product Information 112 / 185 pages 118 CN 121443291 A Thrombosis Hematologic Toxicity Hematologic toxicities (anemia, thrombocytopenia, and neutropenia), including laboratory findings, are the most common adverse reactions attributed to niraparib. These toxicities typically occur within the first two months of treatment.
[0808] In the MAGNITUDE study, the following hematologic parameters were included as inclusion criteria: absolute neutrophil count (ANC) ≥ 1,500 cells / μL; platelets ≥ 100,000 cells / μL and hemoglobin ≥ 9 g / dL.
[0809] • Anemia In the MAGNITUDE study, anemia was the most common adverse reaction (46.2%) and the most frequently observed grade >3 event (28.3%). Anemia typically occurred early in treatment (median time to onset 57 days, range: 1; 636 days); however, 50% of these patients had persistent low-grade chronic anemia. 22.2% of patients experienced dosing interruption, and 13% experienced dose reduction. 26% of patients received at least one anemia-related transfusion. Anemia led to treatment discontinuation in 2.4% of subjects.
[0810] • Thrombocytopenia: In the MAGNITUDE study, 21.2% of treated patients reported thrombocytopenia, while 6.6% experienced grade 3 to 4 thrombocytopenia. The median time from first dose to first onset of action was 43 days. Thrombocytopenia was managed through dose modification (discontinuation 9.4%, dose reduction 2.8%) and platelet transfusion when appropriate (2.4%). Discontinuation occurred in 0.5% of patients, and bleeding events occurred in 1.4% of patients.
[0811] • Neutropenia: In the MAGNITUDE study, 14% of patients experienced neutropenia, with 6.6% reporting grade 3 to 4 neutropenia. The median time from first dose to first report of neutropenia was 50 days. Neutropenia led to treatment discontinuation in 6.6% of patients and dose reduction in 1.4% of patients. In the MAGNITUDE study, 0.9% of patients had co-infections.
[0812] Non-hematologic adverse reactions: Hypertension. Hypertension is an adverse reaction of both components of AKEEGA™. Patients with uncontrolled hypertension (persistent systolic blood pressure [BP] ≥160 mmHg or diastolic blood pressure ≥100 mmHg) were excluded in all combination trials. Hypertension was reported in 31% of patients, of whom 15% were grade ≥3. The median time to hypertension was 56 days.
[0813] Cardiac events. In the MAGNITUDE study, the most common major adverse cardiovascular event [MACE (ischemic heart disease, heart failure)] was ischemic heart disease (1.9%), and heart failure was also reported in 1.9% of patients. In addition, arrhythmias were reported in 12.7% of patients.
[0814] Hepatotoxicity. Hepatotoxicity has been identified as a significant identified risk of abiraterone acetate. Patients with moderate and severe hepatic impairment (NCI classification) and Child-Turcotte-Pugh B and C were excluded from the AKEEGA™ combination studies.
[0815] In the MAGNITUDE study, patients with baseline hepatitis or significantly abnormal liver function tests (serum total bilirubin ≤1.5×ULN or direct bilirubin ≤1×ULN, and AST or ALT ≤3×ULN) were excluded.
[0816] In the MAGNITUDE study, the overall incidence of hepatotoxicity was 12% in both groups. Grade 3 events occurred in 1.4% of patients, and only one patient (0.5%) experienced a Grade 4 event. The incidence of SAEs was 0.9%. The median time to onset of hepatotoxicity in the MAGNITUDE study was 30 days. Hepatotoxicity was managed by dose interruption in 1.4% of patients and by dose reduction in 0.9% of patients. One patient (0.5%) in the MAGNITUDE study discontinued treatment due to hepatotoxicity. Instructions for Use, Pages 113 / 185, 119, CN 121443291 A
[0817] Less Common Adverse Reactions in Clinical Trials The following are selected clinically significant adverse reactions with an incidence of less than 1% and a higher incidence than placebo + AAP in patients treated with nirapaniga AAP or AKEEGA™: Cardiac disease: QT interval prolongation Infections and invasive diseases: urosepsis, conjunctivitis Studies: elevated gamma-glutamyl transferase Metabolic and nutritional disorders: hypertriglyceridemia Skin and subcutaneous tissue diseases: abnormal photosensitivity Laboratory results: hematologic, clinical chemistry and other quantitative data Table 4 presents the worsening of hematologic and chemical laboratory abnormalities from baseline in placebo-controlled cohort 1 of the MAGNITUDE study.
[0818] Table 4: Summary of laboratory abnormalities worsening fro...
Claims
1. A pharmaceutical product approved for marketing by a government regulatory agency for at least one indication, wherein the pharmaceutical product comprises niraparib and abiraterone acetate.
2. The pharmaceutical product of claim 1, wherein the at least one approved indication is metastatic castration-resistant prostate cancer (mCRPC).
3. The pharmaceutical product of claim 1 or 2, wherein the pharmaceutical product is indicated for use in combination with prednisone for the treatment of patients with harmful or suspected harmful breast cancer mutation (BRCAm) mCRPC detected by a test.
4. The pharmaceutical product of claim 3, wherein the pharmaceutical product is administered for a once-daily oral delivery of a dose of 200 mg niraparib and 1,000 mg abiraterone acetate, and is administered in combination with a daily dose of 10 mg prednisone.
5. The pharmaceutical product of claim 3, wherein in the event of myelosuppression with: (i) platelet count < 100,000 / mcL, or (ii) neutrophil count < 1,000 / mcL or hemoglobin count < 8 g / dL; or in the event of other non-hematologic Grade 3 or 4 adverse reactions, the pharmaceutical product is administered orally once daily at a reduced dose of 100 mg niraparib and 1,000 mg abiraterone acetate.
6. The pharmaceutical product of any one of claims 3 to 5, wherein the pharmaceutical product is administered on an empty stomach.
7. The pharmaceutical product of any one of claims 3 to 6, wherein no food is taken within two hours before and one hour after taking the pharmaceutical product.
8. The pharmaceutical product of any one of claims 3 to 7, wherein the patient is concurrently receiving gonadotropin-releasing hormone (GnRH) analog therapy, or the patient has received bilateral orchiectomy.
9. The pharmaceutical product of claim 8, wherein the GnRH analog is selected from triptorelin, nafarelin, goserelin, leuprolide or leuprorelin, histrelin, gonadorelin, and buserelin.
10. The pharmaceutical product of any one of claims 3 to 9, wherein the pharmaceutical product is not administered to a patient with moderate or severe hepatic impairment.
11. The pharmaceutical product of any one of claims 3 to 10, wherein the pharmaceutical product is not co-administered with the CYP3A4 inducer rifampin.
12. The pharmaceutical product of any one of the preceding claims, wherein the pharmaceutical product comprises a pharmaceutical composition comprising a pharmaceutically acceptable carrier; and (i) 100 mg niraparib and 500 mg abiraterone acetate in an oral dosage form (regular strength); or (ii) 50 mg niraparib and 500 mg abiraterone acetate in an oral dosage form (lower strength).
13. The pharmaceutical product of any one of claims 4 to 12, wherein in patients with harmful or suspected harmful BRCAm mCRPC detected by an approved test, the pharmaceutical product elicits a median overall survival (OS) of 30.4 months with a hazard ratio (HR) of 0.788 (95% CI: 0.554, 1.120). 14. The drug product of claim 13, wherein the HR for median OS is 0.663 (95% CI: 0.464, 0.947) after multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from the group consisting of prostate specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (Alk Phos), age, Eastern Cooperative Oncology Group (ECOG) performance status, number of bone lesions, and visceral disease.
15. The drug product of any one of claims 4 to 14, wherein the drug product elicits an improved median time to symptom progression (TSP) when compared to patients receiving placebo and abiraterone acetate plus prednisone, HR 0.562 (95% CI: 0.371, 0.849), in patients with deleterious or suspected deleterious BRCAm mCRPC as tested.
16. The drug product of any one of claims 4 to 15, wherein the drug product elicits an improved median time to cytotoxic chemotherapy (TCC) when compared to patients receiving placebo and abiraterone acetate plus prednisone, HR 0.598 (95% CI: 0.387, 0.924), in patients with deleterious or suspected deleterious BRCAm mCRPC as tested.
17. The drug product of any one of claims 4 to 16, wherein the drug product elicits a median radiographic progression-free survival (rPFS) of 19.5 months, HR 0.553 (95% CI: 0.392, 0.782), in patients with deleterious or suspected deleterious BRCAm mCRPC as tested.
18. The drug product of any one of claims 1 to 17, wherein the drug product comprises 159.40 mg of niraparib mesylate monohydrate equivalent to 100 mg of niraparib free base as active ingredient, and 500 mg of abiraterone acetate.
19. The drug product of any one of claims 1 to 17, wherein the drug product comprises 79.70 mg of niraparib mesylate monohydrate equivalent to 50 mg of niraparib free base as active ingredient, and 500 mg of abiraterone acetate.
20. The drug product of any one of claims 12 to 19, wherein the pharmaceutical composition is an oral dosage form selected from the group consisting of film-coated tablets, tablets, capsules, granules, and sachets.
21. The drug product of claim 20, wherein the pharmaceutical composition is a film-coated tablet further comprising colloidal anhydrous silica, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose, and sodium lauryl sulfate; and a film coating.
22. The drug product of claim 21, wherein the film-coated tablet comprises 100 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monostearate, polyvinyl alcohol, talc, and titanium dioxide.
23. The drug product of claim 21, wherein the film-coated tablet comprises 50 mg niraparib and 500 mg abiraterone acetate; and the film coating comprises iron oxide black, iron oxide red, iron oxide yellow, sodium lauryl sulfate, glyceryl monostearate, polyvinyl alcohol, talc, and titanium dioxide.
24. The drug product of any one of the preceding claims, wherein the drug product is approved for marketing in the European Economic Area (EEA) or Canada.
25. The drug product of any one of the preceding claims, wherein the drug product is a generic drug, an ANDA, an sNDA, an NDA product, or a 505(b)(2) drug product.
26. A method for treating a mCRPC patient who tests positive for a harmful or suspected harmful BRCAm, the method comprising administering to the patient the drug product as defined in any one of the preceding claims in combination with prednisone.
27. The method for treating mCRPC of claim 26, wherein the method of treatment comprises once daily oral administration of the drug product containing 200 mg niraparib and 1,000 mg abiraterone acetate, concurrently with separate daily administration of 10 mg prednisone, until disease progression or unacceptable toxicity occurs.
28. The method for treating mCRPC of claim 26, wherein the method of treatment comprises once daily oral administration of a reduced dose of the drug product containing 100 mg niraparib and 1,000 mg abiraterone acetate, concurrently with separate daily administration of 10 mg prednisone, in the presence of myelosuppression with: (i) platelet count < 100,000 / mcL, or (ii) neutrophil count < 1,000 / mcL or hemoglobin count < 8 g / dL; or in the presence of other non-hematologic Grade 3 or 4 adverse reactions.
29. The method for treating mCRPC of any one of claims 26 to 28, wherein the method of treatment comprises improving the median OS to 30.4 months, HR 0.788 (95% CI: 0.554, 1.120).
30. The method for treating mCRPC of claim 29, wherein the median OS is further improved, HR 0.663 (95% CI: 0.464, 0.947), after multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from the group consisting of PSA, LDH, Alk Phos, age, ECOG grade, number of bone lesions, and visceral disease.
31. The method for treating mCRPC of any one of claims 26-30, wherein the treatment comprises a median TSP improvement with an HR of 0.562 (95% CI: 0.371, 0.849).
32. The method for treating mCRPC of any one of claims 26-31, wherein the treatment comprises a median TCC improvement with an HR of 0.598 (95% CI: 0.387, 0.924).
33. The method for treating mCRPC of any one of claims 26-32, wherein the treatment comprises a median rPFS improvement to 19.5 months with an HR of 0.553 (95% CI: 0.392, 0.782).
34. A method of marketing a drug product comprising niraparib and abiraterone acetate as defined in any one of claims 1-25, the method comprising marketing such drug product.
35. The method of marketing of claim 34, wherein the drug product is a generic drug, an ANDA drug product, a supplemental New Drug Application drug product, an NDA product, or a 505(b)(2) drug product.
36. The method of marketing of claim 34 or 35, wherein the reference formulation of such drug product improves OS, rPFS, TCC, TSP, or TPP.
37. The method of marketing of claim 36, wherein the median OS is 30.4 months with an HR of 0.788 (95% CI: 0.554, 1.120).
38. The method of marketing of claim 37, wherein the HR for the median OS is 0.663 (95% CI: 0.464, 0.947) after multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from the group consisting of PSA, LDH, Alk Phos, age, ECOG grade, bone lesion number, and visceral disease.
39. The method of marketing of any one of claims 36-38, wherein the median TSP is improved with an HR of 0.562 (95% CI: 0.371, 0.849).
40. The method of marketing of any one of claims 36-39, wherein the median TCC is improved with an HR of 0.598 (95% CI: 0.387, 0.924).
41. The method of marketing of any one of claims 36-40, wherein the median rPFS is 19.5 months with an HR of 0.553 (95% CI: 0.392, 0.782).
42. A method of providing for marketing a drug product comprising niraparib and abiraterone acetate as defined in any one of claims 1-25, the method comprising providing for marketing such drug product.
43. The method of making available for sale of claim 42, wherein the drug product is a generic drug, an ANDA drug product, a supplemental New Drug Application drug product, an NDA product, or a 505(b)(2) drug product.
44. The method of making available for sale of claim 42 or 43, wherein the reference formulation for such drug product improves OS, rPFS, TCC, TSP, or TPP.
45. The method of making available for sale of claim 44, wherein the median OS is 30.4 months with an HR of 0.788 (95% CI: 0.554, 1.120).
46. The method of making available for sale of claim 45, wherein the HR for the median OS is 0.663 (95% CI: 0.464, 0.947) after multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from the group consisting of PSA, LDH, Alk Phos, age, ECOG grade, bone lesion number, and visceral disease.
47. The method of making available for sale of any one of claims 44 to 46, wherein the median TSP is improved with an HR of 0.562 (95% CI: 0.371, 0.849).
48. The method of making available for sale of any one of claims 44 to 47, wherein the median TCC is improved with an HR of 0.598 (95% CI: 0.387, 0.924).
49. The method of making available for sale of any one of claims 44 to 48, wherein the median rPFS is 19.5 months with an HR of 0.553 (95% CI: 0.392, 0.782).
50. The drug product of any one of the preceding claims 1 to 25 for use in a method of treating a mCRPC patient who tests positive for a deleterious or suspected deleterious BRCAm, the method comprising administering the drug product in combination with prednisone.
51. The drug product of any one of the preceding claims 1 to 25 for use in the method of claim 50, wherein the method of treatment comprises once-daily oral administration of a dose containing 200 mg of niraparib and 1,000 mg of abiraterone acetate of the drug product, and 10 mg of prednisone, until disease progression or unacceptable toxicity occurs.
52. The drug product of any one of the preceding claims 1 to 25 for use in the method of claim 50, wherein the method of treatment comprises once-daily oral administration of a reduced dose containing 100 mg of niraparib and 1,000 mg of abiraterone acetate of the drug product, and 10 mg of prednisone, in the presence of myelosuppression with: (i) platelet count < 100,000 / mcL, or (ii) neutrophil count < 1,000 / mcL or hemoglobin count < 8 g / dL; or in the presence of other non-hematologic Grade 3 or 4 adverse reactions.
53. The drug product of any one of the preceding claims 1 to 25, for use in a method of any one of claims 50 to 52, wherein the treatment method comprises improving the median OS to 30.4 months with a Hazard Ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
54. The drug product of any one of the preceding claims 1 to 25, for use in the method of claim 53, wherein the median OS is further improved with a Hazard Ratio (HR) of 0.663 (95% CI: 0.464, 0.947) after multivariate Cox regression analysis adjusting for external validation and clinically relevant baseline prognostic factors selected from the group consisting of PSA, LDH, Alk Phos, age, ECOG grade, bone lesion number, and visceral disease.
55. The drug product of any one of the preceding claims 1 to 25, for use in a method of any one of claims 50 to 54, wherein the treatment comprises improving the median TSP with a Hazard Ratio (HR) of 0.562 (95% CI: 0.371, 0.849).
56. The drug product of any one of the preceding claims 1 to 25, for use in a method of any one of claims 50 to 55, wherein the treatment comprises improving the median TCC with a Hazard Ratio (HR) of 0.598 (95% CI: 0.387, 0.924).
57. The drug product of any one of the preceding claims 1 to 25, for use in a method of any one of claims 50 to 56, wherein the treatment comprises improving the median rPFS to 19.5 months with a Hazard Ratio (HR) of 0.553 (95% CI: 0.392, 0.782).
58. A drug product comprising niraparib and abiraterone acetate for use with prednisone or prednisolone in a method for treating adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1 / 2 mutations (germline and / or somatic mutations) who are chemotherapy-naive; wherein BRCA positive status is determined using a validated test method; wherein the daily dose of the drug product is 200 mg of niraparib and 1,000 mg of abiraterone acetate and the daily dose of prednisone or prednisolone is 10 mg until disease progression or unacceptable toxicity occurs; wherein the treatment comprises improving the median overall survival (OS) to 30.4 months with a Hazard Ratio (HR) of 0.788 (95% CI: 0.554, 1.120).
59. The drug product for use according to claim 58, wherein the median OS is further improved with an HR of 0.663 (95% CI: 0.464, 0.947) after multivariate Cox regression analysis adjusted for external validation and clinically relevant baseline prognostic factors selected from the group consisting of PSA, LDH, Alk Phos, age, ECOG grade, bone lesion number, and visceral disease.
60. The drug product for use according to claim 58 or 59, wherein the treatment comprises improving the median TSP with an HR of 0.562 (95% CI: 0.371, 0.849).
61. The drug product for use according to any one of claims 58 to 60, wherein the treatment comprises improving the median TCC with an HR of 0.598 (95% CI: 0.387, 0.924).
62. The drug product for use according to any one of claims 58 to 61, wherein the treatment comprises improving the median rPFS to 19.5 months with an HR of 0.553 (95% CI: 0.392, 0.782).
